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 ABSTRACT 
 
This thesis details a methodology utilising various synthetic pathways towards cyclisation 
precursors suitable for use in Prins and carbonyl-ene cyclisations to effect 2,3,4-
trisubstituted piperidines. Once the precursors were synthesised, we were interested in the 
stereochemical outcomes of the cyclisations, in particular identity and rational of the kinetic 
and thermodynamic products and their variation due to differing substituents on C2. 
Previous work in the Snaith group has addressed various other substitution patterns and 
2,3,4-trisubstituted piperidines are central components of a vast array of drug targets and 
natural products, so it follows that these should also be sought via similar processes. 
Synthesis of the precursors proved to be much more challenging than anticipated, hence 
many different routes were investigated with fluctuating successes.  
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 ABBREVIATIONS 
ala  alanine 
Alk  alkyl chain 
BDPP  (2S,4S)-2,4-Bis(diphenylphosphino)pentane 
COD  cyclooctadiene 
DCM  dichloromethane 
DIBAL-H diisobutylaluminium hydride 
DMAP  4-dimethylaminopyridine 
DMF  dimethylformamide 
DMP  Dess-Martin periodinane 
DMSO  dimethyl sulfoxide 
e.e.  enantiomeric excess 
EIMS  electron impact mass spectrometry 
ESMS  electrospray mass spectrometry 
EWG  electron withdrawing group 
ile  isoleucine 
Im-H  imidazole 
LAH  lithium aluminium hydride 
LDA  lithium diisopropylamide 
leu  leucine 
M  molar 
NMDA  N-methyl-D-aspartate 
PCC  pyridinium chlorochromate 
PDC  pyridinium dichromate 
phe  phenylalanine 
phg  phenylglycine 
RT  room temperature 
SFC  supercritical fluid chromatography 
t, tert  tertiary 
TBAF  tetra-n-butylammonium fluoride 
TBDPS  tert-butyldiphenylsilyl 
TBS  tert-butylsilyl 
TEMPO  (2,2,6,6-Tetramethylpiperidin-1-yl)oxyl 
TFA  trifluoroacetic acid 
TFAA  trifluoroacetic anhydride 
THF  tetrahydrofuran 
TLC  thin layer chromatography 
TMS  trimethylsilyl 
TOF  time of flight 
triflate  trifluoromethanesulfonate 
Trt  trityl, triphenylmethyl 
Ts  tosyl, para-toluenesulfonyl 
val  valine 
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1 INTRODUCTION 
 
The piperidine ring is a fragment found extensively in natural products and biologically active 
pharmaceuticals,1,2,3,4,5 making research into the stereocontrolled synthesis of diverse 
polysubstituted derivatives, an area of great activity. There is constantly demand for greater 
selectivity for the target and reduction of side effects from potential new drugs which leads 
to a higher molecular complexity requirement in order to achieve this.6 Substituted 
piperidines have a good record of being useful targets for drug discovery.7  
 
Natural products containing the piperidine ring structure include quinine (1) and quinidine 
(2), which have been used as antimalarials for several hundred years;8 dienomycins (3), 
which have antibacterial activity and (-)-incarvillateine (4), which has potent analgesic 
properties.9 (Figure 1)  
 
 
Figure 1: Natural products containing piperidine rings 
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Drug molecules that include the piperidine ring structure have a wide variety of targets. 
Compounds found in the patent literature1 could potentially be used to treat, amongst 
others; Parkinson’s, Alzheimer’s, psychosis, cognitive and neurological disorders, migraine, 
inflammation, arthritis, asthma, diabetes, obesity, hypertension, cancer, depression, anxiety 
and epilepsy.1,10,11,12 Drug molecules containing the piperidine moiety are also active against 
bacterial infection, autoimmune conditions, prostate disorders, emesis and growth 
disorders.13 The number of potential targets makes simple, versatile routes to substituted 
piperidines highly sought after.   
 
1.1 Piperidine synthesis in the literature  
 
There are four main synthetic routes to poly-substituted piperidines found in the 
literature.14,15,16,17 These are reduction of piperidinones;18 reduction of pyridines either 
partially to di- or tetrahydropyridines19,20 or fully to yield piperidines;21 cycloadditions, for 
example imino- or aza-diene [4+2] Diels-Alder type reactions;22 heterocycle closure from 
linear precursors.23 Here follows brief examples of when this type of chemistry has been 
used to synthesise piperidines in the recent literature.  
 
1.1.1 Piperidinone reduction  
 
A good use of reduction from a piperidinone is seen in Yue and co-workers’ stereoselective 
synthesis of a CCR3 antagonist, which works against inflammation particularly in asthma and 
allergic rhinitis.18 A key fragment is (S)-3-(4-fluorobenzyl)piperidine (8) which can be made in 
three steps from the simple piperidinone 5. (Scheme 1)  
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Scheme 1: a) TFAA, toluene; b) 4-fluorobenzaldehyde; c) KOtBu, THF; d) Pd/C, H2, 55 psi, MeOH;  
e) Ir(COD)(BDPP)BF4, MeOH, DCM, H2, 55 psi; f) LAH, THF, 15-30 °C; g) (R)-mandelic acid, MeCN;  
h) LAH, THF/ toluene, 15-40 °C. 
 
The first step was already well studied24 to give 6 which then needed to be stereoselectively 
reduced to give the desired (S)-product. The double bond could be removed by simple 
hydrogenation to give compound 7 as a racemic mixture, which was further reduced with 
lithium aluminium hydride to give racemic product 8. This method gave an overall yield of 
the desired product of just 25 %. To improve on this, as the authors were looking to scale up 
to 20 kg, an asymmetric hydrogenation process was desired. A screen for a suitable catalyst 
was run to select one that would give good selectivity and adequate loading and an iridium 
complex was chosen. After reaction, the catalyst was removed by filtration to give the 
benzyllactam 7 with 88 % e.e. After reduction to the piperidine, the overall yield of 
enantiomerically pure product was 79 %, a great improvement over the racemic methods.   
 
1.1.2 Pyridine reduction 
 
A piperidine was made by reduction of the corresponding pyridine when Kohn and co-
workers were looking at synthesising novel muscarinic receptor antagonists.19 Muscarinic 
receptors are G-protein coupled receptors (GPCRs) located in the cell membrane, 
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predominately in cells of the central nervous system. Malfunctions in these receptor systems 
have been linked to a number of conditions including Alzheimer’s and Parkinson’s along with 
irritable bowel syndrome, urinary incontinence, schizophrenia and chronic obstructive 
pulmonary disease25 so research into antagonists holds high importance.  
 
The targets sought were derivatives of the bicyclic amine 9. (Figure 2)  
 
 
Figure 2 
 
After the reportedly straightforward synthesis of 2,5-disubstituted pyridines (10), these were 
reduced to piperidines by various methods dependent upon the R group in the 2-position. 
(Scheme 2) 
 
Scheme 2: a)i) PtO2, H2, HCl; ii) ethyl acrylate, 80 °C; b) KO
tBu, 110 °C, 1 h;  
c) conc. Aq. HCl, 100 °C, 14 h 
 
For pyridines 10c and 10e a mixture of PtO2, H2 and acid gave the best results.
26 These were 
then converted into the Dieckmann cyclisation precursors (11) by heating with ethyl acrylate. 
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In the case of 10c the R group was prone to reduction, leaving a product mixture of 
approximately 1:1 11c:11R=Me. With both substrates c and e, the catalytic reduction was 
stereoselective to give single diastereomers which were deduced as the cis-isomers. The 
reduced side product was seen as both cis- and trans- isomers in approximately equal 
amounts. This suggests the C2 substituents, when not short aliphatic chains, form a complex 
with the PtO2 surface to give the cis addition of hydrogen during the reductions.  
 
The fused ring was made by Dieckmann condensation of the two esters to give products 12 - 
16. Acid decarboxylation of 12, 15 and 16 gave the desired amines 17, 20 and 21 respectively. 
Use of these same conditions to convert 13 and 14 into products 18 and 19 gave complex 
mixtures.  
 
1.1.3 Cycloadditions  
 
The use of an N-alkyl iminium ion and an alkene in an extension to Diels-Alder type 
cyclisations has been used to make highly substituted piperidines.27 (Scheme 3)  
 
 
Scheme 3 
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The stereochemical outcome of these reactions employing 2-azadienes as in Scheme 3 was 
investigated by Nelson et al.22 The N-alkenyl iminium ion dienes (23) were made from the 
corresponding N-alkoxymethyl enamines (22) by treatment with Lewis acid. The enamines 
were in turn derived from allylic amines. The end product can be designed from this point, 
either by adding base to give product 26 or alternatively a nucleophile, or excess dienophile, 
will add to give product 25.  
 
Using allyltrimethylsilane as an electron-rich dienophile afforded 100 % endo-product. 
(Scheme 4) 
 
 
Scheme 4: a) trimethylallylsilane, TiCl4, CH2Cl2, -78 °C 
 
The authors of this work speculate that the endo transition state, as seen in Scheme 4, 
allows stabilisation of the iminium ion. If a nucleophile is present it could attack from either 
face but due to steric clashing it will preferentially add opposite to the existing substituents. 
In the above example, excess silane can act as a nucleophile to directly alkylate the 
tetrahydropyridinium adduct. A 2:1 preference in the stereochemistry at C2 is seen but with 
substituents larger than methyl this is further exaggerated.  
 
If the dienophile moiety is particularly bulky, for example cyclooctene, steric effects take 
control of the transition state and the exo-product is seen exclusively.  
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1.1.4 Cyclisation from a linear precursor  
 
There are many methods of ring closure. An interesting example comes from the Snaith 
group, forming the piperidine ring with a radical cyclisation.28 Cyclisation precursors were 
synthesised in four steps from amino acids, introducing one chiral centre from the start of 
the synthesis. 
 
 
Scheme 5: a) Bu3SnH, AIBN, benzene, 80 °C  
 
The radical cyclisation was first carried out with tributyltin hydride which gave high yields (up 
to 99 %) and a mixture of the two possible diastereomeric products. The major product was 
identified as the trans-piperidine (29) by a series of NMR experiments. It is thought this is 
due to the R group sitting in an axial position in the chair-like transition state. (Scheme 6)  
 
 
Scheme 6 
 
The R group is preferentially axial to avoid pseudo A1,3 strain with the sulfonamide. The 
minor cis-product (28) arises from this group lying in an equatorial position. This theory is 
substantiated by varying the size of the R group. As the size is increased, the relative amount 
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of minor product is decreased. In contrast, the size of the ester group has little effect on the 
ratio of products.  
 
When the hydride source was substituted for the bulkier tris(trimethylsilyl)silane, the yield 
was slightly reduced but the selectivity was increased to over 90 % in favour of the trans-
piperidine (29) with R groups larger than methyl.  
 
1.1.5 Potential difficulties with asymmetric synthesis  
 
Each of these methods carries problems dependent upon the target molecule. For example 
in 1991 Whitten and co-workers noted the problem of epimerisation with their attempts to 
make 3-(S)-phosphonoacetyl-2-(R)-piperidinecarboxylic acid (30).23 (Figure 3)  
 
 
 
Figure 3 
 
This compound is a competitive antagonist of the NMDA receptor complex. Inhibition of the 
receptor, which normally binds glutamic acid, showed therapeutic promise for central 
nervous system disorders such as epilepsy, migraine, anxiety and neurodegenaration linked 
with several other conditions.29 Whitten’s first synthesis of 30 (Scheme 7) employed 
complete reduction of pyridine 31, via the methyl esters, to give mostly the cis-diacid in high 
yield. This stereochemistry was locked by using a cyclic anhydride intermediate (33). Despite 
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this effort, epimerisation of C3 in compound 34 was visible by TLC. Deprotection gave a 1:1 
ratio of cis-(35) and trans-product 36.  
 
 
Scheme 7: a) MeOH, HCl; b) Pd(OH)2, H2; c) 1M HCl; d) CbzCl; e) (CH3CO)2O; f) LiCH2PO(OEt)2;  
g) C6H5CH2Br, HN(C6H11)2; h) 6M HCl 
 
When the racemic products were analysed for affinity to the NMDA receptor it was found 
that the cis-isomer (35) was much more potent that the trans- (36). These results fit with the 
computer model prediction as although both compounds fit into the binding site, the cis-
isomer can align the phosphate to mimic the natural substrate much better.  
 
To remedy the problems that occurred in this synthesis, a new approach to forming the 
piperidine was undertaken. Instead of starting from a pre-formed heterocycle, a linear, chiral 
precursor was made from D-aspartic acid (37).  
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Scheme 8: a) MeOH, SOCl2; b) CH3CO2C(CH3)3, HClO4; c) Br(CH2)3Cl; d) PhFBr, Pb(NO3)2, NEt(
iPr)2;  
e) NaI; f) LDA, 2,6-diisopropylphenol; g) LiCH2PO(OCH2CH3)2; h) TFA, TMSI;  
i) Propylene oxide, MeOH.  
 
The use of the phenylfluorenyl protecting group helped minimize racemisation at C2. The 
cyclisation of 39 proceeded by forming the enolate with LDA at -78 °C then allowing the 
reaction to continue at -35 °C for several hours. Cautious quenching of the resultant 
piperidinyl enolate, by keeping the temperature low, and careful choice of proton source 
ensured that significant amounts of the more stable trans-isomer were not formed. When 
bulky 2,6-diisopropylphenol was used as the proton source at low temperature the cis-
isomer (40) was produced exclusively. Use of acetic acid produced large amounts of the 
trans-isomer. Phosphonation and deprotection followed with no apparent epimerisation 
giving amino acid 30 which was shown to be a potent NMDA glutamate antagonist.  
 
1.2 The carbonyl-ene reaction  
 
A carbonyl-ene reaction is a specialised case of the ene reaction between an alkene with an 
allylic hydrogen and an enophile, in this case a carbonyl. This is an attractive method of 
forming a carbon-carbon bond and introducing a chiral centre into a molecule with a high 
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degree of regio- and stereoselectivity. There is a migration of the double bond and a 1,5- 
hydrogen shift onto the carbonyl oxygen. (Scheme 9)  
 
 
Scheme 9 
 
The mechanism of ene reactions may be considered to be concerted or step-wise and will 
vary depending on the specific reaction and conditions. The ene component could either be 
considered as a nucleophile or as a 4-electron coupling partner, similar to a Diels-Alder type 
reaction. It follows that electron-rich alkenes react faster than electron-poor alternative and 
that the eneophile should be electron deficient to allow a good rate of reaction.  
 
The carbonyl-ene reaction is also appealing due to the potential for 100 % atom economy 
and therefore there is no need to remove the metallic waste generated from metal-based 
nucleophiles used in other C-C bond forming reactions.  
 
1.2.1 Intramolecular carbonyl-ene cyclisations  
 
If the carbonyl and the alkene are part of the same molecule and at a suitable separation an 
intramolecular carbonyl-ene reaction may proceed to give a cyclised product. This is more 
entropically favourable than the equivalent intermolecular reaction so can be done under 
milder conditions with little or no acid promoter. There are three classes of this reaction, 
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dependent upon how the two functionalities are connected in the linear molecule.30 
(Scheme 10)  
 
 
Scheme 10 
 
A type I reaction involves attack of the carbonyl onto the internal carbon of the alkene and 
type II attacks at the terminal end of a double bond. Type III reactions are rare but a few 
examples have been observed.31,32  
 
1.2.2 Piperidines from carbonyl-ene cyclisations  
 
If a nitrogen atom lies between the carbonyl and the alkene in the precursor then a 
piperidine ring will be formed in the reaction, creating two new stereogenic centres. The 
relative stereochemistry of these in type I cyclisations has been shown previously in the 
Snaith group to depend on whether the conditions used favour the kinetic product (cis) or 
allow equilibration to the thermodynamic alternative (trans).33,34 (Scheme 11)  
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Scheme 11 
 
The reactions shown in Scheme 11 proceeded, with chain length R of up to four additional 
carbon atoms, with reasonable yields. For the Lewis acid catalysed reactions the 
diastereomeric ratio was up to 93:7 in favour of the trans-product and the Brønsted acid 
catalyst gave d.r. of > 98:2 in favour of the cis-product. The stereochemistry has been 
confirmed with X-ray analysis of the crystalline products. 
 
It was found that if the Lewis acid MeAlCl2 was used to aid the cyclisation at -78 °C, the 
major product was cis, but raising the temperature to 25 °C gave mostly trans 
stereochemistry. These observations are strong evidence for the designation of kinetic and 
thermodynamic products as they show that with greater energy input the system is able to 
equilibrate and form the more stable product. By increasing the temperature further to 
61 °C the preference is much more pronounced. The reversibility of the reaction was further 
confirmed by heating cis piperidines in the presence of MeAlCl2 to yield the trans-isomer.  
 
Other Lewis acids were tested to see their effects on the stereochemical outcome. 
Aluminium chloride was found to favour cis-product. Scandium triflate and tin tetrachloride 
proved good catalysts for the reaction but gave little or no control over the stereochemistry. 
Alternative Lewis acids that showed little or no catalytic effect were ferric chloride, zinc 
bromide, ytterbium triflate and copper (II) triflate. 
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Similar investigations into Brønsted acids showed p-toluenesulfonic acid did not catalyse the 
reaction at low temperature and trifluoromethane sulfonic acid was effective but gave only 
limited selectivity. Three equivalents of concentrated hydrochloric acid however gave 
quantitative cyclisation and a ratio of 95:5 in favour of the kinetic product at -78 °C. A small 
amount of chloride 41 was also produced in this reaction but could be simply converted back 
to product (42) by stirring the mixture with silica gel or aqueous ammonia to induce 
elimination of HCl. (Scheme 12)   
 
 
Scheme 12  
 
1.2.3 Rationale of stereochemistry  
 
Carbonyl-ene ring closure was thought to be a completely concerted process due to the 
precedent set by studies on the closure of citronellal. This process had been proven to give 
the thermodynamic product directly, with no kinetic intermediate.35  
 
The results from earlier Snaith group work, using Lewis acid under equilibrating conditions, 
agreed with this concerted mechanism but the formation of the kinetic product when using 
Brønsted acids or Lewis acids at low temperature could not be explained by the classical 
concerted mechanism.33  
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Using crotyl aldehydes 43 and 45 a study was devised to test the nature of the mechanism. 
(Scheme 13)  
 
 
Scheme 13: Concerted mechanism probe  
 
It was proposed that if the mechanism were concerted then the E-alkene (43) would result in 
the trans-product (44) and the Z-alkene (45) would yield cis-piperidine (46) due to the 
transition states shown.  
 
In fact, when aldehydes 43 and 45 were subjected to cyclisation conditions, using Lewis acid, 
only cis-piperidine (46) was produced. This means the mechanism must be a step-wise non-
concerted pathway as laid out in Scheme 14. 
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Scheme 14 
 
As only the cis-piperidine is formed, cation 47 must have a lower energy than the trans-
cation 48. This can be rationalised by the intramolecular stabilisation given when the oxygen 
lone pair overlaps with the empty p-orbital at the cationic centre. This only occurs in the cis-
cation as it is geometrically unfavourable for the trans-cation. (Figure 4)  
 
 
Figure 4: Stabilisation of cis-cation by oxygen lone pair 
 
1.3 Natural product applications  
 
Synthesis of 2,3,4-trisubstituted piperidines will lead to new synthetic routes to natural 
products such as the Dienomycins and Elaeokanine C. (Figure 5)  
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Figure 5 
 
The dienomycins were first isolated by Umezawa et al. in the late 1960’s from Streptomyces 
strain MC67-C1.36 They were the first microbial products isolated with piperidine and 
phenylbutadiene structures and they were found to show antibiotic activity against 
mycobacteria. There have been various syntheses of these molecules previously; racemic 
dienomycin C was made in 1996 by Troin37 using iron tricarbonyl complexes to catalyse a 
Mannich-type cyclisation to form the piperidine structure. (Scheme 15). 
 
 
 
Scheme 15: a) CH2Cl2; b) p-toluenesulfonic acid, 50 °C, toluene; c) trimethylamine N-oxide (TMANO);  
d) H+; e) L-selectride, -50 °C, THF  
 
 
Compound 49 was formed as both cis- and trans- diastereomers, as a mixture of 
enantiomers. The C2 isomers were easily separated by flash chromatography, giving mixtures 
at C3 to carry forwards to further reactions. The C2 (R)-isomer depicted in Scheme 15 was 
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carried forwards to make dienomycin C (51a). The stereoselectivity of the C4 hydroxyl is 
determined by the base used in the final step. When sodium borohydride at 20 °C was used, 
the trans product 51b was favoured 85:15 but using L-selectride at -50 °C, as shown in 
Scheme 15, greatly favoured the natural product with a d.r. of 98:2 (51a:51b). 
 
A few years later a fully asymmetric synthesis was laid out by Comins and Green38 using 
enantiomerically pure reagents and a stereoselective reduction of the resulting piperidone 
using lithium tri-sec-butylborohydride (L-selectride). Very shortly after this publication Troin 
released a refinement of the tricarbonyliron method to give both (+)- and (-)- dienomycin C 
as the absolute configuration of the streptomyces-isolated compound was still unknown.39  
 
Syntheses of the more potent dienomycins A and B are as yet unpublished but they should 
be feasible using the chemistry outlined above.  
 
1.4 Project aims  
 
This project aims to find a flexible stereocontrolled synthesis to 2,3,4-trisubstituted 
piperidines, opening routes to the dienomycins and elaeokanine C. 
 
 1.4.1 Methodology  
 
-Amino acids can be derivatized to exploit their natural chirality. This gives the 
stereochemistry of C2 from the beginning of the synthesis. For example, Scheme 16 shows 
that protection of the amine allows for manipulation of the acid group.  
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Scheme 16: a) SOCl2, MeOH; b) TsCl, Et3N; c) LiBH4; d) DMSO, (COCl)2, Et3N, DCM; 
 e) R’’CH2R’P+Ph3I
-, n-BuLi, THF; f) K2CO3, CH3CN, CH2=CHCO2Me; g) DIBAL-H; h) HCl or MeAlCl2 
 
Conversion to the aldehyde will allow Wittig olefination to introduce the alkyl chain at C3 of 
the piperidine as well as providing the double bond required in the carbonyl-ene cyclisation. 
N-Alkylation can then be used to introduce the carbonyl moiety followed by acid catalysed 
cyclisation to close the piperidine ring structure. The stereochemical outcomes of these 
reactions would be expected to follow those seen in previous work in the Snaith group on 
3,4-disubstitued systems as detailed above.  
 
1.4.2 Natural product syntheses  
 
Elaeokanine C (52) can be conceivably reached using very similar chemistry starting from 
readily available pyroglutamic acid (53) (Scheme 17).  
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Scheme 17: a) SOCl2, MeOH; b) DIBAL-H; c) C(CH2CH2CH3)2P
+Ph3I
-, n-BuLi, THF; d) Br(CH2)3OTBS;  
e) TBAF; f) DMSO, (COCl)2, Et3N, DCM; g) HCl, -78 °C; h) LiAlH4; i) O3 
 
Based on previous results from the Snaith group, Brønsted acid mediated cyclisation is 
expected to give the desired cis-substitution pattern at C3 and C4 and the synthesis will be 
completed by reduction of the amide and oxidative cleavage of the alkene. 
 
 
Scheme 18: a) HCl; b) TBSCl, DMF, im-H; c) functionalization of C3; d) KOH then Boc2O; e) DMSO, 
(COCl)2, Et3N, DCM; f) olefination of C2; g) TBAF; h) R’’COCl, DMAP; i) TFA 
 
Scheme 18 outlines a general route to the dienomycins and their derivatives from an 
oxazolidinone (54). Once again, Brønsted acid mediated cyclisation will be employed to 
generate the cis-cyclisation product (55), with the pre-existing C2 stereochemistry being 
provided by the locked cyclic starting material.  
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2 SYNTHESIS OF LINEAR PRECURSORS 
 
In order to investigate the outcomes of the ring closing reactions, linear precursors needed 
to be synthesised.  
 
2.1 Amino Acid Derived Precursors  
 
2,3,4-trisubstituted piperidines have three stereocentres leading to eight possible 
stereoisomers. In order to reduce the number of stereochemical outcomes, amino acids 
were chosen as suitable starting materials. They are a naturally occurring source of 
enantiopure chirality therefore eliminating synthetic steps and reducing the complications of 
interpreting the results of cyclisation.  
 
The first amino acid used was serine (56), as the side chain terminates with a hydroxyl group, 
which could be a useful functional handle in the completed piperidine.  
 
2.1.1 Methylation and N-Protection  
 
Producing the methyl ester40 (57) proceeded smoothly in near quantitative yield and was 
followed by tosylation of nitrogen41 to mask it from subsequent reactions, affording 58 in 
good yield (Scheme 19). 
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Scheme 19: a) SOCl2, MeOH >99 %; b) TsCl, Et3N, DCM 86 %  
 
2.1.2 O-protection  
 
In the next step (Scheme 20), the alcohol was protected with a tert-butyldimethylsilyl 
protecting group (59). 
 
 
Scheme 20: a) TBSCl, Im-H, DMF. 90 % 
 
Initially this reaction gave low yields (<10 %). Various different sets of reaction conditions 
were attempted with somewhat increased yields. After returning to the primary literature43 
the initial reaction was repeated at 1 M – 1.5 M concentration, increased from 0.2 M – 0.3 M, 
giving 90 % yield at room temperature. The remaining unreacted alcohol was easily removed 
by recrystallization and the excess silyl chloride eluted much more slowly than product from 
a silica column.   
 
The tosylation and silylation reactions were combined into a one-pot procedure as detailed 
in the literature44 but this only produced a 28 % yield over the two steps so the separate 
steps were favoured.  
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2.1.3 Reduction of the ester  
 
The original research plan involved reducing ester 59 directly to the corresponding aldehyde 
using diisobutylaluminium hydride (DIBAL-H) in DCM at -78 °C.45 Unfortunately the reaction 
did not run smoothly, leaving what appeared by 1H-NMR to be ester with the silyl group 
cleaved. The spectrum was fairly clean and showed no signals at ~0.8 and 0.0 ppm for the 
silyl t-butyl and methyl groups respectively. All other signals expected for the ester (59) were 
present with their appropriate integrals and there was no aldehyde signal around 10 ppm.  
 
ESMS gave a single peak at 296.2 which relates to ester 58 [M+Na]+. This route was 
abandoned for the simpler full reduction to the alcohol (60), followed by a controlled 
oxidation to the aldehyde (61). (Scheme 21)  
 
 
Scheme 21: (a) DIBAL-H, DCM (b) LiBH4, THF 97 % (c) PCC, DCM 85 %  
 
Reduction of ester 59 to alcohol 60 was initially attempted using sodium borohydride as the 
hydride source46 but this required 2.5 equivalents to see disappearance of starting material 
by TLC. Unfortunately 1H-NMR analysis suggested removal of both the tosyl and the silyl 
protecting groups after work-up. The material recovered contained a tosyl group but the 
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integrals were disproportionately large compared to any of the other signals (~6 - 7 times 
greater than expected). The rest of the spectrum could not be clearly interpreted as starting 
material or product. There were also extra signals seen at 0.95 ppm and 0.10 ppm (both 
singlets, integral approximately 3:2) for the silyl group, suggesting that it had, at least in part, 
been removed during the reaction.  
 
A white solid was recovered that was insoluble in chloroform but an NMR spectrum was run 
in D2O showing this was tosic acid.  
 
Repeating the experiment with lithium borohydride41,47 required only a small excess of the 
hydride source with gentle heating to give alcohol 60 in excellent yield.  
 
2.1.3.1 Racemic equivalents  
 
The first four steps of this synthesis were also repeated with racemic starting materials in 
order to prove the e.e. of these products. This could be achieved by comparison of chiral 
HPLC data or NMR comparison of amides made from reaction of the compounds with 
Mosher’s Acids (62). (Figure 6)  
 
 
Figure 6: Mosher's acids 
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Yields for the racemic series were good to excellent for methylation (>99 %), tosylation 
(93 %), silylation (86 %) and reduction (75 %).  
 
2.1.4 Oxidation  
 
Oxidation of the primary alcohol 60 proved more difficult than anticipated. Oxidants tested 
were PCC (63), TEMPO (64), PDC (65), Dess-Martin periodinane (66) and activated DMSO 
(Swern conditions).  
 
 
Figure 7: Oxidising agents 
 
The initial procedure involving PCC48 (63) (1.5 eq) also used Celite® to help remove the 
chromium waste after the reaction. This caused problems as the reaction mixture was 
filtered through silica but recovery of material was poor. The recovered organic material 
proved to be mostly unreacted starting material with ~10 % aldehyde present. The PCC was 
tested for quality with a substrate known to give good results and gave 75 % aldehyde in 
unoptimised conditions. As PCC was the first reagent tested, it was side lined due to the vast 
number of other oxidants available.  
 
A series of Swern oxidations (Scheme 22, Table 1) were performed under various 
conditions49,50 but none of these showed any promise.  
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Scheme 22: General Swern oxidation 
 
Reaction Temp. after 
base addition 
Time after base 
addition 
Quench 
temperature 
Results 
A -78 °C 4 h RT Aldehyde, no Si, unsaturated? 
B RT - - 2 aldehydes, many products. 
C -78 °C 15 min -78 °C Slow/no reaction. 
D -78 °C 1 h -78 °C Slow/no reaction. 
E -25 °C 30 min -25 °C 2 aldehydes, many products. 
Table 1: Swern oxidations 
 
Reaction A was left at -78 °C for four hours after addition of base before allowing to warm to 
room temperature for quenching. A significant aldehyde signal was seen in the 1H-NMR 
spectrum but the signals for the TBS group were absent. The aliphatic region of the spectrum 
was also very confused, with many extra signals indicating the intended product was not 
obtained and a variety of related compound were probably present. ESMS possibly indicates 
some form of chloro-adduct. There are several peaks that have a counterpart 2 mass units 
apart, with approximate 3:1 intensities, as expected for a chlorine containing compound. A 
peak at m/z 281.9 could possibly relate to [M+Na]+ for compound 67 (Figure 8) and IR 
spectroscopy indicates there may be unsaturated compounds present. 
 
 
30 
 
 
Figure 8 
 
Reaction B was allowed to warm to room temperature immediately after addition of base. 
Two signals were seen in the aldehyde region of the spectrum but all other signals were 
highly degraded indicating multiple similar compounds present.  
 
Reaction C was left 15 minutes after base addition before quenching at -78 °C. This allowed 
only minimal reaction. The signals were more intact than had been previously seen but only 
a trace of aldehyde was visible.  
 
Reaction D was the same as C except the time was increased to one hour before quenching 
at -78 °C and again only limited reaction occurred.  
 
As temperature was governing the extent of reaction, an intermediate temperature was 
tested. Reaction E involved addition of base at -78 °C, then immediate warming to -25 °C and 
stirring for 30 minutes before quenching at this temperature. Two aldehyde signals were 
observed of equal intensity with degradation of the rest of the signals. 
 
Swern oxidations were not producing the anticipated product and giving no recoverable 
starting material so alternative oxidants were sought.  
 
31 
 
Jurczak had demonstrated the desired oxidation in high yield using the TEMPO radical (64) 
and sodium hypochlorite as co-oxidant.50 Following his procedure gave only 1 - 2 % aldehyde 
after several attempts. The Dess-Martin Periodinane (66) was also tested,51,52 again resulting 
in similar levels of aldehyde in the reaction mixture after a prolonged reaction time of 
several days.  
 
2.1.5 Phenylalanine Route  
 
As the synthesis involving serine derivatives had stalled at the oxidation step, a search of the 
literature for Wittig olefinations on aminoaldehydes suggested L-phenylalanine (68) as a 
successful starting point.53,54,55 Although the phenyl function would be less useful than an 
alcohol in the finished piperidine we were interested in seeing the effect of steric bulk at C2 
on the outcome of the ring closing step. The work on serine could be revisited at a later date.  
 
An advantage of phenylalanine over serine in the synthesis is the absence of the alcohol as 
there would be no silylation required to mask it. The large silyl group may have also been a 
contributing factor to the failure of some of the oxidations due to its bulk. 
 
 
Scheme 23: a) NaBH4, I2, THF 78 %; b) TsCl, Et3N, DMAP, DCM 99 % 
 
As in Scheme 23 the -amino alcohol 70, the analogue of serine derivative 60, has been 
made in just two steps instead of four. Reduction of the amino acid using sodium 
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borohydride and iodine56 had not been used as the first step with serine as this would have 
given two indistinguishable primary alcohols that would have in effect racemised the 
products. The reaction proceeded smoothly on a 25 g scale to give 78 % yield after 
recrystallisation. The tosylation step to follow was as before but used 10 mol% DMAP to 
catalyse a faster reaction.56 
 
2.1.6 Oxidation of Protected Alcohol  
 
Oxidations of this alcohol were attempted as with the protected serinol, starting with 
PCC/Celite®. These conditions produced several different aldehyde products but none in 
significant quantities. The next test was TEMPO with sodium hypochlorite but this resulted in 
hardly any reaction at all. Starting material was recovered with a trace of aldehyde present. 
A DMP oxidation was next attempted which gave four aldehyde signals by 1H-NMR, the 
largest accounting for ~6 % of the sample. PDC
57 (65) was also tested but again produced 
very little aldehyde. 
 
A different approach to PCC oxidations was then found which used 3 equivalents of oxidant, 
instead of 1.5 equivalents as previously used, and did not involve Celite® in the reaction 
mixture.58 This gave much better recovery of organic material and the products were 
separated by column chromatography to give clean aldehyde (71) in good yield (Scheme 24).  
 
 
Scheme 24: a) 3 eq. PCC, Celite®, DCM 79 %; b) 3 eq. PCC, DCM 75 % 
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When this reaction, with an increased amount of PCC, was tested with the Celite® present, 
aldehyde was produced but the recovery of material was lower, decreasing the yield. This 
evidence suggests that the product became stuck to the Celite® leading to difficulties in 
removal by filtration.  
 
The improved PCC method was used with protected serinol 60 and also showed good 
conversion to aldehyde. Increasing the reaction time from 4 hours to 20 hours proved more 
convenient and increased yields without degradation of the aldehydes produced, especially 
for reactions on a larger scale. The best yields obtained were 75 % and 85 % for 
phenylalaninol and serinol respectively. These would most likely be improved with further 
optimisation. 
 
2.1.7 Wittig olefinations  
 
In order to incorporate the alkene required to close the piperidine ring via a carbonyl-ene 
reaction, and at the same time add functionality to C3, Wittig olefinations were employed.  
 
 
Scheme 25: a) Ph3P
+CHRR'X-, KOtBu*, THF (* not required to produce 76) 
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Scheme 25 shows various reactions that were attempted. Compounds 72 and 73 are not 
suitable for cyclisation as they lack the necessary allylic hydrogen as shown in the 
mechanism below (Scheme 26). These reactions were used to test the chemistry, to see if 
the substrates would withstand the Wittig conditions without degradation.  
 
 
Scheme 26 
 
Other Wittig olefinations using non-stabilised ylides to give alternative aliphatic chains in 
position C3 may be desired. If these prove difficult or low yielding, compounds 72 and 73 
leave the possibility of introducing the aliphatic chains by metathesis.  
 
A stabilised ylide was also tested,59 producing compound 76. This particular example can 
also not be used directly for cyclisation as it has no available protons. The ester could 
however be reduced to give a product with opposite stereochemistry to the one attainable 
from using a non-stabilised ylide. This is due to the outcome of the Wittig olefination when 
using non-symmetrical ylides. With a stabilised ylide the major product is the E-alkene, but if 
the ylide is non-stabilised the major product is the Z-alkene (Scheme 27).  
 
 
Scheme 27 
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Compounds 74 and 75 were synthesised from the isopropyl ylide 78, which was made in situ 
from the iodo-precursor 77 (Scheme 28). 
 
 
Scheme 28: a) KOtBu, THF 
 
Alkene 75 was synthesised by this method only in modest yield (~35 %). Alkene 74 was still 
not possible to produce under the same conditions (RT, 16 h) suggesting that the bulk of the 
TBS group may have been preventing the reaction.  
 
2.1.8 Alternative forward synthesis  
 
Due to the low yield and non-reproducibility of the reaction, the next step of functionalising 
the nitrogen (75 → 81) was not attempted but instead an alternative synthetic route was 
pursued (Scheme 29).  
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Scheme 29: a) X(CH2)3OTBS, Cs2CO3; b) PCC; c) ylide 78 
 
The functionalization of the nitrogen was attempted with both chloro- and iodo-substituted 
alkyl chains, both with equally disappointing results.60 Compound 79 was isolated but only 
with 9 % maximum yield.  
 
 
Figure 9 
 
Compound 82 (Figure 9) was isolated from these reactions indicating that the halogen was 
being eliminated faster than the alkylation could occur.  
 
The small amount of compound 79 that was produced was subjected to the now usual PCC 
oxidation conditions (3 eq. PCC, DCM, RT, 16 h) and aldehyde 80 was isolated by 
chromatography. Not enough of this material was brought through to test the Wittig 
olefination.  
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2.1.9 Tritylation  
 
The acidity of the amine proton was suspected to be the source of the difficulties in the 
above reactions. Trityl protection had been reported to reduce this acidity so the project 
moved in this direction.  
 
 
Scheme 30: a) SOCl2, MeOH; b) TrtCl, Et3N; c) LiBH4 
 
The earlier protection strategy of producing the methyl ester from the amino acid then 
reducing this, once protected, to the alcohol was undertaken (Scheme 30). Unfortunately 
the lithium borohydride reduction did not work as well as expected; it gave a 50/50 mixture 
of ester and alcohol, even after addition of extra equivalents of LiBH4 and increasing the 
time to ten days.  
 
An alternative route was then found in which the reduction of the amino acid precedes the 
trityl protection (Scheme 31).61  
 
 
Scheme 31: a) I2, NaBH4; b) TrtCl, Et3N 
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The alternative route is shown in Scheme 31, which also removes one synthetic step. This 
synthetic route was not initially chosen due to the possibility of double tritylation onto the 
oxygen as well as the nitrogen. This was fortunately found not to be an issue in this example. 
Reduction of phenylalanine had successfully been used previously in the project (Scheme 23). 
The tritylation product 85a was isolated in 96 % yield after chromatography.  
 
 
Scheme 32: a) DMSO, (COCl)2, Et3N, DCM 98 %; b) Ph3P
+CH2I
-, KOtBu, THF 98 % 
 
The next steps shown in Scheme 32 proceeded in high yield and were easily purified with 
column chromatography.62 The problems returned when trying to install an alkyl chain 
during the Wittig olefination.  
 
 
Figure 10 
 
Each time the reaction was attempted with ylide 78, the only recoverable product was 
triphenylmethane. Various sets of conditions were trialled including changing the amount of 
ylide used, the temperature and the reaction time; but all gave triphenylmethane as the 
major product (80 - 90 %).  
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When ylide 88 was examined, the same happened but to a lesser extent. Around 37 % 
product was achieved with 53 % triphenylmethane also recovered.  
 
 
Scheme 33: Experimental outcomes of various Wittig olefinations 
 
The only literature reference found for removal of a trityl group to give triphenyl methyl, 
instead of trityl alcohol, involved a single electron transfer. This is not possible under the 
reaction conditions used.  
 
Scheme 34 shows a possible mechanism to explain these results.  
 
 
Scheme 34: Interaction between amine and ylide 47 
 
Firstly, the ylide is rapidly bound to the nitrogen as seen in Scheme 34. At this point, if R = H, 
the Wittig olefination occurs as expected. It is unclear if the N-P bond is broken before this 
or as part of the work-up. The expected product is found in quantitative yield.  
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Scheme 35: Possible detritylation mechanism 
 
If there is a proton to the phosphorus in the ylide as in the case of 89 and 90, it can be 
delivered to the trityl group via a six-membered cyclic transition state as seen in Scheme 35.  
 
The triphenylmethane was collected as a white solid but the larger fragment was never 
recovered so it was not possible to tell at what point the N-P bond is broken.  
 
2.1.10 Temporary Protection Strategy  
 
A temporary protection strategy was tested to see if the nitrogen could be blocked to allow 
formation of the substituted alkenes. (Scheme 36) 
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Scheme 36: Proposed temporary protection 
 
It was hoped that the extra base (in practice added as a solution with the first ylide) would 
deprotonate the nitrogen and remove the possibility of a reversible first step. This would 
leave all of the ylide bound to nitrogen so that the second, substituted ylide could then go 
on to react as desired.  
 
A TLC analysis immediately after the aldehyde and ylide were combined showed no 
aldehyde remaining, presumably all in the protected form, so the second ylide was added. 
After an overnight stir the intense red colour associated with the second ylide was still 
present and indeed after work up compound 87 was isolated. This suggests that the 
formation of the N-P bond is in fact reversible, and rapidly so. The result also suggests that 
the aminium ion could be shielded from deprotonation by the base (in this case bulky 
potassium tert-butoxide), probably due to steric hindrance from the six phenyl groups 
surrounding it. 
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2.1.11 Detritylation  
 
The small amount of compound 90 that was produced from previous reactions was taken 
forward to test the detritylation step which was deemed a partial success. The much more 
available compound 87 was then used to optimise this reaction which became problematic, 
not in the detritylation itself, but in the work up stages.63 Initially, the hydrochloride salt of 
amine 91 was sought, as it was thought the free amine would be too volatile. This was done 
by basifying the reaction mixture prior to organic extraction and then re-acidifying with HCl. 
This gave dissapointing yields and after further experimentation it was found that the initial 
extraction was removing trityl alcohol only. A second extraction was required in order to 
extract the product from the aqueous layer. The free amine was found to be much simpler 
to produce. It was found to be extremely water soluble so difficult to extract during work up. 
The final procedure involved extraction of the trityl alcohol followed by evaporation of the 
water to dryness to leave the product as a residue in reasonable yield and purity.  
 
It was decided to continue with the unsubstituted alkene (91) as there was the possibility of 
installing functionality by metathesis. This was probably best left until one of the last stages 
in the synthesis due to the high cost of the catalysts. 
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Scheme 37: Possibilities using metathesis 
 
Scheme 37 outlines the next synthetic route towards the piperidine. Starting with a 
monosilylation of 1,3-propanediol,64,65 followed by a Swern oxidation produces a protected 
aldehyde which can then be used in a reductive amination with amine 91.66 From this 
compound there were various options available. We could have continued as laid out in 
Scheme 37 to furnish a piperidine by ring closing metathesis, with the option to functionalise 
at the double bond, e.g. dihydroxylation, epoxide formation, etc. Alternatively the double 
bond of compound 92 could be functionalised by metathesis then the initial plan to close the 
ring by the well precedented carbonyl-ene cyclisation could be followed. In addition to this 
amine 91 could be protected with a tosyl group to fit in with previous cyclisations performed 
in the Snaith group. This compound would then be alkylated as in Scheme 29a followed by 
metathesis to introduce the functionality required for cyclisation.  
 
Amine 91 was alkylated by means of a reductive amination to produce 92a (Scheme 38) 
 
 
 
Scheme 38: i) Na2SO4, DCM; ii) NaBH4, MeOH 
 
The maximum yield obtained after multiple attempts of this reaction was only 18 % so the 
route was not pursued any further.  
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2.1.12 Avoiding metathesis  
 
Tritylation had not furnished a particularly elegant route to the linear piperidine precursors. 
It was decided to introduce the alkyl chain that would form C4 - C6 of the finished piperidine 
before working on the double bond constituent as had been done up to this point. Scheme 
39 below shows the forward synthesis towards the cyclisation precursor. 
 
 
Scheme 39: a)i) O=CH(CH2)2OTBPDS, Na2SO4, DCM; ii) NaBH4, MeOH, 70 %;  
b) DMSO, (COCl)2, Et3N, DCM; c) TsCl, DMAP, Et3N, DCM 
 
Beginning with phenylalaninol (69a) a reductive amination was performed in reasonable 
yield. The left hand route (Scheme 39) shows a Swern oxidation followed by tosylation of the 
nitrogen. This resulted in a complex mixture of products so the steps were reversed. 
Tosylation of 93a gave a less than satisfactory yield due to competition from the free 
hydroxyl group.  
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2.1.12.1 Parallel protection strategy  
 
Due to the low-yielding tosylation reaction, the synthesis was revised to include a protection 
of the hydroxyl group and allow tosylation to proceed freely. 
 
 
Scheme 40: a) TBSCl, Et3N, DCM; b)i) O=CH(CH2)2OTBDPS, Na2SO4, DCM; ii) NaBH4, MeOH;  
c) TsCl, Et3N, DCM; d) AcOH/THF/H2O 
 
Scheme 40 shows the parallel protection strategy employed. Initially, the hydroxyl group of 
phenylalaninol (69a) was protected67 followed by a reductive amination onto the amine. The 
silylation proceeded in excellent yield (98 %) but the reductive amination produced only 
traces of product after multiple alterations to the reaction mixture such as changes to the 
temperature, time and concentration. The steps were reversed to produce the doubly 
silylated product (98a) yielding 99 % and 91 % respectively over the two steps. The 
subsequent tosylation proceeded in a much more respectable yield than with the free 
hydroxyl group (70 %) but unfortunately the selective deprotection that followed could not 
be achieved.68,69,70  
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When the deprotection was attempted using aqueous acetic acid in THF at 20 °C for 16 
hours, no reaction occurred. When the time was extended up to 72 hours a double 
desilylation resulted in the diol. Heating at 50 °C for 16 hours again resulted in recovery of 
unreacted compound 99, but extending this time again resulted in the diol as the only 
product of the reaction.  
 
This was unexpected as the tert-butyldiphenylsilyl protecting group was thought to be much 
more stable than the tert-butyldimethylsilyl group, making it non-labile under the reaction 
conditions used.71  
 
Another approach involved using a THP protected alcohol in place of the second silicon-
based protecting group used to alkylate the nitrogen but problems producing a mono 
protected propanediol lead to this method being abandoned.  
 
As the monosilylated compound 95a was not accessible via this route and it would have 
added an extra two synthetic steps, the previous synthesis with tosylation in the presence of 
the free hydroxyl was resumed despite the disappointing yields (max. 50 %).  
 
2.1.13 Completion of linear precursor synthesis  
 
The remainder of the synthesis as shown in Scheme 41 proceeded smoothly.  
 
The Swern oxidation of alcohol 95a to aldehyde 96a was clean and high yielding. Initially the 
Wittig olefination was attempted using potassium tert-butoxide as the base as had by now 
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become a standard procedure, but this furnished no reaction. This was probably due to 
steric hindrance.  
 
The tert-butoxide anion is fairly large and when combined with the triphenylphosphonium 
cation, it was little surprise that the reaction was unsuccessful. This reagent was used first as 
it is a standard agent used in the literature for ylide production and is easily handled in its 
granular form in the laboratory. When the reaction failed the base was changed to n-
butyllithium, which turned out to be a very effective base in this reaction and compound 
100a was synthesised in good yield.72  
 
 
Scheme 41: a) DMSO, (COCl)2, Et3N, DCM, 95 %; b) 
iPrP+Ph3I
-, n-BuLi, THF, 84 %; c) TBAF, THF, 65 %;  
d) DMSO, (COCl)2, Et3N, DCM, 87 % e) acid  
 
Once the double bond had been installed, the deprotection with TBAF73 and oxidation 
followed in good yield to produce a linear cyclisation precursor (102a).  
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2.1.14 Stereochemistry  
 
Now that a complete synthetic route had been worked out (Scheme 42) racemic equivalents 
of each of the compounds were made to allow for measurement of the e.e. in each case.  
 
 
Scheme 42: Completed synthetic route 
 
The compounds synthesised from enantiomerically pure L-phenylalanine were compared 
with those made from a racemic mixture of DL-phenylalanine by supercritical fluid 
chromatography. This is a technique similar to HPLC but CO2 cooled and pressurised to keep 
it in a supercritical fluid state is used as the mobile phase. Methanol was used as the co-
solvent to initially solubilise the compound mixtures. The first three compounds (69, 93 & 95) 
showed they had retained the stereochemistry from the chiral starting material (eg 95; 98.6 % 
ee). Unfortunately from the first Swern oxidation (96) all samples showed racemisation (0.4 % 
ee). This is due to the ease of racemisation of -amino aldehydes owing to the planar 
intermediate which can be formed when base is present. (Figure 11)  
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Figure 11: Epimerisation of aldehyde 
 
The Swern procedure used to this point had used triethylamine as the base. There is 
literature precedent that using a bulkier base such as Hünig’s base (Figure 12) and lower 
temperature quenching can prevent -racemisation.49 A longer reaction time may be 
required due to the increased steric bulk.  
 
 
Figure 12: Hünig's base - N,N-diisopropylethylamine 
 
Three variables in the standard Swern oxidation were altered in an attempt to eliminate the 
racemisation that was occurring during the reaction. The standard Swern oxidation 
procedure being followed involved addition of base at -78 °C then, after stirring for 15 
minutes, the mixture was allowed to warm to room temperature prior to quenching with 
water. Firstly the triethylamine was substituted for Hünig’s base but all other aspects 
remained the same. In the second reaction, the quench was performed at -20 °C and in the 
third, the reaction stirred for two hours at -78 °C after addition of the base before quenching 
with water and then allowing to slowly warm to room temperature.  
 
All three of these samples were sent for SFC analysis but each one was deemed to be a 
racemic mixture.  
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2.1.15 Other R-groups installed at position 2  
 
Although it was not possible to synthesise enantiomerically pure linear precursors by the 
above methods, this is not in fact important when looking at the stereochemical outcomes 
of the ring closing reactions as we were interested, at this stage, in the diastereocontrol in 
these cyclisations. For this reason, due to the availability, variety and the time spent in 
arriving at a synthetic pathway, further amino acids were chosen as starting materials 
(Figure 13).  
 
 
Figure 13: Other amino acid side chains used 
 
For each of these amino acids, the route shown in Scheme 42 was followed with varying 
successes dependant largely on steric effects. 
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Table 2: Yields obtained following Scheme 42. * Reductions of leu and ile were taken through without 
distillation due to difficulty in collecting product and cleanliness of 1H-NMR spectra.  
** Tosylation occurred on oxygen.  
 
Table 2 shows the yields obtained from the reactions shown in Scheme 42. Some of the 
routes began with the commercially available amino alcohol as the reduction from the 
amino acid was difficult and collection of the products was complicated by the product 
volatility.74 The routes for leucine and isoleucine are incomplete due to insufficient time and 
the exploration of more profitable avenues instead, but it is expected there would be little 
problem based on the reactivity of the valine example as they are structurally similar.  
 
tert-Leucine was abandoned after the tosylation as the yield was very low. This was 
presumably due to the steric crowding around the reaction centre. This was even more 
apparent for phenylglycine as the yield was even lower and after more detailed analysis it 
was found that the tosyl group had been added to the free hydroxyl terminus, being more 
accessible than the amine nitrogen.  
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The alanine reactions were not optimised and not continued along this path as a more 
efficient route was being pursued that would retain the integrity of the stereogenic centre. 
 
2.2 Introduction of the stereogenic centre by use of a chiral auxiliary  
 
A chiral auxiliary is a unit employed to control the stereochemical outcome of an otherwise 
non-stereoselective reaction. The inherent chirality of the auxiliary can be transferred to the 
molecule of interest usually by controlling the position of various reactants in a transition 
state during the reaction in question.  
 
2.2.1 Early literature occurrences  
 
One of the first uses of a chiral auxiliary was by Corey in 1975 in his synthesis of 
prostaglandin intermediates.75 Starting from either isomer of pulegone (103) he synthesised 
(+)-8-phenylmenthol (104) which is then used as the chiral auxiliary.76 
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Scheme 43: Use of a chiral auxiliary in the synthesis of prostaglandin intermediates  
 
Scheme 43 shows how addition of a Lewis acid to the acrylate ester of (+)-8-phenylmenthol 
(105) causes a conformational change which is postulated to block the rear face of the 
acrylate. This means that during the Diels-Alder addition only the front face is available so 
only the endo adduct (106) is produced. After several more synthetic steps the target 
molecule (108), a key intermediate in the synthesis of prostaglandins, was successfully 
produced in an optically pure state.  
 
As this type of procedure became more popular, the need for a more accessible auxiliary 
was necessary so alternatives such as trans-2-phenylcyclohexanol (109)77 and trans-2-(1- 
phenyl-1-methylethyl) cyclohexanol (110)78 were developed. 
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Figure 14 
 
2.2.2 tert-Butanesulfinamide  
 
Since their introduction, many small chiral molecules have been used as auxiliaries. One 
which has been extensively studied by Ellman and co-workers is t-butanesulfinamide (111).79  
 
 
Figure 15: (R)-(+)- and (S)-(-)-t-butanesulfinamide 
 
The imines formed on reaction with these compounds are stable and easily isolated. 
Additionally, the sulfinyl group activates the imine and it is easily removed by brief 
treatment with mild acid.  
 
 
Scheme 44: use of t-butanesulfinamide as a chiral auxiliary  
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Ellman et al. produced a whole range of aldimines (112) and ketimines (113) in excellent 
yields. They even showed imines synthesised from unreactive, sterically hindered and 
electronically deactivated starting materials.  
 
Addition of Grignard reagents to sulfinyl aldimines 112 again give very good yields and 
diastereoselectivities. Aliphatic and aromatic aldimines were successfully used with alkyl, 
aryl and vinyl Grignard reagents, followed by decoupling with hydrochloric acid, to give an 
array of -branched amines.  
 
2.2.3 Stereocontrolled installation of R-group at position 2  
 
In just two synthetic steps a whole range of R-groups could be installed at what would 
become position 2 in the finished piperidine. This method meant that a wider scope of 
functionalities could be used than was possible from amino acids. 
 
 
Scheme 45 
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The two routes shown in Scheme 45 reach the same product but with opposite 
stereochemistry.80 The lower route turned out to be slightly higher yielding and also has the 
benefit of differentiation of R-groups one synthetic step later.81,82,83  
 
There was the possibility that the Grignard reagent would add to 115 in the 4 position 
instead of the desired 2 position. All of the 1H-NMR data show no evidence of this as the 
imine proton is no longer seen.  
 
The stereochemical outcome of the Grignard addition is governed by the stereochemistry of 
the six membered ring transition state formed between the sulfinimine and the magnesium 
bromide as seen in Figure 16.79 
 
 
Figure 16: six-membered ring formed during the Grignard addition.  
 
A regular six-membered ring in a chair conformation is able to form as the lone pair on the 
sulfur causes it to adopt a tetrahedral shape. From this transition state it is easy to see that 
R1 is delivered to the same face as the sulfur-oxygen double bond. This is how the chiral 
auxiliary works to install a stereogenic centre with reliable specific stereochemistry that will 
remain after the auxiliary has been removed. In most examples there was only a single 
diastereomer seen by 1H-NMR spectroscopy. When the R-group is very small (methyl) a 
minor isomer is also recovered as up to 33 % of the overall product yield.  
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2.2.4 Completion of linear cyclisation precursor synthesis  
 
This route removes the need to oxidise an -amino alcohol so there is no possibility of 
racemisation of the newly installed stereocentre. (Scheme 46)  
 
 
Scheme 46: a) HCl, MeOH; b)TsCl, Et3N, DMAP, DCM; c)i) I(CH2)3OTBS, Cs2CO3, DMF;  
ii) HCl or TBAF/THF; d) DMSO, (COCl)2, Et3N, DCM  
 
Removal of the chiral auxiliary was straightforward by stirring with hydrochloric acid in 
anhydrous ether for 30 minutes.84 Extraction of the amine (117) was difficult due to water 
solubility and in some cases volatility. Various methods were investigated, including 
trituration with ether, steam distillation from aqueous sodium hydroxide and organic 
extraction from an aqueous work-up, but all failed. For these reasons the amine was left as 
the hydrochloride salt and the excess acid and solvent evaporated off leaving a product that 
was clean enough to be used without further purification.  
 
2.2.4.1 Alkylation of the amine  
 
Initially the plan had been to resume the synthesis as set out in Scheme 42 with a reductive 
amination onto the amine with the same aldehyde as previously used. Unfortunately, even 
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with addition of extra base equivalents to neutralise the hydrochloride salt, or addition of 
butyllithium to precipitate out LiCl and release the free amine, multiple attempts at 
reductive amination failed.  
 
Instead the salt was tosylated, again with additional equivalents of base present. This 
product was then easily separated by chromatography to remove any impurities (118).  
 
A simple SN2 substitution reaction followed. Firstly a silylated chloropropanol was used but 
the yield and efficiency were disappointingly low. A Finkelstein substitution was employed to 
produce the corresponding iodide which was a much more potent alkylating agent.85 The 
Finkelstein product had to be used crude as column chromatography promoted elimination 
of HI and subsequent desilylation to leave 2-propenol as the only recoverable product. The 
iodide was also susceptible to decomposition under UV light so the Finkelstein substitution 
and following alkylation reactions (119) were conducted in complete darkness.  
 
2.2.4.2 Desilylation and oxidation  
 
Once these complications were understood they were simple to accommodate. The TBS 
group used as protection for the alcohol during the alkylation was found to be particularly 
labile in the reaction mixture used. This allowed it to be cleanly and effectively removed with 
dilute hydrochloric acid during the workup of the alkylation in most cases. This was a very 
useful consequence as it removed a synthetic step from the overall synthesis. In the rare 
examples where the protecting group was not removed 1M TBAF in THF followed by 
chromatography yielded the alcohol.  
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A standard Swern oxidation followed by chromatography gave the aldehydes ready for 
cyclisation in high yield (120).  
 
2.2.5 Variety of side-chains  
 
Introducing the side-chain by way of a Grignard addition allows for almost any R-group to be 
inserted. There is much greater scope than the limitations of using amino acids as the 
starting material. For comparison to the amino acid derived syntheses above, work was 
undertaken on methyl, isopropyl and benzyl side-chains, relating to alanine, valine and 
phenylalanine respectively. Other R-groups investigated were allyl, prenyl and nitrile. If time 
and resources had permitted, a vinyl side chain would also have been studied. These 
unsaturated alkyl chains will allow for different functionality to be added to the finished 
piperidine to allow for further manipulation.   
 
 
Table 3: percentage yields of reactions.  
* yield over two steps. **desilylation by TBAF required 
 
Table 3 shows the outcomes of the reactions shown in Scheme 45 and Scheme 46.  
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Although the reaction with allyl Grignard occurred in good yield (116d), when the reaction 
was repeated with prenyl Grignard there was almost no reaction (116e). A very small 
amount of product was recovered but the main isolated compound was unreacted imine. 
This was quite unexpected as the structural difference is at the opposite end of the molecule 
to that involved on the reaction. This reaction may require additional investigation.  
 
There were several attempts made to introduce the nitrile from trimethylsilyl cyanide with 
scandium (III) triflate86 and cesium fluoride87 but all of these were unfruitful. The referenced 
articles show additions of a nitrile group to similar tert-butanesulfinimines but none of the 
referenced compounds were -unsaturated imines so this may have added extra 
complication.  
 
Due to the difficulty in isolating the free amine (117) after removal of the chiral auxiliary 
yields were not recorded but instead the residues were used crude for the following 
tosylation (118). The combined yields shown over the two steps are excellent, showing the 
deprotection was very efficient.  
 
The alkylation (119) and subsequent Swern oxidation (120) of three of the four remaining 
substrates progressed well to give the linear cyclisation precursors. The fourth, isopropyl, did 
not alkylate well under the same conditions. Optimisation of this reaction would begin with 
extending the time and/or increasing the temperature to encourage more favourable 
collisions.  
 
Alkylation of the allyl variant gave excellent yield but this was the only example not to 
spontaneously desilylate upon mild acid work up. A separate step using TBAF was required.  
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3 CYCLISATIONS 
 
Previous work in the Snaith group has shown a marked difference in the relative 
stereochemistry of the two stereocentres produced during the carbonyl-ene ring closure 
dependent upon the type of acid catalyst used. Brønsted acids at low temperature favour 
formation of the kinetic product, whereas Lewis acids at elevated temperature allow for 
equilibration to the thermodynamic product.23,24  
 
3.1 Isomers from cyclisation  
 
Assuming fixed stereochemistry at position 2 there are four possible outcomes of the ring 
closing reactions as shown in Figure 17. The enantiomer to each of these would also be 
formed, although undetectable by 1H-NMR, if the linear precursor was not enantiomerically 
pure. Not all of these isomers were expected to be formed or be detectable in each instance 
but their ratios are variable dependent upon the reaction conditions. In most cases only two 
isomers were detected and occasionally a third. 
 
 
Figure 17: Possible isomers from ring closure 
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During the cyclisation, the six-membered ring is formed preferentially into a chair 
conformation. The tosyl group protecting the nitrogen is very large and has been seen in 
previous work in the Snaith group to force the substituent on C2 into the usually 
unfavourable axial position as shown in figure 18.88,89,90  
 
 
Figure 18 
 
3.2 Brønsted acid catalysis  
 
Brønsted acids used at low temperature favour the formation of the kinetic product. In this 
research hydrochloric acid was used as it had previously given the best results for the Prins 
cyclisation to give 3,4-disubstituted piperidines.15 There are a few methods of introducing 
the catalyst into the reaction mixture, either as a concentrated aqueous solution or bubbling 
HCl gas through the reaction mixture to give a saturated solution. Both methods have their 
flaws and virtues. As the reactions are taking place at -78 °C, concentrated aqueous acid 
(~36 %) is prone to freezing into an ice droplet on contact with the solvent. This calls for 
additional equivalents to be used to compensate for acid that is trapped and therefore not 
part of the reaction mixture. It means essentially that an unknown number of equivalents 
are in the reaction mixture. In addition, due to the low temperature, reaction times are 
extended and this poses operational difficulties in maintaining a constant temperature.  
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Conversely using compressed HCl gas allows much faster reactions, typically less than one 
hour rather than up to 48 hours, so temperature control is not an issue. It does however 
require a much more complex apparatus setup and there is no control to the amount of HCl 
used.  
 
3.2.1 HCl gas cyclisations  
 
In previous work in the Snaith group, bubbling HCl gas through a solution of the cyclisation 
precursor had proved an effective way of introducing the catalyst. Unfortunately, when this 
method was used with the compounds synthesised in this thesis, cyclisation did not occur, 
but instead the linear molecule (120) was cleaved, possibly into the compounds shown in 
scheme 47. 
 
 
Scheme 47: Cleavage of cyclisation precursor by HCl gas. 
 
Compound 121 was isolated in up to 85 % yield indicating this is the major reaction that 
occurs faster than cyclisation can occur. Reaction times were typically 5 – 10 minutes only. 
The structure above is tentatively suggested although has not yet been fully confirmed.  
 
Mass spectrometry could identify the cation of the other fragment but X could not be 
identified by any of the spectroscopic techniques used. It is most likely another chloride.  
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3.2.2 Concentrated aqueous HCl cyclisations  
 
As using HCl gas was unsuccessful, concentrated aqueous HCl was used instead. This time 
cyclisation did occur and the results are shown in table 4.   
 
 
Table 4: Results of conc. HCl cyclisations 
* from 1H-NMR of crude sample 
 
 
There were two and in some cases three products isolated from this set of reactions as 
shown in Scheme 48.  
 
 
Scheme 48: outcomes of cyclisation reactions 
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In all cases the major product was piperidine 122 with the stereochemistry 2S*,3S*,4R*. This 
has been confirmed with an X-ray structure of crystals of the major product when R was 
benzyl. (Figure 19)  
 
 
 
 
 
Figure 19: 122c SSR 
 
The minor product was piperidine 123 (2S*,3S*,4S*), again confirmed using X-ray diffraction. 
In order to crystallise the piperidine it was necessary to derivatise the free hydroxyl with a 
bulky group, in this case as a bromobenzoate. The data show that all of the substituent 
groups are in the axial positions. (Figure 20)  
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Figure 20: der-123c SSS  
 
When R = Me the stereochemistry of the minor product is not entirely clear from the NMR 
data and crystals were not grown. By comparison to other NMR data it is clear that it is not 
piperidine 124a (Figure 21). This can also be deduced by looking at the coupling constants at 
H3 and H4. In the 2S*,3R*,4R* isomer both of these hydrogen atoms lie in axial positions and 
so would have a large coupling constant (<9.5 Hz) between the two protons with a dihedral 
angle of 180 °.  
 
 
 
Figure 21: piperidine 124a 
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One proton signal visible in the spectrum of the crude mixture is a ddd and has coupling 
constants of 5.3 Hz, 7.2 Hz and 13.4 Hz. This is from H4. The proton must be axial with the 
large coupling to H5, leaving only smaller J values for the interaction to H3, indicating that it 
cannot also be axial. Assuming H2 lies equatorially would give piperidine 122a which is the 
major product. This leads to one of two conclusions: the methyl group is small enough to 
allow it to lie equatorial without a steric clash with the N-tosyl giving the 2R*,3S*,4R* isomer; 
the conformation is not chair-shaped so the coupling constants are less useful in 
determining the stereochemistry. No C2 substituent has been seen in the equatorial position 
in previous work, but due to the different substitution pattern in this substrate this could 
now be the case. This could be resolved by growing crystals to obtain X-ray analysis.  
 
3.3 Lewis acid catalysis  
 
Previous work in the Snaith group had determined that the most efficient Lewis acid catalyst 
for carbonyl-ene cyclisation is methylaluminium dichloride15,91. Coordination of the oxygen 
to the Lewis acid during the reaction stabilises the intermediate and should allow formation 
of the thermodynamic product. Increasing the temperature to introduce more energy into 
the system should also facilitate this.  
 
Results from the cyclisations are shown in table 5. 
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Table 5: Lewis acid catalysed cyclisation results. 
*see HCl data, RSR speculative only 
 
 
As with the Brønsted acid catalysed cyclisations, the major products at low temperature 
were piperidines 122. The major allyl piperidine was derivatised with 4-bromobenzyl 
chloride to allow crystallisation in order to prove the stereochemistry by X-ray diffraction. 
(Figure 22) 
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Figure 22: der-122d 
 
The same piperidine as seen with the Brønsted acid catalyst when there is a methyl group at 
position 2 is seen again here as a minor product. As discussed earlier this could potentially 
be the 2R*,3S*,4R* isomer (125) (Figure 23) but confirmation by X-ray analysis is required. 
 
 
Figure 23: 2R,3S,4R piperidine 
 
The minor products when the R-group is benzyl or allyl are again those seen previously. 
 
An interesting side product of the benzyl cyclisations is a tricycle formed through an intra-
molecular Friedel-Crafts type alkylation (126). The Lewis acid in the reaction mixture 
facilitates this. The reaction is quite slow as this product was only isolated from reactions left 
70 
 
for a prolonged time. Additionally 126 was formed as a by-product (~25 %) from the hydroxyl 
derivatisation used to enable crystallisation of the piperidines. (Scheme 49) 
 
 
Scheme 49: Rearrangement of piperidine 122c to tricycle 126 
 
The tricycle is made from the major product of the cyclisation reactions, which was initially a 
little surprising as the benzyl and alkene groups are anti-periplanar to one another. This can 
be seen in the image below showing the X-ray diffraction data of the crystallised compound. 
(Figure 24)  
 
Figure 24: Tricycle 126 
The centre of the image shows H2 and H3 on opposite faces of the piperidine ring 
 
 
H2 
H3 
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It is possible that a tricycle was also produced from the minor isomer 123c but was in too 
small a quantity to extract from the product mixture. 
 
3.4 Discussion of results 
 
Initially, the axial conformation of the substituent on C3 was unexpected, especially as the 
major product of all of the cyclisation reactions. This should be disfavoured due to 1,3-diaxial 
interactions across the ring. Evidence was found in the 1H-NMR data. The coupling constants 
for H3 showed no large (>9 Hz) J values which would indicate a dihedral angle approaching 
180 ° between H3 and either H2 or H4. We knew H2 was lying in the equatorial position due to 
steric hindrance from the tosyl group as mentioned above. Using coupling constants in this 
way assumes the six-membered ring is in a chair conformation. These assumptions were 
confirmed, at least in the solid state, by the crystal X-ray diffraction data (Figures 19, 20 & 
22). 
 
In previous work from the Snaith group,48 this type of compound had been seen as a 
component of the reaction mixture. (Scheme 50) 
 
 
Scheme 50: cyclisation data from related work in the Snaith group 
 
The component in 33 % yield has the alkene substituent, in addition to the R group, in the 
axial position. 
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The formation of the major isomer in these reactions can be rationalised by looking at the 
transition state of the ring closing reaction. (Scheme 51) 
 
 
Scheme 51: formation of the kinetic product 
 
With the alkene substituent in the axial position, the partial cationic character is stabilised by 
the lone pair on the oxygen. This is not possible when the oxygen is axial so piperidine 122 is 
likely to be the kinetic product. 
 
This same stabilisation could occur with the oxygen axial and the alkene equatorial, as has 
been seen in previous Snaith group work. Presumably the gauche interaction between the 
bulky alkene and the axial R group (and the OH), plus the 1,3-diaxial interaction between the 
OH and the R group, combine to disfavour this stereoisomer. 
 
It is unclear from the cyclisation data whether piperidine 123 or 124 is the thermodynamic 
product. What the data do show is that, when more energy is put into the system or the 
reaction time is increased, 122 can transform into the other stereoisomers. This is because 
the reactions are in equilibrium until they are quenched, so the kinetic product can ring-
open and reform in an energetically more favourable conformation.  
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3.5 Bicyclic piperidines  
 
Detailed below (Scheme 52) is the synthesis towards a cyclisation precursor (133) that would 
ring-close to form two possible bicyclic piperidine regioisomers, each with stereocentres at 
positions 2, 3 and 4 (134, 135).  
 
 
Scheme 52: a) CeCl3.7H2O, THF, MeLi, 81 % or MeMgBr, THF, 76 %; b) KH, Et2O, CCl3CN, 45 %;  
c) EtOH, NaOH, H2O, 33 %; d) TsCl, Et3N, DMAP, DCM, 45 %; e)(i) Cs2CO3, I(CH2)3OTBS, DMF;  
(ii) HCl, 60 %; f) DMSO, (COCl)2, Et3N, DCM. 
 
3.5.1 Methylation of cyclohexenone  
 
Cerium (III) was used to direct the 1,2- rather that 1,4-addition of methyl into cyclohexenone 
(127). The literature procedure for the dehydration of cerium chloride92 was very time 
consuming and not all that effective. It involved heating the heptahydrate at > 150 °C for 24 
hours under vacuum to draw off the water. Problems included a remainder of hydrated 
compound in the centre of the flask and also blockage of the vacuum tube due to 
sublimation of the dehydrated product. After multiple attempts, the procedure was much 
improved by flame drying of the compound under high vacuum for periods of a few minutes, 
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followed by grinding by pestle and mortar and repeating 2-3 times. This method also 
controlled sublimation and gave a much more consistent, granular dehydrated cerium 
chloride.  
 
Once this problem had been overcome, the methylation was fairly straightforward and the 
product (128) easily purified by column chromatography. An alternative methylation utilising 
Grignard chemistry was also investigated93. This was much simpler to prepare than the 
cerium chloride method and gave a crude product that was exceptionally clean by NMR 
analysis and that had been methylated at the correct position. Unexpectedly, when using 
compound 128 made by Grignard addition, no reaction occurred in the subsequent 
nucleophilic addition and rearrangement reactions. The reason for this is unclear and with 
limited time to investigate, the cerium chloride method was returned to, to bring material 
through.  
 
3.5.2 Forward synthesis to cyclisation precursor  
 
 
Scheme 53 
 
Scheme 53 shows the mechanisms involved in the conversion of alcohol 128 into amide 129. 
This reaction leaves a six-membered ring with the double bond the correct distance from the 
nitrogen to be used in carbonyl-ene cyclisations, just as with the linear cyclisation precursors.  
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After hydrolysis of amide 129 to amine 130, tosylation (131) and alkylation (132) followed as 
had been used previously. Once again, alkylation with tert-butyl(3-iodopropoxy) 
dimethylsilane followed by a mild acidic work up, lead to the desilylated product being 
recovered, therefore eliminating the need for a separate desilylation step. 
 
3.5.3 Oxidation  
 
A Swern oxidation of alcohol 132 gave aldehyde 133 as seen by 1H-NMR analysis of the crude 
product. Upon purification by column chromatography, the aldehyde underwent 
spontaneous cyclisation on the silica surface to give piperidine 134.  
 
Further investigation of this reaction is required along with controlled cyclisations to 
determine the stereochemical and regiochemical outcomes of the ring closure.  
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4 NATURAL PRODUCT SYNTHESIS 
 
The natural product elaeokanine C (136, Figure 25) is one of a family of alkaloids isolated 
from sub-tropical trees and shrubs of the genus Elaeocarpus. It comprises an indolizidine 
with substitution at positions 2, 3 and 4 of the piperidine moiety, which is in keeping with 
the other work in this thesis.  
 
 
Figure 25: (-)-elaeokanine C 
 
4.1 Previous syntheses of Elaeokanine C  
 
Several of the Elaeocarpus alkaloids were isolated by Johns and co-workers in the early 
seventies.94,95 At this time there was insufficient spectroscopic evidence to assign absolute 
stereochemistry so only relative stereochemistries were reported.  
 
Scheme 54 shows the major intermediates in a synthesis of Elaeokanine C by Gribble et al.96 
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Scheme 54: Synthesis of (±) Elaeokanine C by Gribble et al. 1988 
 
A key step in this synthesis was the tandem Mannich-aldol condensation between the shown 
pyrollium and benzyl 3-oxohexanoate. This successfully achieved the correct relative 
stereochemistry at positions 2 and 3 but there was poor selection at position 4. Only 25 % of 
the recovered product was the naturally occurring isomer shown in Figure 25.  
 
A fully stereocontrolled synthesis was published in 1991 by Comins and Hong.97 They used a 
chiral auxiliary to direct cyclisation and maintain stereocontrol. (Scheme 55)  
 
 
Scheme 55: synthesis of elaeokanine C by Comins and Hong, 1991.  
R = (-)-8-(4-phenoxyphenyl)methyl 
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The end product was the unnatural enantiomer (+)-elaeokanine C which was isolated with 
over 95 % optical purity.  
 
4.2 Synthesis using carbonyl-ene cyclisation  
 
A proposed synthesis of elaeokanine C (136) from readily available pyroglutamate (137) is 
laid out in Scheme 56. This shows the synthesis of the unnatural enantiomer as the starting 
material, (S)-pyroglutamate, is much cheaper than the alternative enantiomer. 
 
 
Scheme 56: Initial synthesis plan of elaeokanine C from pyroglutamate 
 
4.2.1 Methylation of pyroglutamate  
 
The first step of the synthesis was methylation of pyroglutamate following the method used 
by Aggarwal et al.98 (Scheme 57)  
 
79 
 
 
Scheme 57: a) SOCl2, MeOH, 0 °C, 2 hr 
 
Following the literature procedure led to an incomplete reaction, so the reaction time was 
extended. This produced the unexpected result of ring-opening, firstly to methyl glutamate 
and eventually to dimethyl glutamate (scheme 58). This was verified by making an authentic 
sample from glutamic acid.  
 
 
Scheme 58: Products from extended methylation reaction time 
 
A time-trial study was conducted to find the optimum reaction time. The results are shown 
in Table 6. 
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Table 6: methylation time-trial results 
 
The optimum time was found to be two hours. Some of the material is still non-methylated 
and a small portion has also ring-opened but the overwhelming majority is the desired 
methylpyroglutamate (141).  
 
4.2.2 Continuation of synthesis  
 
After optimisation of the methylation of pyroglutamate, the product was reduced to alcohol 
138 in good yield (83 %).99,100 It was not possible from this point to oxidise this alcohol to the 
corresponding aldehyde (139) in preparation for a Wittig olefination to install what would 
become the side chain at position 3 of the closed piperidine. Synthesis of the aldehyde was 
also attempted as a partial reduction from 141 using DIBAL101,44 but this was similarly 
unsuccessful. In preparation for the Wittig olefination reaction the appropriate ylide was 
constructed as shown in Scheme 59.  
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Scheme 59: Preparation of ylide 
 
As installation of this ylide was not possible via the proposed route, due to the required 
aldehyde being unobtainable at this point, a second synthetic route was devised (Scheme 60) 
which involved a change in order of work on the alcohol and amide. 
 
4.2.3 Alternative route  
 
 
Scheme 60 
 
Starting from alcohol 138, a protecting group would be added to enable installation of the N-
alkyl group, before returning to the original plan of alcohol oxidation followed by Wittig 
olefination. This would use the same ylide as previously constructed and result in the same 
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cyclisation precursor (140). From this point the original route is resumed and completed to 
give the natural product (136) (scheme 61).  
 
  
Scheme 61: a) HCl; b) LiAlH4; c) O3 
 
From the previous work done by the Snaith group,33,34 it is thought that the correct 
stereochemical outcome of the cyclisation reaction could be achieved under kinetic 
conditions i.e. Brønsted acid at low temperature.  
 
4.2.4 Synthetic problems encountered  
 
Various silicon based groups (TMS, TBS, TBDPS) were used to protect the alcohol102 whilst 
work was focussed on alkylation of the amide. Multiple alkylation methods based on 
literature precedent103,104,105,106,107,108 were followed with very little success. These all involve 
use of a halogenated alkylating agent with various bases and solvents used. Alkylation was 
also attempted, unsuccessfully, with the free alcohol (138) and the methyl ester (137).  
 
The targets of these alkylations are shown in figure 25. 
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Figure 26: Alkylation targets sought 
 
Of those shown in Figure 26, some targets were achieved. Compound 142 was made as a 
proof of technique with an alkyl halide that was available at the time. Unfortunately this 
compound could not be used further as both protecting groups were the same and therefore 
indistinguishable in future reactions. When the same method was employed with a different 
protecting group (TBDPS) there was again no reaction. The following two compounds (n-
butyl and ethyl heptanoate) were again method tests taken from the literature, but were not 
made in good enough yield to continue.  
 
Acetals 143 and 144 were isolated in 71 % and 69 % yield respectively but the alcohol 
deprotections lead to decomposition.  
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Compound 145 was made using 1-bromo-3-chloropropane with microwave radiation. 
Terminal alkene 146 was the major product of this reaction and was in fact a more useful 
compound for further reaction. The alkene was subsequently synthesised using allyl bromide 
under the microwave conditions in 91 % yield. A hydroboration of alkene 146 to alcohol 147 
led to many compounds that were inseparable by TLC so once again this branch of the 
synthesis was dropped. 
 
4.2.5 Future work  
 
As the microwave reactions had shown good successes this seems like a good alkylation 
method to pursue. A possible forward synthesis is shown in Scheme 62 using - 
propiolactone as the alkylating agent.  
 
 
 
Scheme 62: Proposed synthesis of cyclisation precursor 
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5 EXPERIMENTAL  
 
Instruments  
 
Analytical thin layer chromatography (TLC) was performed on Merck 60G UV254 pre coated 
glass-backed plates and visualised by UV (254 nm) or a variety of commonly used TLC dips. 
Infra red spectra were recorded as thin films (neat) on a Perkin Elmer 100 FTIR spectrometer. 
1H-NMR and 13C-NMR were recorded in the solvent stated at 300 and 400 MHz (1H-NMR) 
and 75 and 100 MHz (13C-NMR), respectively, using Bruker AV 300, Bruker AVIII 300 and 
Bruker AVIII 400 spectrometers. Chemical shifts are reported as δ values (ppm) referenced 
to tetramethylsilane. The term “stack” is used to describe a region where resonance arising 
from non-equivalent nuclei are coincident, and multiplet, m, is used to describe a region 
where resonances arising from a single nucleus (or equivalent nuclei) are coincident, but 
coupling constants cannot be readily assigned. 1H-NMR multiplets are assigned as follows: s 
= singlet, d = doublet, t = triplet, q = quartet, quin = quintet, sex = sextet, etc. Coupling 
constants are quoted to the nearest 0.5 Hz. Apparent doublets seen in aromatic protons are 
noted app d. In the case of unseparated isomers the ppm quoted is the major component 
with the minor component given in square brackets.  13C-NMR notations used are Ar = 
aromatic, Q = quaternary. Mass spectra were recorded on a Micromass ZABspec 
spectrometer utilizing electrospray ionisation in most cases and reported as m/z. HRMS 
were recorded on a Micromass LCT spectrometer using a lock incorporated in the mobile 
phase. 
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Chemicals and Reagents  
 
Tetrahydrofuran (THF) and diethyl ether (Et2O) were distilled from sodium benzophenone 
ketyl. Dichloromethane (CH2Cl2) was distilled from CaH2. Toluene was distilled from sodium 
and used immediately. Alternatively, dry solvents were drawn from a PureSolv EN solvent 
purification system. Other chemicals were used as purchased, unless otherwise stated. 
Aqueous solutions are saturated unless otherwise stated. Flash column chromatography was 
carried out using Merck 60 (40 - 60 μm mesh) silica gel.  
 
Evaporation and concentration under reduced pressure was carried out at (50 - 500 mBar). 
Residual solvent was removed under high vacuum (1 mBar).  
 
Reactions 
  
All reactions were carried out under an Argon atmosphere in flame-dried or oven-dried 
glassware where necessary. Molecular sieves (3 and 4 Å) were activated by flame-heating 
under high vacuum for 15 min and used immediately.  
Unless otherwise stated all reactions were followed by aqueous workup, extracted into an 
organic solvent (stated), dried with magnesium sulfate and concentrated under reduced 
pressure. 
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General procedures  
 
Solvent molarities are given with respect to the reactant used in 1 eq unless otherwise 
stated.  
 
 
Procedure A – methylation of amino acids  
 
Amino acid (1 eq) was dissolved in methanol (1 M) at 0 °C then thionyl chloride (1 eq) was 
added dropwise. The solution was stirred at 0 °C for 60 minutes then continued at room 
temperature for 72 hours. The reaction mixture was concentrated under reduced pressure 
to yield the target compound.  
 
Procedure B – Tosylation  
 
Amine (1 eq) was suspended in CH2Cl2 (0.6 M) at 0 °C and triethylamine (2 eq) was added 
dropwise. After stirring at 0 °C for 15 minutes p-toluene sulfonyl chloride (1 eq) [and DMAP 
(10 mol%) in some cases] in minimal CH2Cl2 was slowly added. The reaction mixture was 
stirred for the prescribed time, warming to room temperature. The mixture was 
concentrated under reduced pressure and the resulting residue taken up into ethyl acetate, 
precipitating a white solid which was removed by filtration under suction. The filtrate was 
washed with NaHCO3 and water. The aqueous layers were further extracted with ethyl 
acetate and the combined organic layers were dried over MgSO4, filtered and concentrated.  
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Procedure C – PCC oxidation  
 
To a stirred suspension of PCC (3 eq) in DCM (0.04 M) at room temperature was added 
alcohol (1 eq) in DCM (0.2 M) over 10 minutes. After stirring for the specified time, ether 
was added and stirring continued for a further 15 minutes. The solvents were carefully 
decanted then additional ether added to the residue to repeat the process twice more. The 
combined ether extracts were washed with brine then dried and filtered through a plug of 
silica before removing solvents.  
 
Procedure D – Wittig olefination 1  
 
To a solution of ylide precursor (2 eq) in THF (0.25 M) at 0 °C, was added potassium tert-
butoxide (2 eq). The mixture stirred for 30 minutes then aldehyde (1 eq) in chilled (0 °C) THF 
(0.65 M) was added to the ylide over 15 minutes inducing loss of the bright colour. After 15 
minutes at 0 °C the temperature was slowly raised to 50 °C for a further 20 hours. The 
mixture was cooled to ambient temperature before water and 1 M aq. HCl were added to 
dissolve the precipitate. The product was extracted twice with ethyl acetate, washed with 
brine then purified by column chromatography.  
 
Procedure E – N-alkylation  
 
Amine (1 eq) was dissolved in DMF (0.1 M) before cesium carbonate (1.5 eq) and 
halogenated alkyl group (1.5 eq) were added. The mixture was stirred at room temperature 
overnight before diluting with water and 1 M HCl. After 1 hour the products were extracted 
into ether and purified by column chromatography.  
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Procedure F – Swern oxidation  
 
Oxalyl chloride (1.1 eq) in DCM (0.4 M) was cooled to -78 °C. DMSO (2.4 eq) in DCM (2 M) 
was added dropwise and stirred for 10 minutes. A solution of alcohol (1 eq) in DCM (1 M) 
was added dropwise and the reaction stirred for a further 15 minutes. Triethylamine (5 eq) 
was added dropwise and after 15 minutes the mixture was allowed to warm to room 
temperature before quenching with water and extracting into DCM.  
 
Procedure G – Reductive amination  
 
Amine (1 eq) was dissolved in DCM (1.0 M) and sodium sulfate (1.02 eq) was added. 
Aldehyde (1 eq) in DCM (1.75 M) was added slowly and the mixture stirred at room 
temperature overnight. Sodium borohydride (1.5 eq) was added, immediately followed by 
anhydrous methanol (1.0 M). After 60 minutes the reaction was quenched with saturated 
NaHCO3 and the products extracted into DCM and washed with brine.  
 
Procedure H – Wittig Olefination 2  
 
To a solution of ylide precursor (3 eq) in THF (0.05 M) at 0 °C, was added a solution of n-
butyllithium [1.6 M/hex] (3 eq) dropwise. The mixture stirred for 15 minutes before cooling 
to -78 °C then aldehyde (1 eq) in chilled (0 °C) THF (0.1 M) was added to the ylide dropwise 
inducing loss of the bright colour. After 15 minutes at -78 °C the temperature was slowly 
raised to room temperature and the mixture stirred until no more aldehyde was visible by 
TLC. Water was added and the product was extracted with ethyl acetate, washed with brine 
then purified by column chromatography.  
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Procedure I – Addition of Grignard reagent  
 
A solution of imine (1 eq) in DCM (0.25 M) was cooled to -50 °C. A solution of Grignard 
reagent (3 eq) was added dropwise. The mixture was allowed to warm to room temperature 
overnight (The cooling Dewar was left in position but no further dry ice was added). The 
reaction was quenched with saturated aq. ammonium chloride and products extracted into 
ethyl acetate.  
 
Procedure J – Brønsted acid mediated cyclisation.  
 
To a solution of linear precursor (1 eq) in DCM (0.033 M) at -78 °C was added concentrated 
HCl [~37 %] (3 eq). After 24 - 48 hours the reaction was quenched with water and the 
products extracted into DCM.  
 
Procedure K – Lewis acid mediated cyclisation 
  
Linear precursor (1 eq) was dissolved in DCM (0.05M) and cooled to the appropriate 
temperature before a solution of MeAlCl2 [1M] (2 eq) was added dropwise. After the 
prescribed time the reaction was quenched with water and the products extracted into DCM. 
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57  
(S)-3-Hydroxy-1-methoxy-1-oxopropan-2-ammonium chloride40 
 
 
General procedure A was followed using the following amounts:  
Methanol (1 M, 300 mL)  
Thionyl chloride (1 eq, 285.71 mmol, 20.75 mL)  
L-serine (1 eq, 285.71 mmol, 30.00 g)  
Yield: 4.28 g (>99 %) white solid 
 
mp 164-165 °C [lit. 161-162 °C]; Rf 0.36 (50 % MeOH in EtOAc); IR (cm
-1) 3344 (OH), 2918 
(NH3
+), 1745 (CO2Me); 
1H-NMR (300 MHz, D2O)  4.25 (dd, 1H, J = 3.5, 4.0 Hz (CH)), 4.07 (dd, 
1H, J = 4.0, 12.5 Hz (CHH)), 3.96 (dd, 1H, J = 3.5, 12.5 Hz (CHH)), 3.82 (s, 3H (OCH3)); 
13C-NMR 
(75 MHz, D20)  167.5 (C=O), 57.91 (CH2), 53.38 (NCH), 52.39 (OCH3); m/z (ES) [M+H]
+ 120.1; 
C4H10NO3 requires 120.0661, found 120.0660 
 
Racemate:  
mp 135-138 °C; IR (cm-1) 3394 (OH), 2907 (NH3
+), 1739 (CO2Me); 
1H-NMR (300 MHz, D2O) 
4.26 (dd, 1H, J = 3.5, 4.0 Hz (CH)), 4.09 (dd, 1H, J = 4.0, 12.5 Hz (CHH)), 4.00 (dd, 1H, J = 3.5, 
12.5 Hz (CHH)), 3.84 (s, 3H (OCH3)); 
13C-NMR (75 MHz, D2O)  168.9 (C=O), 59.2 (CH2), 54.7 
(NCH), 53.7 (OCH3); m/z (EI) [M+H]
+ 120 
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58  
(S)-Methyl-3-hydroxy-2-(4-methylphenylsulfonamido)propanoate41  
 
 
 
General procedure B was followed with the following amounts used:  
Methyl serinate hydrochloride (51) (1 eq, 121.74 mmol, 18.94 g)  
DCM (0.6 M, 400 mL)  
Triethylamine (2 eq, 243.48 mmol, 33.94 mL)  
p-Toluene sulfonyl chloride (1 eq, 121.74 mmol, 23.21 g)  
Time: 48 hours  
Crude product was recrystallized from EtOAc/hexanes yielding a white solid (28.63 g, 86 %)  
 
mp 87-88 °C [lit. 92-93 °C]; Rf 0.68 (25 % Hexane in EtOAc); IR (cm
-1) 3480 (OH), 3269 (NH), 
1743 (CO2Me), 1434 (Ar), 1327/1161 (SO2N); 
1H-NMR (300 MHz, CDCl3)  7.74 (app d, 2H 
(ArH)), 7.32 (app d, 2H (ArH)), 5.49 (d, 1H, J = 7.5 Hz (NH)), 3.99-3.94 (m, 1H (CH)), 3.89 (dd, 
2H, J = 3.5, 6.5 Hz (CH2)), 3.63 (s, 3H (OCH3)), 2.43 (s, 3H, (ArCH3)), 1.56 (t, 1H, J = 6.5 Hz 
(OH)); 13C-NMR (75 MHz, CDCl3)  170.2 (C=O), 143.9 (ArSO2), 136.1 (ArCH3), 129.8 (ArHCSO2), 
127.2 (ArHCCH3), 63.7 (CH2), 57.6 (NCH), 52.9 (OCH3), 21.5 (ArCH3); m/z (ES) [M+Na]
+ 296.1; 
C11H15NO5SNa requires 296.0569, found 296.0568 
 
Racemate:  
mp 81-83 °C; IR (cm-1) 3487 (OH), 3272 (NH), 1745 (CO2Me), 1427 (Ar), 1326/1159 (SO2N); 
1H-NMR (300 MHz, CDCl3) 7.74 (app d, 2H (ArHSO2)), 7.31 (app d, 2H (ArHCH3)) 5.54 (d, 1H, 
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J = 7.5 Hz (NH)), 3.97 (dt, 1H, J = 6.5, 7.5 Hz (CH)), 3.89 (dd, 2H, J = 3.5, 6.5 Hz (CH2)), 3.63 (s, 
3H (OCH3)), 2.43 (s, 3H (ArCH3)), 2.16 (t, 1H, J = 6.5 Hz (OH)); 
13C-NMR (75 MHz, CDCl3)  
170.2 (C=O), 143.9 (ArSO2), 136.4 (ArCH3), 129.8 (ArHCSO2), 127.2 (ArHCCH3), 63.7 (CH2), 
57.6 (NCH), 53.0 (OCH3), 21.6 (ArCH3); m/z (ES) [M+Na]
+ 296.0; C11H15NO5SNa requires 
296.0569, found 296.0561 
 
59  
(S)-Methyl-3-(tert-butyldimethylsilyloxy)-2-(4-methylphenylsulfonamido)propanoate44  
 
 
(N-Tosyl)-methyl serinate (58) (1 eq, 3.66 mmol, 1.00 g) was dissolved in DCM (10 mL) at 0 °C. 
Imidazole (2 eq, 7.32 mmol, 498 mg), TBSCl (1.25 eq, 4.57 mmol, 697 mg) and DMF (2 mL) 
were added successively. The reaction mixture was stirred continuously, whilst warming to 
room temperature, for 72 hours. The reaction was quenched with saturated NH4Cl (aq.) (15 
mL) at 0 °C, diluted with water (100 mL) and the product extracted with diethyl ether (3 x 50 
mL). The combined organic layers were washed with brine (50 mL), dried over MgSO4, 
filtered and concentrated to give a colourless oil, which solidified on standing. This was 
recrystallised from EtOAc/Hex, concentrated to a yellow oil, then separated by flash 
chromatography eluting with 25 % EtOAc in hexane. The product was concentrated to give a 
white solid (0.71 g, 51 %).  
 
One-pot synthesis from methyl serinate hydrochloride:  
To a stirred suspension of methyl serinate hydrochloride (57) (1 eq, 6.43 mmol, 1 g) and p-
toluene sulfonyl chloride (1 eq, 6.43 mmol, 1.23 g) in a mixed solvent of chloroform and 
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dichloromethane (1:1, 6 mL total) at 0 °C, was added triethylamine (2 eq, 12.86 mmol, 1.79 
mL). The mixture was stirred at room temperature for 60 hours. Imidazole (2 eq, 12.86 mmol, 
0.88 g), TBDMSCl (1 eq, 6.43 mmol, 0.97 g) and DMF (0.6 mL) were added successively at 
0 °C and the reaction mixture stirred at room temperature for 48 hours. 
 
Saturated ammonium chloride solution (3 mL) was added dropwise with vigorous stirring at -
5 °C. The product was extracted with hexane and washed with 5 % citric acid (2 x 15 mL), 
water (2 x 15 mL), saturated NaHCO3 (10 mL) and water (10 mL). The organic layer was dried 
over MgSO4, filtered and concentrated to yield a pale yellow oil. Flash chromatography over 
silica with hexane and ethyl acetate (4:1) gave a translucent white solid (0.64 g, 26 %).  
 
mp 45 - 47 °C [lit. 56-57 °C]; Rf 0.71 (40 % EtOAc in hexane); IR (cm
-1) 3270 (NH), 1743 
(CO2Me), 1434 (Ar), 1327/1162 (SO2N); 
1H-NMR (300 MHz, CDCl3)  7.73 (app d, 2H (ArH)), 
7.29 (app d, 2H (ArH)), 5.36 (d, 1H, J = 9.0 Hz (NH)), 4.52-4.00 (m, 1H (CH)), 3.95 (dd, 1H, J = 
3.0, 10.0 Hz (CHH)), 3.76 (dd, 1H, J = 3.5, 10.0 Hz (CHH)), 3.54 (s, 3H (OCH3)), 2.42 (s, 3H 
(ArCH3)), 0.82 (s, 9H (Si
tBu)), 0.00 (s, 3H (SiMe)), -0.02 (s, 3H (SiMe)); 13C-NMR (75 MHz, 
CDCl3) 171.5 (C=O), 144.7 (ArSO2), 139.0 (ArCH3), 130.7 (ArHCSO2), 128.2 (ArHCCH3), 65.6 
(CH2), 58.6 (NCH), 53.5 (OCH3), 26.7 (SiCCH3), 22.6 (ArCH3), 19.7 (SiCCH3), -3.7 (SiCH3); m/z 
(ES) [M+Na]+ 410.1; C17H29NO5SSiNa requires 410.1433, found 410.1431  
 
Racemate:  
mp 80-82 °C; Rf 0.68 (33 % EtOAc in hexane); 
1H-NMR (300 MHz, CDCl3) 7.62 (app d, 2H 
(ArHSO2)), 7.18 (app d, 2H (ArHCH3)), 5.24 (d, 1H, J = 9.0 Hz (NH)), 3.92 (ddd, 1H, J = 3.0, 3.5, 
9.0 Hz (CH)), 3.84 (dd, 1H, J = 3.0, 10.0 Hz (CHH)), 3.65 (dd, 1H, J = 3.5, 10.0 Hz (CHH)), 3.44 (s, 
3H (OCH3)), 2.31 (s, 3H (ArCH3)), 0.71 (s, 9H (Si
tBu)), -0.11 (s, 3H (SiMe)), -0.13 (s, 3H (SiMe)); 
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13C-NMR (75 MHz, CDCl3) 170.0 (C=O), 143.5 (ArSO2), 137.2 (ArCH3), 129.6 (ArHCSO2), 
127.1 (ArHCCH3), 64.5 (CH2), 57.6 (NCH), 52.4 (OCH3), 25.6 (SiCCH3), 21.5 (ArCH3), 18.1 
(SiCCH3), -5.6 (SiCH3); m/z (ES) [M+Na]
+ 410.1; C17H29NO5SSiNa requires 410.1433, found 
410.1440  
 
60  
N-Tosyl-(R)-2-amino-3-(tert-butyldimethylsilyloxy)propan-1-ol44  
 
 
To [N,O]-protected methyl serinate (59) (1 eq, 100.96 mmol, 39.13 g) in THF (300 mL) at 0 °C, 
was added portionwise lithium borohydride (1.25 eq, 126.20 mmol, 2.75 g). The solution was 
allowed to warm to room temperature then stirred for an additional 48 hours at a slightly 
elevated temperature (40 - 50 °C) until no more starting material was seen by TLC.  
 
The reaction mixture was cooled to 0 °C then quenched with slow addition of sat. NH4Cl (aq). 
The mixture was diluted with water (200 mL) then extracted with ethyl acetate (250 mL) and 
washed with brine (200 mL). The combined aqueous layers were further extracted with 
EtOAc (3 x 100 mL) then the organic layers were dried over MgSO4, filtered and concentrated 
to yield 35.16 g (97 %) as a dark brown oil. An analytical sample was purified by column 
chromatography, eluting with 25 % EtOAc in hexane to give a colourless oil.  
 
Rf 0.40 (50 % EtOAc in hexane); IR (cm
-1) 3518 (OH), 3286 (NH), 2929/2857 (CH, CH2), 
1329/1158 (SO2N); 
1H-NMR (300 MHz, CDCl3)  7.76 (app d, 2H (ArHSO2)), 7.30 (app d, 2H 
(ArHCH3)), 5.19 (d, 1H, J = 7.5 Hz (NH)), 3.63 (dd, 2H, J = 4.0, 10.5 Hz (CH2OH)), 3.52 (dd, 2H, J 
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= 5.0, 10.0 Hz (CH2OSi)), 3.30-3.24 (m, 1H (CH)), 2.42 (s, 3H (ArCH3)), 1.71 (brs, 1H (OH)), 0.83 
(s, 9H (tBuSi)), -0.00 (s, 3H (MeSi)), -0.02 (s, 3H (MeSi)) [literature agreement]; 13C-NMR (75 
MHz, CDCl3) 143.6 (ArSO2), 137.5 (ArCH3), 129.8 (ArHCSO2), 127.1 (ArHCCH3), 63.5 (CH2OSi), 
63.0 (CH2OH), 55.5 (NCH), 25.8 (ArCH3), 21.5 (SiCCH3), 18.1 (SiCCH3), -5.6 (SiCH3); m/z (ES) 
[M+Na]+ 382.2; C16H29NO4SSiNa requires 382.1484, found 382.1480 
 
Racemate:  
mp 58-61 °C; Rf 0.55 (33 % EtOAc in hexane); IR (cm
-1) 3479 (OH), 3211 (NH), 2930-2850 
(CH2CHCH2), 1304/1157 (SO2N), 1244 (OH), 1105 (C-OH); 
1H-NMR (300 MHz, CDCl3) 7.76 
(app d, 2H (ArHSO2)), 7.29 (app d, 2H (ArHCH3)), 5.17 (d, 1H, J = 7.5 Hz (NH)), 3.63 (dd, 2H, J = 
4.0, 10.0 Hz (CH2OH)), 3.52 (dd, 2H, J = 5.0, 10.0 Hz (CH2OSi)), 3.31-3.22 (m, 1H (CH)), 2.41 (s, 
3H (ArCH3)), 1.71 (brs, 1H (OH)), 0.83 (s, 9H (Si
tBu)), -0.00 (s, 3H (SiMe)), -0.01 (s, 3H (SiMe)); 
13C-NMR (75 MHz, CDCl3)  143.5 (ArSO2), 137.5 (ArCH3), 129.7 (ArHCSO2), 127.0 (ArHCCH3), 
63.3 (CH2OSi), 62.8 (CH2OH), 55.5 (NCH), 25.7 (SiCCH3), 21.5 (ArCH3), 18.1 (SiCCH3), -5.6 
(SiCH3); m/z (ES) [M+Na]
+ 382.2; C16H29NO4SSiNa requires 382.1484, found 382.1487 
 
61  
N-Tosyl-(S)-2-amino-3-(tert-butyldimethylsilyloxy)propanal  
 
 
General procedure C was followed using the following quantities:  
PCC (3 eq, 16.69 mmol, 3.60 g) in DCM (125 mL)  
Protected serinol (1 eq, 5.56 mmol, 2 g) in DCM (25 mL)  
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Time: 4 ½ hours  
Yield: brown oil (1.68 g, 84.5 %)  
 
Rf 0.65 (40 % EtOAc in hexane); IR (cm
-1) 3280 (br) (NH), 2929 (C=O), 1333/1159 (SO2N); 
1H-
NMR (300 MHz, CDCl3)  9.54 (s, 1H, (CHO)), 7.74 (app d, 2H (ArHSO2)), 7.30 (app d, 2H 
(ArHCH3)), 5.47 (d, 1H, J = 6.5 Hz (NH)), 4.09 (dd, 1H, J = 3.5, 10.5 Hz (CHHOSi), 3.86-3.80 (m, 
1H (CH)), 3.71 (dd, 1H, J = 5.0, 10.5 Hz (CHHOSi)), 2.42 (s, 3H (ArCH3)), 0.82 (s, 9H (
tBuSi)), 
0.014 (s, 3H (MeSi)), 0.007 (s, 3H (MeSi)); 13C-NMR (100 MHz, CDCl3) 198.3 (CHO), 134.5 
(Ar), 129.8 (Ar), 129.7 (Ar), 129.3 (Ar), 128.9 (Ar), 128.7 (Ar), 127.4 (Ar), 127.1 (Ar), 62.3 
(CHCHO), 36.4 (PhCH2CH), 21.5 (ArCH3); m/z (ES) [M+Na]
+ 326.1; C16H17NO3SNa requires 
326.0827, found 326.0819 
 
69a  
(S)-2-Amino-3-phenylpropan-1-ol109  
 
 
To a suspension of sodium borohydride (2.4 eq, 363.22 mmol, 13.74 g) in THF (1 M, 150 mL) 
at 0 °C was added L-phenylalanine (1 eq, 151.34 mmol, 25.00 g). A solution of iodine (1 eq, 
151.34 mmol, 38.41 g) in THF (1.9 M, 80 mL) was added dropwise over 3 hours with 
immediate loss of the iodine colouration on contact with the stirring mixture. The reaction 
was heated at reflux for 20 hours then chilled to 0 °C and methanol (1.5 M, 100 mL) was 
added cautiously. Vigorous gas evolution and dissolution of the precipitate were observed. 
The solvents were removed in vacuo to give a thick white slurry which was dissolved in 20 % 
KOH solution (300 mL) and stirred at room temperature for 16 hours. The solution was 
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extracted with DCM (4 x 200 mL) and the combined organic layers washed with water (2 x 
200 mL) and brine (200 mL). The solution was dried over MgSO4, filtered and concentrated 
to yield a pale green solid (25.71 g, 112 % crude). The product was recrystallised from 
toluene to give a white solid (17.74 g, 78 %).  
 
Rf 0.32 (5 % DCM in MeOH); mp 89-91 °C [lit. 91-92 °C]; IR (cm
-1) 3356/3299 (NH2), 3022 
(br) (OH), 1064 (C-OH); 1H-NMR (300 MHz, CDCl3) 7.37-7.21 (stack, 5H (ArH)), 3.67 (dd, 1H, 
J = 4.0, 10.5 Hz (CHHOH)), 3.41 (dd, 1H, J = 7.0, 10.5 Hz (CHHOH)), 3.19-3.11 (m, 1H (NCH)), 
2.83 (dd, 1H, J = 5.0, 13.5 Hz (CHHPh)), 2.56 (dd, 1H, J = 8.5, 13.5 Hz (CHHPh)), 1.72 (brs, 3H 
(OH, NH2)); 
13C-NMR (100 MHz, CDCl3) 138.7 (QAr), 129.2 (Ar), 128.6 (Ar), 126.4 (Ar), 66.4 
(CH2OH), 54.1 (CH), 41.0 (PhCH2); m/z (EI) [M – CH3O]
+ 120.0 
 
69c  
(S)-2-Amino-3-methylbutan-1-ol110 
 
 
To a suspension of sodium borohydride (2.4 eq, 204.87 mmol, 7.75 g) in THF (0.9 M, 222 mL) 
at 0 °C was added L-valine (1 eq, 85.36 mmol, 10.0 g). A solution of iodine (1 eq, 85.36 mmol, 
21.67 g) in THF (1.5 M, 56 mL) was added dropwise over 30 minutes with immediate loss of 
the iodine colouration on contact with the stirring mixture. After evolution of gas was 
complete, the reaction was heated at reflux for 20 hours then chilled to 0 °C and methanol 
was added cautiously until complete dissolution of the precipitate was observed. After 30 
minutes the solvents were removed in vacuo to give a thick white slurry which was dissolved 
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in 20 % KOH solution (170 mL) and stirred at room temperature for 16 hours. The solution 
was extracted with DCM (3 x 170 mL). The product was distilled with the Kugelrohr 
apparatus (85 °C, ~5 mmHg) to give a white solid (5.66 g, 64 %).  
 
mp 30-32 °C; IR (cm-1) 3338/3284 (NH2), 3081 (br) (OH), 1606 (NH2); 
1H-NMR (300 MHz, 
CDCl3) 3.64 (dd, 1H, J = 4.0, 10.5 Hz (CHHOH)), 3.29 (dd, 1H, J = 9.0, 10.5 Hz (CHHOH)), 2.56 
(ddd, 1H, J = 4.0, 6.5, 9.0 Hz (NCH)), 1.90 (brs, 3H (OH, NH2)), 1.56 (dsept, 1H, J = 4.0, 6.5 Hz 
(CHMe2)), 0.93 (d, 3H, J = 4.0 Hz (Me)), 0.91 (d, 3H, J = 4.0 Hz (Me)) [literature agreement]; 
13C-NMR (100 MHz, CDCl3) 64.7(CH2OH), 58.5 (CHN), 31.4 (CHMe2), 19.3 (Me), 18.4 (Me); 
m/z (EI) [M – H3O]
+ 84.0 
 
70  
N-Tosyl-(S)-2-amino-3-phenylpropan-1-ol 58 
 
 
General procedure B was followed using the following amounts:  
Phenylalaninol (69a) (1 eq, 89.23 mmol, 13.50 g)  
DMAP (10 mol%, 8.92 mmol, 1.09 g)  
Triethylamine (2 eq, 178.56 mmol, 24.89 mL)  
DCM (0.45 M, 200 mL)  
Tosylchloride (1.05 eq, 93.74 mmol, 17.87 g)  
DCM (0.9 M, 100 mL)  
Time: 20 hours  
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The crude product was purified by column chromatography, eluting with 5 % DCM in 
methanol to give pure product as a pale yellow oil which solidified on standing (26.92 g, 
99 %).  
 
Rf 0.47 (5 % MeOH in DCM); mp 58-60 °C [lit. 63-67 °C]; IR (cm
-1) 3449 (OH), 3156 (Ar), 
1599 (NH), 1381/1158 (SO2N), 1035 (C-OH); 
1H-NMR (300 MHz, CDCl3) 7.59 (app d, 2H 
(ArH)), 7.20-7.14 (stack, 5H (ArH)), 7.00-6.96 (stack, 2H (ArH)), 5.26 (d, 1H, J = 7.0 Hz (NH)), 
3.63 (dd, 1H, J = 4.0, 11.0 Hz (CHHOH)), 3.54-3.44 (stack, 2H (CHHOH, NCH)), 2.77 (dd, 1H, J = 
7.0, 13.5 Hz (CHHPh)), 2.66 (dd, 1H, J = 7.0, 13.5 Hz (CHHPh)), 2.40 (s, 1H (ArCH3)), 1.49 (brs, 
1H (OH)); 13C-NMR (100 MHz, CDCl3) 143.3 (QAr), 137.0 (QAr), 136.8 (Ar), 129.6 (ArH), 
129.1 (ArH), 128.5 (ArH), 126.9 (ArH), 126.6 (ArH), 63.9 (CH2OH), 56.7 (CH), 37.7 (CH2Ph), 
21.5 (ArCH3); m/z (ES) [M+Na]
+ 328.1; C16H19NO3SNa requires 328.0983, found 328.0968 
 
71  
N-Tosyl-(S)-2-amino-3-phenylpropanal  
 
 
General procedure C was followed using the following quantities:  
PCC (3 eq, 2.46 mmol, 529 mg) in DCM (20 mL)  
Alcohol 70 (1 eq, 0.82 mmol, 250 mg) in DCM (5 mL)  
Time: 3½ hours  
The crude product was purified by column chromatography, eluting with 40 % EtOAc in 
hexane, to yield a pale yellow oil. (196 mg, 79 %)  
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Rf 0.41 (40 % EtOAc in hexane); IR (cm
-1) 3267 (NH), 1705 (C=O), 1598 (NH), 1331/1221 
(SO2N); 
1H-NMR (300 MHz, CDCl3)  9.54 (s, 1H (CHO)), 7.61 (app d, 2H (ArH)), 7.27- 7.17 
(stack, 5H (ArH)), 7.08-7.02 (stack, 2H (ArH)), 5.15 (d, 1H, J = 6.0 Hz (NH)), 4.04 (dt, 1H, J = 6.0, 
6.5 Hz (CHN)), 3.05 (d, 2H, J = 6.5 Hz (CH2)), 2.42 (s, 1H (ArCH3)); 
13C-NMR (100 MHz, CDCl3) 
198.3 (CHO), 134.5 (Ar), 129.8 (Ar), 129.7 (Ar), 129.3 (Ar), 128.9 (Ar), 128.7 (Ar), 127.4 (Ar), 
127.1 (Ar), 62.3 (CHCHO), 36.4 (PhCH2), 21.5 (ArCH3); m/z (ES) [M+Na]
+ 326.1; C16H17NO3SNa 
requires 326.0827, found 326.0819  
 
72  
N-Tosyl-(R)-1-(tert-butyldimethylsilyloxy)but-3-en-2-amine  
 
 
General procedure D was followed using the following amounts:  
Methyltriphenylphosphonium iodide (2 eq, 4.20 mmol, 1.70 mg) in THF (2.8 mL)  
Potassium tert-butoxide (2 eq, 4.20 mmol, 471 mg)  
Aldehyde 61 (1 eq, 1.40 mmol, 500 mg) in chilled THF (2.8 mL)  
Ylide colour: bright yellow  
Purification was by column chromatography, eluting with 20 % ethyl acetate in hexane to 
yield a yellow oil. (78 mg, 16 %)  
 
Rf 0.50 (20 % EtOAc in hexane); IR (cm
-1) 1623 (=), 1503(Ar), 1360/1164 (SO2N), 1057 (SiO); 
1H-NMR (300 MHz, CDCl3) 7.75 (app d, 2H (ArH)), 7.30 (app d, 2H (ArH)), 5.68 (ddd, 1H, J = 
6.5, 10.5, 17.0 Hz (RCH=)), 5.15 (dd, 1H, J = 1.5, 10.5 Hz (=CHH)), 5.10 (dd, 1H, J = 1.5, 17.0 Hz 
(=CHH)), 5.02 (d, 1H, J = 6.0 Hz (NH)), 3.85-3.64 (m, 1H (CH)), 3.52 (d, 1H, J = 4.5 Hz (CHHO)), 
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3.51 (d, 1H, J = 5.5 Hz (CHHO)), 2.43 (s, 3H (ArCH3)), 0.85 (s, 9H (
tBu)), 0.01 (s, 3H (Me)), -0.01 
(s, 3H (Me)); 13C-NMR (100 MHz, CDCl3) 141.5 (QAr), 137.6 (QAr), 131.4 (CH=), 129.3 (ArH), 
128.3 (ArH), 117.7 (=CH2), 70.7 (CH2O), 56.7 (CHN), 30.6 (Q
tBu), 25.9 (tBu), 21.3 (ArCH3), -2.3 
(Me); m/z (ES) [M+Na]+ 378.2 
 
73  
N-Tosyl-(S)-1-phenylbut-3-en-2-amine 
 
 
General procedure D was followed using the following amounts:  
Methyltriphenylphosphonium iodide (2 eq, 1.32 mmol, 533 mg) in THF (2.5 mL)  
Potassium tert-butoxide (2 eq, 1.32 mmol, 148 mg)  
Aldehyde 71 (1 eq, 0.66 mmol, 200 mg) in chilled THF (1 mL)  
Ylide colour: bright yellow  
Purification was by column chromatography, eluting with 5 % methanol in DCM to yield a 
yellow oil. (162 mg, 82 %)  
 
Rf 0.37 (20 % EtOAc in hexane); IR (cm
-1) 2979 (NH), 1718 (=), 1156 (SO2N); 
1H-NMR (300 
MHz, CDCl3) 7.60 (app d, 2H (ArH)), 7.22 (stack, 5H (ArH)), 7.03 (app dd, 2H (ArH)), 5.68 
(ddd, 1H, J = 6.0, 10.5, 17.0 Hz (RCH=)), 5.04 (d, 1H, J = 17.0 Hz (=CHH)), 5.02 (d, 1H, J = 10.5 
Hz (=CHH)), 4.46 (d, 1H, J = 7.5 Hz (NH)), 4.01 (dddd, 1H, J = 5.0, 5.5, 6.0, 7.5 Hz (CH)), 2.84 
(dd, 1H, J = 5.0, 12.5 Hz (CHHPh)), 2.78 (dd, 1H, J = 5.5, 12.5 Hz (CHHPh)), 2.41 (s, 3H (ArCH3)) 
[lit. agreement]112; 13C-NMR (100 MHz, CDCl3)143.0 (QAr), 138.0 (QAr), 137.2 (CH=), 136.1 
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(QAr), 129.5 (Ar), 129.4 (Ar), 128.5 (Ar), 127.1 (Ar), 126.8 (Ar), 116.3 (=CH2), 56.9 (CH), 42.0 
(CH2), 21.5 (CH3); m/z (ES) [M]
+ 301.0  
 
75  
N-Tosyl-(S)-4-methyl-1-phenylpent-3-en-2-amine  
 
 
General procedure D was followed using the following quantities:  
Isopropyltriphenylphosphonium iodide (2 eq, 1.65 mmol, 712 mg) in THF (1.70 mL)  
Potassium tert-butoxide (2 eq, 1.65 mmol, 185 mg)  
Aldehyde 71 (1 eq, 0.82 mmol, 250 mg) in chilled THF (1 mL)  
Ylide colour: Deep red  
Purification was by column chromatography, eluting with 10 % EtOAc in hexane to give a 
yellow oil. (162 mg, 82 %)  
 
IR (cm-1) 2917/2849 (NH), 1739 (=), 1160 (SO2N); 
1H-NMR (300 MHz, CDCl3) 7.81 (app d, 
2H (ArH)), 7.50-6.95 (stack, 7H (ArH)), 5.54 (d, 1H, J = 9.5 Hz (CH=)), 5.26 (d, 1H, J = 8.5 Hz 
(NH)), 4.14 (dddd, 1H, J = 6.0, 7.5, 8.5, 9.5 Hz (CH)), 3.45 (s, 3H (ArCH3)), 2.95 (dd, 1H, J = 6.0, 
14.0 Hz (CHH)), 2.85 (dd, 1H, J = 7.5, 14.0 Hz (CHH)), 2.42 (s, 3H (CH3)), 2.39 (s, 3H (CH3)), 
2.33 (s, 3H (ArCH3)); 
13C-NMR (100 MHz, CDCl3) 141.5 (QAr), 137.6 (QAr), 136.7 (=CMe2), 
136.6 (QAr), 130.2 (ArH), 129.7 (ArH), 129.4 (ArH), 128.7 (ArH), 127.8 (ArH), 126.9 (=CH), 
57.3 (CH), 43.5 (CH2), 21.7 (CH3), 21.5 (CH3), 21.5 (ArCH3); m/z (ES) [M+Na]
+ 352.1 
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76  
N-Tosyl-methyl-(S,E)-4-amino-5-phenylpent-2-enoate  
 
 
To a solution of aldehyde 71 (1 eq, 1.64 mmol, 500 mg) in DCM (13 mL) was added methyl 
(triphenylphosphoranylidene)acetate (2 eq, 3.28 mmol, 1.10 g). The reaction was stirred at 
RT overnight. The solvent was removed to yield a pink solid which was purified by column 
chromatography, eluting with 40 % EtOAc in hexane to give a white solid. (240 mg, 48 %)  
 
Rf 0.54 (40 % EtOAc in hexane); IR (cm
-1) 3259 (NH), 1702 (unsaturated ester), 1597 (NH), 
1303/1147 (SO2N), 928 (trans =); 
1H-NMR (300 MHz, CDCl3) 7.57 (app d, 2H (ArH)), 7.21 
(stack, 5H (ArH)), 6.99 (stack, 2H (ArH)), 6.76 (dd, 1H, J = 6.0, 15.5 Hz (=CHCH)), 5.81 (dd, 1H, 
J = 1.5, 15.5 Hz (=CHCO)), 4.47 (d, 1H, J = 7.5 Hz (NH)), 4.14 (ddt, 1H, J = 6.0, 6.5, 7.5 Hz (CH)), 
3.70 (s, 3H (OCH3)), 2.81 (dd, 2H, J = 6.5, 10.0 Hz (CHH)), 2.79 (dd, 2H, J = 6.5, 10.0 Hz (CHH)), 
2.41 (s, 3H (ArCH3)); 
13C-NMR (100 MHz, CDCl3) 166.2 (C=O), 146.4 (=CHCH), 143.5 (QAr), 
137.1 (QAr), 135.2 (QAr), 129.5 (ArH), 129.4 (ArH), 128.7 (ArH), 127.1 (ArH), 126.8 (ArH), 
122.0 (=CHC=O), 55.5 (CH), 51.7 (OCH3), 41.1 (CH2), 21.5 (ArCH3); m/z (ES) [M+Na]
+ 382.1; 
C19H21NO4SNa requires 382.1089, found 382.1093  
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79  
N-Tosyl-(S)-2-((3-(tert-butyldimethylsilyloxy)propyl)amino)-3-phenylpropan-1-ol  
 
 
Procedure E was followed using the following amounts:  
Amine 70 (1 eq, 6.55 mmol, 2.00 g) in anhydrous DMF (65 mL)  
Cesium carbonate (1.5 eq, 9.82 mmol, 3.20 g)  
tert-Butyl(3-iodopropoxy)dimethylsilane (1.15 eq, 7.53 mmol, 2.26 g) in minimal DMF  
Yield: colourless oil (1.13g, 36 %)  
 
Rf 0.90 (50 % EtOAc in hexane); IR (cm
-1) 3511 (OH), 2928 (NR3), 1599 (Ar), 1254/833 
(SiMe2), 1152 (SO2N), 1088 (C-O); 
1H-NMR (300 MHz, CDCl3)  7.68 (app d, 2H (ArH)), 7.21 
(stack, 5H, ArH)), 7.02 (app dd, 2H (ArH)), 4.00 (ddt, 1H, J = 4.0, 5.0, 9.5 Hz (CH)), 3.69 (stack, 
4H, (CH2OH, CH2N)), 3.40 (t, 2H, J = 7.5 Hz (CH2OSi)), 2.73 (dd, 1H, J = 9.5, 13.5 Hz (CHHPh)), 
2.54 (dd, 1H, J = 5.0, 13.5 Hz (CHHPh)), 2.41 (s, 3H, (ArCH3)), 1.93 (m, 2H (CH2CH2N)), 1.65 
(brs, 1H, (OH)), 0.91 (s, 9H (SitBu)), 0.07 (s, 6H (SiMe)) ; 13C-NMR (100 MHz, CDCl3) 143.3 
(QAr), 137.7 (QAr) 137.6 (QAr), 129.7 (ArH), 129.0 (ArH), 128.6 (ArH), 127.3 (ArH), 126.6 
(ArH), 62.4 (CH2OH), 62.1 (CH), 60.4 (CH2OSi), 41.8 (CH2N), 35.8 (CH2Ph), 34.0 (CH2CH2N), 
25.9 (SitBu), 21.5 (ArCH3), 18.3 (QSi
tBu), -5.3 (SiCH3); m/z (ES) [M+Na]
+ 500.3; C25H39NO4SiSNa 
requires 500.2267, found 500.2261 
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80  
N-Tosyl-(S)-2-((3-(tert-butyldimethylsilyloxy)propyl)amino)-3-phenylpropanal 
 
 
General procedure C was followed using the following quantities:  
PCC (3 eq, 0.63 mmol, 135 mg) in DCM (5 mL)  
Alcohol 79 (1 eq, 0.21 mmol, 100 mg) in DCM (1 mL)  
Time: 20 hours  
Purified by column chromatography, eluting with 25 % EtOAc in hexane, to yield a yellow 
residue (37 mg, 37 %)  
 
Rf 0.91 (50 % EtOAc in hexane); IR (cm
-1) 2931 (NR3), 16.2 (Ar), 1256/830 (SiMe), 1153 
(SO2N), 1730 (CHO); 
1H-NMR (300 MHz, CDCl3) 9.69 (s, 1H (CHO)), 7.55 (app d, 2H (ArH)), 
7.20 (stack, 5H (ArH)), 7.07 (stack, 2H, (ArH)), 4.54 (m, 1H, (CH)), 3.56 (stack, 5H (CH2OSi, 
CH2N, CHHPh)), 2.76 (dd, 1H, J = 8.0, 14.5 Hz (CHHPh)), 2.41 (s, 3H (ArCH3)), 1.70 (m, 2H 
(CH2CH2N)), 0.87 (s, 9H (Si
tBu)), 0.02 (s, 3H (SiMe)), 0.02 (s, 3H (SiMe)); 13C-NMR (100 MHz, 
CDCl3) 199.0 (CHO), 143.6 (QAr), 137.2 (QAr), 137.1 (QAr), 129.7 (ArH), 129.0 (ArH), 128.6 
(ArH), 127.3 (ArH), 126.7 (ArH), 68.2 (CH), 60.1 (CH2O), 44.8 (CH2N), 33.2 (CH2CH2N), 29.7 
(CH2Ph), 25.9 (Si
tBu), 21.5 (ArCH3), 18.2 (QSi
tBu), -5.4 (SiMe); m/z (ES) [M+Na]+ 498.3; 
C25H37NO4SiSNa requires 498.2210, found 498.2107 
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83  
(S)-1-Methoxy-1-oxo-3-phenylpropan-2-aminium chloride113 
 
 
 
General procedure A was followed using the following amounts:  
L-phenylalanine (1 eq, 151.34 mmol, 25.00 g)  
Methanol (1 M, 150 mL)  
Thionyl chloride (1 eq, 151.34 mmol, 11.00 mL)  
Yield: 32.18 g white solid (99 %)  
 
mp 156 – 160 °C [lit. 159 °C]; Rf 0.11 (25% EtOAc in Hexane); IR (cm
-1) 2839 (NH3
+), 1743 
(C=O), 1583 (Ar); 1H-NMR (300 MHz) (CDCl3/DMSO)  8.65 (brs, 3H (NH3
+)), 7.31-7.18 (stack, 
5H (ArH)), 4.15 (dd, 1H, J = 6.0, 7.0 Hz (CH)), 3.66 (s, 3H (OCH3)), 3.21 (dd, 1H, J = 6.0, 14.0 Hz 
(CHH)), 3.12 (dd, 1H, J = 7.0, 14.0 Hz (CHH)); 13C-NMR (100 MHz)  169.1 (C=O), 134.2 (QAr), 
129.2 (ArH), 128.4 (ArH), 127.1 (ArH), 53.3 (OCH3), 52.3 (CH), 35.8 (CH2); m/z (ES) [M+H]
+ 
180.1; C10H15NO2 requires 180.1025, found 180.1017 
 
84  
N-Trityl-methyl-(S)-3-phenyl-2-aminopropanoate 114 
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A mixture of amine 83 (1 eq, 1.16 mmol, 250 mg), triphenylmethyl chloride (1 eq, 1.16 mmol, 
323 mg) and triethylamine (2 eq, 2.32 mmol, 0.32 mL) in DCM (0.2 M, 6 mL) was stirred for 
48 hours. The mixture was diluted with water and product extracted with DCM then purified 
by column chromatography to yield a clear oil (488 mg, >99 %).  
 
Rf 0.78 (25 % EtOAc in hexane); IR (cm
-1) 3303 (NH), 1600 (C=O), 1021 (C-O); 1H-NMR (300 
MHz, CDCl3)  7.45-7.11 (stack, 20H (ArH)), 3.55 (dt, 1H, J = 6.0, 11.0 Hz (CH)), 3.03 (s, 3H 
(OCH3)), 2.98 (dd, 1H, J = 6.0, 12.5 (CHH)), 2.92 (dd, 1H, J = 6.0, 12.5 Hz (CHH)), 2.62 (d, 1H, J 
= 11.0 Hz (NH)) [lit. agreement]; 13C-NMR (100 MHz, CDCl3) 174.9 (C=O), 145.9 (QArTrt), 
137.5 (QArPh), 129.8 (ArH), 128.8 (ArH), 128.2 (ArH), 127.8 (ArH), 126.7 (ArH), 126.3 (ArH), 
71.0 (QTrt), 58.4 (CH), 51.3 (OCH3), 42.4 (CH2); m/z (ES) [M+Na]
+ 444.2; C29H27NO2Na 
requires 444.1939, found 444.1928 
 
85a  
N-Trityl-(S)-3-phenyl-2-aminopropan-1-ol 114 
 
 
Reduction of 84:  
Ester 84 (1 eq, 1.19 mmol, 500 mg) was dissolved in THF (0.33 M, 3.60 mL) at 0 °C then 
lithium borohydride (1.25 eq, 1.48 mmol, 32 mg) was added in one portion. The mixture was 
warmed to 45 °C and stirred for 72 hours. After an aqueous workup a 50/50 mixture of 
starting material and product was recovered.  
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Tritylation of 69a:  
Amine 69a (1 eq, 1.65 mmol, 250 mg) was dissolved in DCM (0.2 M, 8.25 mL), then 
triethylamine (1 eq, 1.65 mmol, 230 l) and trityl chloride (1 eq, 1.65 mmol, 460 mg) were 
added. The mixture was stirred at room temperature for several days before an aqueous 
workup. Purification by column chromatography yielded a clear oil (592 mg, 91 %).  
 
Rf 0.60 (25 % EtOAc in hexane); IR (cm
-1) 3604 (OH), 3452 (NH), 1506 (Ar); 1H-NMR (300 
MHz, CDCl3)  7.60-7.50 (stack, 6H (ArH)), 7.33-7.079 (stack, 12H (ArH)), 6.94-6.89 (stack, 2H 
(ArH)), 3.11 (dd, 1H, J = 2.5, 11.0 Hz (CHHOH)), 2.93 (dd, 1H, J = 4.5, 11.0 Hz (CHHOH)), 2.81 
(dddd, 1H, J = 2.5, 4.5, 5.0, 9.5 Hz (CH)), 2.51 (dd, 1H, J = 9.5, 13.0 (CHHPh)), 2.28 (dd, 1H, J = 
5.0, 13.0 (CHHPh)), 1.92 (brs, 2H (NH, OH)) [lit. agreement]; 13C-NMR (100 MHz, CDCl3) 
145.0 (QAr), 138.0 (QAr), 129.2 (ArH), 128.8 (ArH), 128.1 (ArH), 126.2 (ArH), 126.0 (ArH), 
76.1 (QTrt), 66.8 (CH2OH), 56.5 (CH), 39.1 (CH2Ph); m/z (ES) [M+Na]
+ 416.2; C28H27NONa 
requires 416.1990, found 416.1973 
 
85b  
N-Trityl-(S)-2-aminopropan-1-ol  
 
 
L-alaninol (1 eq, 6.66 mmol, 500 mg) was dissolved in DCM (0.2 M, 35 mL), then 
triethylamine (1 eq, 6.66 mmol, 928 l) and trityl chloride (1 eq, 6.66 mmol, 1.86 g) were 
added. The mixture was stirred at room temperature for 48 hours before an aqueous 
workup. Purification by column chromatography, eluting with 20 % EtOAc in hexane, yielded 
a clear oil (1.71 g, 81 %).  
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Rf 0.38 (25 % EtOAc in hexane); IR (cm
-1) 3460 (NH), 3254 (br) (OH), 1594 (Ar); 1H-NMR 
(300 MHz, CDCl3) 7.56-7.52 (stack, 6H (ArH)), 7.31-7.17 (stack, 9H (ArH)), 3.16 (dd, 1H, J = 
4.0, 10.5 Hz (CHHOH)), 3.05 (dd, 1H, J = 5.0, 10.5 Hz (CHHOH)), 2.77 (m, 1H (CH)), 1.88 (brs, 
2H (NH, OH)), 0.66 (d, 3H, J = 6.5 Hz (Me)); 13C-NMR (100 MHz, CDCl3) 146.8 (QAr), 128.8 
(ArH), 127.9 (ArH), 126.5 (ArH), 72.0 (QCPh3), 67.0 (CH2OH), 49.5 (CH), 19.8 (CH3); m/z (ES) 
[M+Na]+ 340.3; C22H23NONa requires 340.1677, found 340.167  
 
86a  
N-Trityl-(S)-2-amino-3-phenylpropanal 114  
 
 
General procedure F was followed using the following amounts:  
Oxalyl chloride (1.1 eq, 75.47 mmol, 6.39 mL) in DCM (0.45 M, 150 mL)  
DMSO (2.4 eq, 164.66 mmol, 11.70 mL) in DCM (2 M, 35 mL)  
Alcohol 85a (1 eq, 68.61 mmol, 27.00 g) in DCM (1 M, 70 mL)  
Triethylamine (5 eq, 343.05 mmol, 47.81 mL)  
The product was purified by column chromatography to yield a colourless crystalline solid 
(26.4 g, 98 %).  
 
Rf 0.70 (25 % EtOAc in hexane); IR (cm
-1) 3031 (NH), 1720 (CHO), 1595/1488 (Ar); 1H-NMR 
(300 MHz, CDCl3)  8.85 (d, 1H, J = 2.2 Hz (CHO)), 7.42-7.15 (stack, 20 H (ArH)), 3.57 (ddd, 1H, 
J = 2.0, 6.5, 7.0 Hz (CHN)), 2.79 (dd, 1H, J = 7.0, 16.5 Hz (CHHPh)), 2.78 (brs, 1H (NH)), 2.73 
(dd, 1H, J = 6.5, 16.5 Hz (CHHPh)) [lit. agreement]; 13C-NMR (100 MHz, CDCl3) 203.2 (CHO), 
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145.9 (QAr), 136.7 (QAr), 129.9 (ArH), 128.7 (ArH), 128.6 (ArH), 128.1 (ArH), 126.9 (ArH), 
126.7 (ArH), 71.0 (QNCPh3), 63.0 (CHN), 38.7 (CH2Ph); m/z (EI) [C6H5]
+ 77.0, [PhCH2]
+ 91.1, 
[Trt]+ 243.1 
 
87  
N-Trityl-(S)-1-phenylbut-3-en-2-amine 114 
 
 
Procedure D was followed using the following amounts:  
Methyltriphenylphosphonium iodide (2 eq, 5.11 mmol, 2.07 g) in THF (0.25 M, 10 mL)  
Potassium t-butoxide (2 eq, 5.11 mmol, 573 mg)  
Aldehyde 86a (1 eq, 2.55 mmol, 1.00 g) in minimal THF  
The product was purified by column chromatography, loading by solid adsorption to silica, 
eluting with 10 % EtOAc in hexane, to yield a clear oil (979 mg, 98 %)  
 
Rf 0.86 (25 % EtOAc in hexane); IR (cm
-1) 3027 (NH), 1595/1489/1447 (Ar); 1H-NMR (300 
MHz, CDCl3)  7.56-7.52 (stack, 6H (ArH)), 7.31-7.08 (stack, 12H (ArH)), 6.90 (app dd, 2H 
(ArH)), 5.54 (ddd, 1H, J = 7.5, 10.5, 17.0 Hz (=CH)), 4.79 (d, 1H, J = 17.0 Hz(=CHHtrans)), 4.75 (d, 
1H, J = 7.5 Hz (=CHHcis)), 3.24 (ddd, 1H, J = 5.0, 8.0, 10.5 Hz (CH)), 2.30 (dd, 1H, J = 5.0, 13.0 
Hz (CHHPh)), 2.17 (dd, 1H, J = 8.0, 13.0 Hz (CHHPh)), 1.68 (s, 1H (NH)) [lit. agreement]; 13C-
NMR (100 MHz, CDCl3) 147.0 (QArTrt), 141.6 (=CH), 138.7 (QAr), 129.8 (ArH), 129.0 (ArH), 
127.9 (ArH), 127.7 (ArH), 126.3 (ArH), 126.0 (ArH), 113.4 (=CH2), 71.53 (QTrt), 57.3 (CH), 43.6 
(CH2); m/z (ES) [M+Na]
+ 412.1; C29H27NNa requires 412.2041, found 412.2052 
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89  
N-Trityl-(S,Z)-1-phenylpent-3-en-2-amine 
 
 
Procedure D was followed using the following amounts:  
Ethyltriphenylphosphonium iodide (2 eq, 2.55 mmol, 1.07 g) in THF (0.25 M, 5 mL)  
Potassium t-butoxide (2 eq, 2.55 mmol, 287 mg)  
Aldehyde 86a (1 eq, 1.28 mmol, 500 mg) in minimal THF  
The product was purified by column chromatography, loading by solid adsorption to silica, 
eluting with 10 % EtOAc in hexane, to yield a clear oil (191 mg, 37 %)  
 
Rf 0.90 (10 % EtOAc in hexane); IR (cm
-1) 3022 (NH), 1597/1481 (Ar) 1H-NMR (300 MHz, 
CDCl3)  7.58-7.50 (stack, 6H (ArH)), 7.35-7.11 (stack, 12H (ArH)), 7.06-7.00 (stack, 2H (ArH)), 
5.14-4.98 (stack, 2H (HC=CH)), 3.56-3.46 (m, 1H (CH)), 2.36 (dd, 1H, J = 5.0, 12.5 (CHHPh)), 
2.25 (dd, 1H, J = 8.5, 12.5 (CHHPh)), 1.28 (brs, 1H (NH)), 0.88 (d, 3H (Me)); 13C-NMR (100 
MHz, CDCl3) 145.0 (QAr), 136.6 (QAr), 135.2 (=CH), 129.2 (ArH), 128.6 (ArH), 127.7 (ArH), 
127.0 (ArH), 126.2 (ArH), 125.9 (ArH), 125.7 (=CH), 76.2 (QTrt), 51.6 (CH), 42.8 (CH2Ph), 11.6 
(Me); m/z (ES) [M+Na]+ 426.3; C30H29NNa requires 426.2198, found 426.2183 
 
90  
N-Trityl-(S)-4-methyl-1-phenylpent-3-en-2-amine  
 
113 
 
 
Procedure D was followed using the following amounts:  
Isopropyltriphenylphosphonium iodide (2 eq, 10.22 mmol, 4.42 g) in THF (0.25 M, 20 mL)  
Potassium t-butoxide (2 eq, 10.22 mmol, 1.15 g)  
Aldehyde 86a (1 eq, 5.11 mmol, 2.0 g) in minimal THF  
The product was purified by column chromatography, loading by solid adsorption to silica, 
eluting with 2 % EtOAc in hexane, to yield a yellow oil (918 mg, 43 %)  
 
Rf 0.83 (25% EtOAc in Hexane); IR (cm
-1) 2923 (NH), 1597/1446 (Ar); 1H-NMR (300 MHz) 
(CDCl3)  7.53-7.49 (stack, 6H (ArH)), 7.32-7.11 (stack, 12H (ArH)), 6.95-6.92 (stack, 2H (ArH)), 
4.71 (dsept, 1H, J = 1.0, 9.0 Hz (=CH)), 3.37 (ddd, 1H, J = 5.0, 8.0, 9.0 Hz (CH)), 2.42 (dd, 1H, J 
= 5.0, 12.5 Hz (CHH)), 2.32 (dd, 1H, J = 8.0, 12.5 Hz (CHH)), 1.71 (brs, 1H (NH)), 1.37 (d, 1H, J = 
1.0 Hz (CH3)), 0.83 (d, 3H, J = 1.0 Hz (CH3)); 
13C-NMR (100 MHz)  147.0 (QArTrt), 143.9 
(=CMe2), 139.2 (QArPh), 130.0 (ArH), 129.5 (ArH), 129.0 (ArH), 128.3 (ArH), 127.7 (ArH), 
126.2 (ArH), 125.7 (=CH), 72.3 (QTrt), 53.4 (CH), 44.2 (CH2), 25.5 (CH3trans), 17.6 (CH3cis); m/z 
(ES) [M+Na]+ 440.2; C31H31NNa requires 440.2354, found 440.2357 
 
91  
(S)-1-Phenylbut-3-en-2-amine115 
 
 
Tritylated amine 87 (1 eq, 4.24 mmol, 1.65 g) was dissolved in anhydrous acetone (0.12 M, 
35 mL) and concentrated HCl (6 M, 0.71 mL) was added. The reaction mixture was heated at 
reflux for 3 hours before dilution with water. The aqueous portion was extracted into DCM 
114 
 
to remove trityl alcohol. The aqueous layer was then evaporated to dryness to yield a yellow 
solid (568 mg, 73 %)  
 
IR (cm-1) 2914 (NH), 1585 (Ar); 1H-NMR (300 MHz, D2O)  7.34-7.15 (stack, 5H (ArH)), 5.79 
(ddd, 1H, J = 7.5, 10.5, 17.0 Hz (=CH)), 5.24 (d, 1H, J = 10.5 Hz (=CHH)), 5.19 (d, 1H, J = 17.0 Hz 
(=CHH)), 3.97 (q, 1H, J = 7.5 Hz (CHN)), 2.94 (dd, 2H, J = 1.0, 7.5 Hz (CH2Ph)) [Lit. agreement]; 
13C-NMR (100 MHz, CDCl3) 136.6 (QAr), 131.4 (=CH), 128.6 (ArH), 127.7 (ArH), 125.9 (ArH), 
117.7 (=CH2), 56.5 (CH), 44.1 (CH2); m/z (ES) [M+H]
+ 148.1; C10H14N requires 148.1126, found 
148.1127 
 
3-(tert-Butyldiphenylsilyloxy)propan-1-ol116 
 
 
To a solution of propane diol (3 eq, 109.14 mmol, 7.89 mL) in DCM (0.5 M, 73 mL), was 
added triethylamine (1.5 eq, 54.57 mmol, 7.61 mL) and t-butyldiphenylsilyl chloride (1 eq, 
36.38 mmol, 10 g). After 18 hours at room temperature the reaction mixture was diluted 
with DCM and washed with water and then brine. The crude product was purified by column 
chromatography, eluting with 20 % EtOAc in hexane, to yield a white solid (9.98 g, 87 %).  
 
Rf 0.54 (25 % EtOAc in hexane); IR (cm
-1) 2926/2859 (CH), 3598 (CO), 1095 (SiO); 1H-NMR 
(300 MHz, CDCl3)  7.70-7.66 (stack, 4H (ArH)), 7.48-7.37 (stack, 6H (ArH)), 3.85 (t, 2H, J = 5.5 
Hz (CH2OSi)), 3.85 (q, 2H, J = 5.5 Hz (CH2OH)), 2.36 (t, 1H, J = 5.5 Hz (OH)), 1.81 (quin, 2H, J = 
5.5 Hz (CH2CH2O)), 1.05 (s, 9H (
tBu)) [Lit. agreement]; 13C-NMR (100 MHz, CDCl3) 135.6 
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(QAr), 133.3 (ArH), 129.8 (ArH), 127.8 (ArH), 63.3 (CH2OH), 62.0 (CH2OSi), 34.3 (CH2CH2O), 
26.8 (tBu), 19.1 (QtBu); m/z (ES) [M+Na]+ 337.3 
 
3-(tert-Butyldiphenylsilyloxy)propanal116 
 
 
Procedure F was followed using the following amounts:  
Oxalyl chloride (1.1 eq, 9.09 mmol, 0.77 mL) in DCM (0.4 M, 23 mL)  
DMSO (2.4 eq, 19.84 mmol, 1.41 mL)  
3-((tert-butyldiphenylsilyl)oxy)propan-1-ol (1 eq, 8.27 mmol, 2.6 g) in DCM (0.8 M, 10 mL)  
Triethylamine (5 eq, 41.30 mmol, 5.75 mL)  
The product was purified by column chromatography to yield a yellow oil (2.54 g, 98 %).  
 
Rf 0.52 (20 % EtOAc in heptane); IR (cm
-1) 2931/2888 (CH), 1729 (C=O), 1093 (Si-O); 1H-
NMR (300 MHz, CDCl3)  9.84 (t, 1H, J = 2.0 Hz (CHO)), 7.68 (app dd, 4H (ArH)), 7.48-7.36 
(stack, 6H (ArH)), 4.04 (t, 2H, J = 6.0 Hz (CH2O)), 2.63 (dt, 2H, J = 2.0, 6.0 Hz (CH2CH2O)), 1.06 
(s, 9H (tBu)) [Lit. agreement]; 13C-NMR (100 MHz, CDCl3) 201.9 (CHO), 135.5 (ArH), 133.3 
(QAr), 129.8 (ArH), 127.8 (ArH), 58.3 (CH2O), 46.4 (CH2CH2O), 26.7 (
tBu), 19.1 (QtBu); m/z (ES) 
[M+Na]+ 335.3 
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92a  
N-3-(tert-Butyldiphenylsilyloxy)propyl-1-phenylbut-3-en-2-amine  
 
 
Procedure G was followed using the following amounts:  
Amine 91 (1 eq, 13.58 mmol, 2.00 g) in DCM (1 M, 14 mL)  
Na2SO4 (1.02 eq, 13.86 mmol, 1.97 g)  
3-(tert-butyldiphenylsilyloxy)propanal (1 eq, 13.58 mmol, 4.24 g) in DCM (1.75 M, 8.0 mL)  
NaBH4 (1.5 eq, 20.38 mmol, 771 mg)  
MeOH (1 M, 14 mL)  
Yield: 1.11 g, colourless oil (18 %).  
 
Rf 0.23 (15 % EtOAc in hexane); IR (cm
-1) 1586/1574 (Ar), 1101 (OSi); 1H-NMR (300 MHz, 
CDCl3)  7.71-7.64 (stack, 4H (ArH)), 7.50-7.35 (stack, 6H (ArH)), 7.33-7.17 (stack, 5H (ArH)), 
5.68 (ddd, 1H, J = 7.5, 9.0, 15.0 Hz (=CH)), 5.09 (d, 1H, J = 9.0 Hz (=CHH)), 5.06 (dd, 1H, J = 1.5, 
7.5 Hz (=CHH)), 3.68 (t, 2H, J = 6.0 Hz (CH2O)), 3.30 (dt, 1H, J = 7.0, 15.0 Hz (CH)), 2.86- 2.71 
(stack, 3H (CH2N, CHHPh)), 2.61 (dd, 1H, J = 7.0, 11.5 Hz (CHHPh)), 1.82-1.58 (m, 2H, 
CH2CH2O)), 1.29 (brs, 1H (NH)), 1.06 (s, 9H (
tBu)); 13C-NMR (100 MHz, CDCl3)  136.6 (QAr), 
134.0 (QAr), 131.4 (=CH), 130.0 (ArH), 129.9 (ArH), 129.5 (ArH), 128.6 (ArH), 127.7 (ArH), 
125.9 (ArH), 117.7 (=CH2), 63.7 (CH), 61.4 (CH2O), 43.8 (CH2N), 41.9 (CH2Ph), 33.9 (CH2CH2N), 
31.7 (QtBu), 26.8 (tBu) ; m/z (ES) [M+Na]+ 466.3 
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93a  
(S)-2-(3-(tert-Butyldiphenylsilyloxy)propylamino)-3-phenylpropan-1-ol  
 
 
Procedure G was followed using the following amounts:  
Amine 69a (1 eq, 6.40 mmol, 967 mg) in DCM (1 M, 6.5 mL)  
Na2SO4 (1.02 eq, 6.53 mmol, 927 mg)  
3-(tert-butyldiphenylsilyloxy)propanal (1 eq, 6.40 mmol, 2.00 g) in DCM (1.75 M, 4.00 mL)  
NaBH4 (1.5 eq, 9.60 mmol, 363 mg)  
MeOH (1 M, 6.5 mL)  
Yield: 2.86 g, >99 %, purple oil.  
 
IR (cm-1) 3248 (OH), 2930 (CH), 1589 (Ar), 1105 (OSi); 1H-NMR (300 MHz, CDCl3)  7.66 (app 
dd, 4H (ArH)), 7.47-7.36 (stack, 6H (ArH)), 7.31-7.15 (stack, 5H (ArH)), 3.69 (t, 2H, J = 6.0 Hz 
(CH2OSi)), 3.58 (dd, 1H, J = 4.0, 10.5 Hz (CHHOH)), 3.27 (dd, 1H, J = 5.5, 10.5 Hz (CHHOH)), 
2.87 (m, 1H, (CH)), 2.74 (stack, 4H (CH2Ph, CH2N)), 2.03 (brs, 2H (OH, NH)), 1.67 (p, 2H, J = 6.0 
Hz (CH2CH2N)), 1.05 (s, 9H, (
tBu)); 13C-NMR (100 MHz, CDCl3) 138.6 (QAr), 135.6 (ArH), 
133.8 (QAr), 129.6 (ArH), 129.2 (ArH), 128.5 (ArH), 127.7 (ArH), 126.4 (ArH), 62.3 (CH2O), 
62.1 (CH2O), 60.1 (CH), 43.8 (CH2N), 38.1 (CH2Ph), 33.0 (CH2CH2N), 26.9 (
tBu), 19.2 (QtBu); 
m/z (ES) [M+Na]+ 470.5; C28H37NO2SiNa requires 470.2491, found 470.2483 
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93b  
(S)-2-(3-(tert-Butyldiphenylsilyloxy)propylamino)propan-1-ol  
 
 
Procedure G was followed using the following amounts:  
L-alaninol (1 eq, 13.31 mmol, 1.00 g) in DCM (1 M, 13.30 mL)  
Na2SO4 (1.02 eq, 13.58 mmol, 1.93 g)  
3-(tert-butyldiphenylsilyloxy)propanal (1 eq, 13.31 mmol, 4.16 g) in DCM (1.7 M, 8.00 mL)  
NaBH4 (1.5 eq, 19.97 mmol, 755 mg)  
MeOH (1 M, 13.30 mL)  
Yield: 3.27 g, 66 %, colourless oil.  
 
Rf 0.34 (10 % MeOH in DCM); IR (cm
-1) 3299 (OH), 2930 (CH), 1589 (Ar), 1106 (OSi); 1H-
NMR (300 MHz, CDCl3)  7.66 (app dd, 4H (ArH)), 7.46-7.35 (stack, 6H (ArH)), 3.74 (t, 2H, J = 
6.0 Hz (CH2OSi)), 3.57 (dd, 1H, J = 4.0, 10.5 Hz (CHHOH)), 3.24 (dd, 1H, J = 7.0, 10.5 Hz 
(CHHOH)), 2.86 (dd, 1H, J = 7.0, 11.5 Hz (CHHN)), 2.81-2.71 (m, 1H (CH)), 2.66 (dd, 1H, J = 6.5, 
11.5 Hz (CHHN)), 2.12 (brs, 2H (OH, NH)), 1.74 (ddt, 2H, J = 6.0, 6.5, 7.0 Hz (CH2CH2N)), 1.05 
(s, 9H, (tBu)) 1.03 (s, 3H (Me)); 13C-NMR (100 MHz, CDCl3) 135.6 (ArH), 134.9, (ArH), 133.8 
(QAr), 129.7 (ArH), 129.5 (ArH), 127.7 (ArH), 65.4 (CH2OH), 62.4 (CH2OSi), 54.4 (CH), 44.1 
(CH2N), 32.9 (CH2CH2N), 26.9 (
tBu), 19.2 (QtBu), 17.2 (CH3); m/z (ES) [M+H]
+ 372.3; 
C22H34NO2Si requires 372.2359, found 372.2346 
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93c  
(S)-2-(3-(tert-Butyldiphenylsilyloxy)propylamino)-3-methylbutan-1-ol  
 
 
Procedure G was followed using the following amounts:  
L-valinol (1 eq, 9.69 mmol, 1.00 g) in DCM (1 M, 9.70 mL)  
Na2SO4 (1.02 eq, 9.89 mmol, 1.40 g)  
3-(tert-butyldiphenylsilyloxy)propanal (1 eq, 9.69 mmol, 3.03 g) in DCM (1.7 M, 5.80 mL)  
NaBH4 (1.5 eq, 14.54 mmol, 550 mg)  
MeOH (1 M, 9.70 mL)  
Yield: 1.80 g, 47 %, colourless oil. 
  
Rf 0.40 (10 % MeOH in DCM); IR (cm
-1) 3348 (OH), 2931 (CH), 1105 (OSi); 1H-NMR (300 
MHz, CDCl3)  7.72-7.62 (stack, 4H (ArH)), 7.52-7.35 (stack, 6H (ArH)), 3.77 (t, 2H, J = 6.0 Hz 
(CH2OSi)), 3.61 (dd, 1H, J = 4.5, 10.5 Hz (CHHOH)), 3.30 (dd, 1H, J = 7.5, 10.5 Hz (CHHOH)), 
2.84 (dt, 1H, J = 7.0, 11.5 Hz (CHHN)), 2.70 (dt, 1H, J = 7.0, 11.5 Hz (CHHN)), 2.38 (ddd, 1H, J = 
4.5, 7.0, 7.5 Hz (CH)), 2.12 (brs, 2H (OH, NH)), 1.80 (oct, 1H, J = 7.0 Hz (CHMe2)), 1.74 (dt, 2H, 
J = 6.0, 7.0 Hz (CH2CH2N)), 1.07 (s, 9H, (
tBu)) 0.97 (d, 3H, J = 7.0 Hz (Me)), 0.90 (d, 3H, J = 7.0 
Hz (Me)); 13C-NMR (100 MHz, CDCl3) 135.6 (ArH), 134.9, (ArH), 133.8 (QAr), 129.6 (ArH), 
127.7 (ArH), 64.4 (CH), 62.3 (CH2OSi), 60.4 (CH2OH), 44.1 (CH2N), 33.4 (CH2CH2N), 26.9 (
tBu), 
19.7 (CH3), 19.2 (Q
tBu), 17.2 (CH3); m/z (ES) [M+H]
+ 400.3; C24H38NO2Si requires 400.2672, 
found 400.2679 
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93d  
(S)-2-(3-(tert-Butyldiphenylsilyloxy)propylamino)-4-methylpentan-1-ol  
 
 
Procedure G was followed using the following amounts:  
L-leucinol (1 eq, 8.53 mmol, 1.00 g) in DCM (1 M, 8.50 mL)  
Na2SO4 (1.02 eq, 8.70 mmol, 1.24 g)  
3-(tert-butyldiphenylsilyloxy)propanal (1 eq, 8.53 mmol, 2.67 g) in DCM (1.7 M, 5.0 mL)  
NaBH4 (1.5 eq, 12.80 mmol, 484 mg)  
MeOH (1 M, 8.5 mL)  
Yield: 2.22 g, 63 %, colourless oil.  
 
Rf 0.46 (10 % MeOH in DCM); IR (cm
-1) 3301 (OH), 2953 (CH), 1106 (OSi); 1H-NMR (300 
MHz, CDCl3)  7.73-7.63 (stack, 4H (ArH)), 7.49-7.35 (stack, 6H (ArH)), 3.76 (t, 2H, J = 6.0 Hz 
(CH2OSi)), 3.62 (dd, 1H, J = 4.0, 10.5 Hz (CHHOH)), 3.21 (dd, 1H, J = 6.5, 10.5 Hz (CHHOH)), 
2.87-2.65 (stack, 3H (CH2N, CH)), 1.94 (brs, 2H (OH, NH)), 1.74 (dt, 2H, J = 6.0, 6.5 Hz 
(CH2CH2N)), 1.64 (non, 1H, J = 7.0 Hz (CHMe2)), 1.40-1.31 (m, 1H (CHHCH)), 1.28-1.14 (m, 1H 
(CHHCH)), 1.07 (s, 9H (tBu)) 0.93 (s, 3H (Me)), 0.91 (s, 3H (Me)); 13C-NMR (100 MHz, CDCl3) 
135.6 (ArH), 134.9, (ArH), 133.8 (QAr), 129.6 (ArH), 127.7 (ArH), 63.2 (CH2OH), 62.3 
(CH2OSi), 56.7 (CH), 43.9 (CH2N), 41.4 (CH2CH), 33.2 (CH2CH2N), 26.9 (
tBu), 25.0 (CHMe2), 
23.1 (Me), 22.7 (Me) 19.2 (QtBu); m/z (ES) [M+H]+ 414.4; C25H40NO2Si requires 414.2828, 
found 414.2834 
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93e  
(2S,3R)-2-(3-(tert-Butyldiphenylsilyloxy)propylamino)-3-methylpentan-1-ol  
 
 
Procedure G was followed using the following amounts:  
L-isoleucinol (1 eq, 8.53 mmol, 1.00 g) in DCM (1 M, 8.5 mL)  
Na2SO4 (1.02 eq, 8.70 mmol, 1.24 g)  
3-(tert-butyldiphenylsilyloxy)propanal (1 eq, 8.53 mmol, 2.67 g) in DCM (1.7 M, 5.0 mL)  
NaBH4 (1.5 eq, 12.80 mmol, 484 mg)  
MeOH (1 M, 8.5 mL)  
Yield: 2.86 g, 81 %, colourless oil.  
 
Rf 0.40 (10 % MeOH in DCM); IR (cm
-1) 3336 (OH), 2958 (CH), 1106 (OSi); 1H-NMR (300 
MHz, CDCl3)  7.73-7.65 (stack, 4H (ArH)), 7.46-7.35 (stack, 6H (ArH)), 3.75 (t, 2H, J = 6.0 Hz 
(CH2OSi)), 3.56 (dd, 1H, J = 4.5, 10.5 Hz (CHHOH)), 3.25 (dd, 1H, J = 8.0, 10.5 Hz (CHHOH)), 
2.82 (dt, 1H, J = 7.0, 11.5 Hz (CHHN)), 2.63 (dt, 1H, J = 7.0, 11.5 Hz (CHHN)), 2.48 (ddd, 1H, J = 
4.5, 7.0, 8.0 Hz (CH)), 1.91 (brs, 2H (OH, NH)), 1.71 (dt, 2H, J = 6.0, 7.0 Hz (CH2CH2N)), 1.62-
1.53 (m, 1H, (CHCH3)), 1.49-1.39 (m, 1H (CHHCH3)), 1.26-1.10 (m, 1H (CHHCH3)), 1.05 (s, 9H 
(tBu)) 0.91 (t, 3H, J = 7.5 Hz (CH3CH2)), 0.82 (d, 3H, J = 7.0 Hz (CH3CH)); 
13C-NMR (100 MHz, 
CDCl3) 135.6 (ArH), 134.8, (ArH), 133.9 (QAr), 129.6 (ArH), 127.7 (ArH), 62.6 (CH), 62.3 
(CH2OSi), 60.2 (CH2OH), 44.0 (CH2N), 35.4 (CHCH3), 33.4 (CH2CH2N), 26.9 (
tBu), 26.4 (CH2CH3), 
19.2 (QtBu), 14.4 (CH3CH), 11.8 (CH3CH2); m/z (ES) [M+H]
+ 414.3; C25H40NO2Si requires 
414.2828, found 414.2823 
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93f  
(S)-2-(3-(tert-Butyldiphenylsilyloxy)propylamino)-3,3-dimethylbutan-1-ol  
 
 
Procedure G was followed using the following amounts:  
L-tert-leucinol (1 eq, 8.53 mmol, 1.00 g) in DCM (1 M, 8.5 mL)  
Na2SO4 (1.02 eq, 8.70 mmol, 1.24 g)  
3-(tert-butyldiphenylsilyloxy)propanal (1 eq, 8.53 mmol, 2.67 g) in DCM (1.7 M, 5.0 mL)  
NaBH4 (1.5 eq, 12.80 mmol, 484 mg)  
MeOH (1 M, 8.5 mL)  
Yield: 2.09 g, 59 %, colourless oil.  
 
Rf 0.44 (10 % MeOH in DCM); IR (cm
-1) 3353 (OH), 2931 (CH), 1106 (OSi); 1H-NMR (300 
MHz, CDCl3)7.78-7.66 (stack, 4H (ArH)), 7.52-7.38 (stack, 6H (ArH)), 3.78 (t, 2H, J = 6.0 Hz 
(CH2OSi)), 3.61 (dd, 1H, J = 4.5, 10.5 Hz (CHHOH)), 3.32 (dd, 1H, J = 7.0, 10.5 Hz (CHHOH)), 
2.97 (dt, 1H, J = 7.0, 11.5 Hz (CHHN)), 2.77 (dt, 1H, J = 7.0, 11.5 Hz (CHHN)), 2.29 (dd, 1H, J = 
4.5, 7.0 Hz (CH)), 1.80-1.70 (m, 2H (CH2CH2N)), 1.08 (s, 9H (
tBuSi)), 0.95 (s, 9H (tBu)); 13C-NMR 
(100 MHz, CDCl3)135.6 (ArH), 134.8, (ArH), 133.8 (QAr), 129.6 (ArH), 127.7 (ArH), 67.8 (CH), 
62.2 (CH2OSi), 59.9 (CH2OH), 47.4 (CH2N), 34.4 (Q
tBu), 33.7 (CH2CH2N), 27.2 (
tBu), 26.9 (tBuSi), 
19.2 (QtBuSi); m/z (ES) [M+H]+ 414.3; C25H40NO2Si requires 414.2828, found 414.2825 
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93g  
(S)-2-(3-(tert-Butyldiphenylsilyloxy)propylamino)-2-phenylethanol  
 
 
Procedure G was followed using the following amounts:  
L-phenylglycinol (1 eq, 7.29 mmol, 1.00 g) in DCM (1 M, 7.3 mL)  
Na2SO4 (1.02 eq, 7.44 mmol, 1.06 g)  
3-(tert-butyldiphenylsilyloxy)propanal (1 eq, 7.29 mmol, 2.28 g) in DCM (1.7 M, 4.4 mL)  
NaBH4 (1.5 eq, 10.94 mmol, 414 mg)  
MeOH (1 M, 7.3 mL)  
Yield: 2.05 g, 65 %, yellow oil.  
Rf 0.50 (10 % MeOH in DCM); IR (cm
-1) 3302 (OH), 2930 (CH), 1106 (OSi); 1H-NMR (300 
MHz, CDCl3)  7.73-7.62 (stack, 4H (ArH)), 7.45-7.23 (stack, 11H (ArH)), 3.87-3.66 (stack, 4H 
(CH, CH2OSi, CHHOH)), 3.54-3.45 (m, 1H (CHHOH)), 2.71 (dt, 1H, J = 7.0, 11.5 Hz (CHHN)), 
2.60 (dt, 1H, J = 6.5, 11.5 Hz (CHHN)), 2.11 (brs, 2H (OH, NH)), 1.72 (ddt, 2H, J = 6.0, 6.5, 7.0 
Hz (CH2CH2N)), 1.02 (s, 9H, (
tBu)); 13C-NMR (100 MHz, CDCl3) 141.0 (QPh),135.6 (ArH), 
134.8, (ArH), 133.9 (QAr), 129.6 (ArH), 128.6 (ArH), 127.7 (ArH), 127.5 (ArH), 127.1 (ArH), 
66.5 (CH2OH), 64.6 (CH), 62.5 (CH2OSi), 44.6 (CH2N), 32.9 (CH2CH2N), 26.9 (
tBu), 19.2 (QtBu); 
m/z (ES) [M+H]+ 434.3; C27H36NO2Si requires 434.2515, found 434.2522 
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95a  
N-Tosyl-(S)-2-(3-(tert-butyldiphenylsilyloxy)propylamino)-3-phenylpropan-1-ol 
 
 
Procedure B was followed using the following amounts:  
Amine 93a (1 eq, 2.23 mmol, 1.00 g) in DCM (0.11 M, 20 mL)  
Triethylamine (2 eq, 4.47 mmol, 623 l)  
Tosyl chloride (1 eq, 2.23 mmol, 426 mg) in DCM (0.26 M, 8.50 mL)  
The product was purified by column chromatography, eluting with 25 % EtOAc in hexane, to 
yield a green oil (564 mg, 42 %).  
 
Rf 0.48 (25 % EtOAc in hexane); IR (cm
-1) 3524 (OH), 2925 (CH), 1594 (Ar), 1326/1148 
(SO2N), 1086 (CO), 1103 (SiO); 
1H-NMR (300 MHz, CDCl3)  7.62-7.63 (stack, 6H (ArH)), 7.47- 
7.36 (stack, 6H (ArH)), 7.26-7.16 (stack, 5 H (ArH)), 7.03-6.98 (stack, 2H (ArH)), 4.06-3.97 (m, 
1H (CH)), 3.76-3.65 (m, 2H (CH2OSi)), 3.64-3.53 (m, 2H (CH2OH)), 3.40 (dd, 2H, J = 7.5, 8.5 Hz 
(CH2N)), 2.69 (dd, 1H J = 9.0, 13.5 Hz (CHHPh)), 2.58 (dd, 1H, J = 5.5, 13.5 Hz (CHHPh)), 2.41 (s, 
3H (ArCH3)), 2.02 (dd, 1H, J = 5.5, 6.5 Hz (OH)), 1.98-1.87 (m, 2H (CH2CH2N)), 1.08 (s, 9H (
tBu)); 
13C-NMR (100 MHz, CDCl3) 143.3 (QAr), 137.7 (QAr), 127.8 (ArH), 127.3 (ArH), 126.6 (ArH), 
62.5 (CH2OH), 62.2 (CHN), 61.5 (CH2OSi), 42.1 (CH2N), 36.3 (CH2Ph), 34.0 (CH2CH2N),27.0 
(tBu), 21.5 (ArCH3), 19.3 (Q
tBu); m/z (ES) [M+Na]+ 624.5; C35H43NO4SiSNa requires 624.2580, 
found 624.2584 
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95b  
N-Tosyl-(S)-2-(3-(tert-butyldiphenylsilyloxy)propylamino)propan-1-ol 
 
 
Procedure B was followed using the following amounts:  
Amine 93b (1 eq, 0.538 mmol, 200 mg) in DCM (0.1 M, 5.4 mL)  
Triethylamine (2 eq, 1.08 mmol, 150 l)  
Tosyl chloride (2 eq, 1.08 mmol, 205 mg)  
The product was purified by column chromatography, eluting with 15 % EtOAc in hexane, to 
yield a colourless oil (196 mg, 69 %).  
 
Rf 0.48 (15 % EtOAc in hexane); IR (cm
-1) 3516 (OH), 2930 (CH), 1598 (Ar), 1332/1151 
(SO2N), 1088 (CO), 1106 (SiO); 
1H-NMR (300 MHz, CDCl3)  7.62-7.63 (stack, 6H (ArH)), 7.47- 
7.36 (stack, 4H (ArH)), 7.26-7.16 (stack, 2 H (ArH)), 7.03-6.98 (stack, 2H (ArH)), 4.06-3.97 (m, 
1H (CH)), 3.76-3.65 (m, 2H (CH2OSi)), 3.64-3.53 (m, 2H (CH2OH)), 3.40 (dd, 2H, J = 7.5, 8.5 Hz 
(CH2N)), 2.58 (m, 3H (Me)), 2.41 (s, 3H (ArCH3)), 2.02 (dd, 1H, J = 5.5, 6.5 Hz (OH)), 1.98-1.87 
(m, 2H (CH2CH2N)), 1.08 (s, 9H (
tBu)); 13C-NMR (100 MHz, CDCl3) 143.3 (QAr), 137.7 (QAr), 
135.6 (ArH), 133.6 (QAr), 129.7 (ArH), 129.7 (ArH), 127.7 (ArH), 127.2 (ArH), 64.7 (CH2OH), 
61.5 (CH2OSi), 55.8 (CHN), 40.9 (CH2N), 34.3 (CH2CH2N), 26.9 (
tBu), 21.5 (ArCH3), 19.2 (Q
tBu), 
14.3 (CH3) 
 
Further isolated was the doubly tosylated product:  
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1H-NMR (300 MHz, CDCl3)  7.78-7.61 (stack, 8H (ArH)), 7.51-7.22 (stack, 10H (ArH)), 4.19-
4.10 (m, 1H (CH)), 4.05 (dd, 1H, J = 6.5, 9.5 Hz (CHHOTs)), 3.92 (dd, 1H, J = 6.5, 9.5 Hz 
(CHHOTs)), 3.62 (t, 2H, J = 5.5 Hz (CH2OSi)), 3.24 (ddd, 1H, J = 3.5, 8.0, 10.0 (CHHN)), 3.15 
(ddd, 1H, J = 3.5, 8.0, 15.0 (CHHN)), 2.45 (s, 3H (ArCH3)), 2.43 (s, 3H (ArCH3)), 1.87-1.66 (m, 
2H (CH2CH2N)), 1.11 (d, 3H, J = 6.8 Hz (Me)), 1.06 (s, 9H (
tBu)) 
 
95c  
N-Tosyl-(S)-2-(3-(tert-butyldiphenylsilyloxy)propylamino)-3-methylbutan-1-ol  
 
 
Procedure B was followed using the following amounts:  
Amine 93c (1 eq, 0.50 mmol, 200 mg) in DCM (0.1 M, 5.0 mL)  
Triethylamine (2 eq, 1.00 mmol, 140 l)  
Tosyl chloride (2 eq, 1.00 mmol, 191 mg)  
The product was purified by column chromatography, eluting with 15 % EtOAc in hexane, to 
yield a colourless oil (163 mg, 59 %).  
 
IR (cm-1) 3535 (OH), 2931 (CH), 1598 (Ar), 1328/1148 (SO2N), 1104 (SiO), 1086 (CO); 
1H-
NMR (300 MHz, CDCl3) 7.74 (app d, 2H (ArH)), 7.68-7.61 (stack, 4H (Ph)), 7.51-7.31 (stack, 
6H (Ph)), 7.28 (app d, 2H (ArH)), 3.79 (ddd, 1H, J = 4.0, 6.0, 11.5 (CHHOH)), 3.67 (t, 2H, J = 5.4 
Hz (CH2OSi)), 3.60 (ddd, 1H, J = 4.0, 6.0, 11.5 Hz (CHHOH)), 3.46 (dt, 1H, J = 4.0, 10.0 Hz (CH)), 
3.35 (dt, 1H, J = 7.5, 15.0 Hz (CHHN)), 3.31 (dt, 1H, J = 7.5, 15.0 Hz (CHHN)), 2.43 (s, 3H 
(ArCH3)), 2.01 (t, 1H, J = 6.0 Hz (OH)), 1.98-1.87 (m, 2H (CH2CH2N)), 1.79 (dsept, 1H, J = 6.5, 
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10.0 Hz (CHMe2)), 1.07 (s, 9H (
tBu)), 0.93 (d, 3H, J = 6.5 Hz (Me)), 0.68 (d, 3H, J = 6.5 Hz (Me)); 
13C-NMR (100 MHz, CDCl3) 143.2 (QAr), 138.1 (QAr), 135.5 (ArH), 133.6 (QAr), 129.7 (ArH), 
129.5 (ArH), 127.7 (ArH), 127.4 (ArH), 66.8 (CHN), 62.2 (CH2OH), 61.6 (CH2OSi), 42.3 (CH2N), 
33.6 (CH2CH2N), 28.5 (CHMe2), 26.8 (
tBu), 21.5 (ArCH3), 20.7 (CH3), 20.2 (CH3), 19.2 (Q
tBu); 
m/z (ES) [M+Na]+ 576.3; C31H43NO4SiSNa requires 576.2580, found 576.2589 
 
95d  
N-Tosyl-(S)-2-(3-(tert-butyldiphenylsilyloxy)propylamino)-4-methylpentan-1-ol  
 
 
Procedure B was followed using the following amounts:  
Amine 93d (1 eq, 0.48 mmol, 200 mg) in DCM (0.1 M, 4.8 mL)  
Triethylamine (2 eq, 0.97 mmol, 140 l)  
Tosyl chloride (2 eq, 0.97 mmol, 184 mg)  
The product was purified by column chromatography, eluting with 15 % EtOAc in hexane, to 
yield a colourless oil (219 mg, 80 %).  
 
IR (cm-1) 3536 (OH), 2932 (CH), 1599 (Ar), 1324/1146 (SO2N), 1106 (SiO), 1088 (CO); 
1H-
NMR (300 MHz, CDCl3)  7.92-7.00 (stack, 14H (ArH)), 4.06-3.29 (stack, 5H (CH, CH2OSi, 
CH2OH)), 3.23-2.96 (m, 2H (CH2N)), 2.41 (s, 3H (ArCH3)), 2.14-1.56 (stack, 4H (CH2CH2N, 
CH2CH)), 1.08 (s, 9H (
tBu)), 0.93 (s, 6H (Me)), 0.85-0.64 (m, 1H (CHMe2)); 
13C-NMR (100 MHz, 
CDCl3) 143.0 (QAr), 137.6 (QAr), 134.0 (QAr), 130.1 (ArH), 130.0 (ArH), 129.5 (ArH), 129.3 
(ArH), 128.3 (ArH), 63.3 (CH2OH), 61.4 (CH2OSi), 56.9 (CHN), 44.6 (CH2N), 37.8 (CH2CH), 31.7 
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(QtBu), 30.2 (CH2CH2N), 26.8 (
tBu), 25.1 (CHMe2), 23.2 (Me), 21.3 (ArCH3); m/z (ES) [M+Na]
+ 
590.28  
 
95e  
N-Tosyl-(S)-2-(3-(tert-butyldiphenylsilyloxy)propylamino)-4-methylpentan-1-ol  
 
 
Procedure B was followed using the following amounts:  
Amine 93e (1 eq, 0.48 mmol, 200 mg) in DCM (0.1 M, 4.8 mL)  
Triethylamine (2 eq, 0.97 mmol, 140 l)  
Tosyl chloride (2 eq, 0.97 mmol, 184 mg)  
The product was purified by column chromatography, eluting with 15 % EtOAc in hexane, to 
yield a colourless oil (219 mg, 80 %).  
 
IR (cm-1) 3499 (OH), 1603 (Ar), 1332/1158 (SO2N), 1102 (SiO), 1082 (CO); 
1H-NMR (300 
MHz, CDCl3)  7.71-7.13 (stack, 14H (ArH)), 3.73-3.15 (stack, 7H (CH, CH2OSi, CH2OH, CH2N)), 
2.33 (s, 3H (ArCH3)), 1.95-1.17 (stack, 5H (CH2CH2N, CH2CH3, CHCH3)), 0.97 (s, 9H (
tBu)), 0.80 
(t, 3H, J = 6.0 Hz (CH3CH2)), 0.67 (d, 3H, J = 1.5 Hz (CH3CH)). 
13C-NMR (100 MHz, CDCl3) 
143.2 (QAr), 137.6 (QAr), 134.3 (QAr), 130.1 (ArH), 129.7 (ArH), 129.5 (ArH), 129.2 (ArH), 
128.1 (ArH), 64.1 (CHN), 61.4 (CH2OSi) 60.6 (CH2OH), 44.8 (CH2N), 34.5 (CHMe), 31.7 (Q
tBu), 
30.2 (CH2CH2N), 26.9 (
tBu), 26.1 (CH2Me), 21.3 (ArCH3), 18.3 (MeCH), 11.6 (MeCH2); m/z (ES) 
[M+Na]+ 590.3 
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95f  
N-Tosyl-(S)-2-(3-(tert-butyldiphenylsilyloxy)propylamino)-3,3-dimethylbutan-1-ol  
 
 
Procedure B was followed using the following amounts:  
Amine 93f (1 eq, 0.48 mmol, 200 mg) in DCM (0.1 M, 4.8 mL)  
Triethylamine (2 eq, 0.97 mmol, 140 l)  
Tosyl chloride (2 eq, 0.97 mmol, 184 mg)  
The product was purified by column chromatography, eluting with 15 % EtOAc in hexane, to 
yield a colourless oil (61 mg, 22 %).  
IR (cm-1) 3498 (OH), 2859 (CH), 1599 (Ar), 1330/1153 (SO2N), 1106 (SiO), 1086 (CO); 
1H-
NMR (300 MHz, CDCl3)  7.78-7.75 (stack, 2H (ArH)), 7.66-7.64 (stack, 4H (ArH)), 7.48-7.37 
(stack, 6H (ArH)), 7.30-7.28 (stack, 2H (ArH)), 3.82-3.61 (stack, 5H (CH, CH2OSi, CH2OH)), 
3.39-3.34 (m, 2H (CH2N)), 2.44 (s, 3H (ArCH3)), 2.15-1.99 (m, 2H (CH2CH2N)), 1.67 (brs, 1H 
(OH)), 1.05 (s, 9H (tBuSi)), 0.92 (s, 9H, (tBu)); 13C-NMR (100 MHz, CDCl3) 143.2 (QAr), 137.6 
(QAr), 134.3 (QAr), 130.1 (ArH), 129.6 (ArH), 129.5 (ArH), 129.2 (ArH), 128.1 (ArH), 74.4 
(CHN), 61.6 (CH2OSi) 57.7 (CH2OH), 45.2 (CH2N), 31.5 (Q
tBuSi), 30.4 (CH2CH2N), 28.6 (Q
tBu), 
27.3 (tBu), 26.8 (tBuSi), 21.3 (ArCH3); m/z (ES) [M+Na]
+ 590.3 
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95g  
(S)-2-(3-(tert-Butyldiphenylsilyloxy)propylamino)-2-phenylethyl-4-methylbenzene sulfonate  
 
 
Procedure B was followed using the following amounts:  
Amine 93g (1 eq, 0.46 mmol, 200 mg) in DCM (0.1 M, 4.6 mL)  
Triethylamine (2 eq, 0.92 mmol, 129 l)  
Tosyl chloride (2 eq, 0.92 mmol, 176 mg)  
The product was purified by column chromatography, eluting with 15 % EtOAc in hexane, to 
yield a colourless oil (44 mg, 16 %).  
 
IR (cm-1) 3521 (NH), 2929 (CH), 1596 (Ar), 1340/1155 (SO2N), 1109 (SiO), 1088 (CO); 1H-
NMR (300 MHz, CDCl3)  7.75 (app d, 2H (ArH)), 7.61-7.57 (stack, 4H (ArH)), 7.48-7.35 (stack, 
6H (ArH)), 7.33-7.20 (stack, 5H (ArH)), 7.01 (app d, 2H (ArH)), 5.07 (dd, 1H, J = 6.5, 8.0 Hz 
(CH)), 4.07 (m, 2H, CH2OTs)), 3.59 (ddd, 1H J = 4.5, 6.5, 11.0 Hz (CHHOSi)), 3.50 (ddd, 1H J = 
4.5, 7.5, 11.0 Hz (CHHOSi)), 3.26 (dt, 2H, J = 5.5, 10.5 Hz (CH2N)), 2.46 (s, 3H (ArCH3)), 2.17 
(brs, 1H (NH)), 1.84-1.59 (m, 2H (CH2CH2N)), 1.03 (s, 9H (
tBu)). 13C-NMR (100 MHz, CDCl3) 
143.4 (QAr), 138.0 (QAr), 136.1 (QAr), 135.5 (ArH), 133.6 (QAr), 133.5 (QAr), 129.7 (ArH), 
128.7 (ArH), 128..2 (ArH), 128.1 (ArH), 127.7 (ArH), 127.7 (ArH), 127.4 (ArH), 62.2 (CH2OH), 
62.2 (CH), 61.5 (CH2OSi), 42.6 (CH2N), 33.7 (CH2CH2N), 26.9 (
tBu), 21.6 (ArCH3), 19.2 (Q
tBu); 
m/z (ES) [M+Na]+ 610.3 (no negative ion found therefore no free OH i.e. Ts on oxygen) 
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96a  
N-Tosyl-(S)-2-((3-(tert-butyldiphenylsilyloxy)propyl)amino)-3-phenylpropanal 
 
 
Procedure F was followed using the following amounts:  
Oxalyl chloride (1.1 eq, 2.89 mmol, 0.24 mL) in DCM (0.33 M, 8.00 mL)  
DMSO (2.4 eq, 6.30 mmol, 0.45 mL)  
Alcohol 95a (1 eq, 2.63 mmol, 1.58 g) in DCM (1 M, 2.60 mL)  
Triethylamine (5 eq, 13.13 mmol, 1.83 mL)  
The product was purified by column chromatography, eluting with 15 % EtOAc in heptane, to 
yield a yellow oil (1.28 g, 81 %). 
  
Rf 0.20 (15 % EtOAc in heptane); IR (cm
-1) 2927 (CHO), 1656 (Ar), 1326/1144 (SO2N), 1110 
(SiO), 1083 (CO); 1H-NMR (300 MHz, CDCl3)  9.64 (s, 1H (CHO)), 7.64-7.58 (stack, 4H (ArH)), 
7.54-7.51 (stack, 2H (ArH)), 7.46-7.33 (stack, 6H (ArH)), 7.22-7.16 (stack, 5H (ArH)), 7.09-7.04 
(stack, 2H (ArH)), 4.48 (dd, 1H, J = 6.5, 8.0 Hz (CH)), 3.68-3.54 (m, 2H (CH2OSi)), 3.38 (dd, 1H, 
J = 6.0, 14.5 Hz (CHHPh)), 3.28 (ddt, 2H, J = 8.0, 10.0, 15.0 Hz (CH2N)), 2.74 (dd, 1H, J = 8.0, 
14.5 Hz (CHHPh)), 2.40 (s, 3H (ArCH3)), 1.79-1.63 (m, 2H (CH2CH2N)), 1.03 (s, 9H (
tBu); 13C-
NMR (100 MHz, CDCl3) 198.9 (CHO), 143.6 (QAr), 142.6 (QAr), 138.9 (QAr), 137.1 (QAr), 
135.5 (ArH), 129.8 (ArH), 129.0 (ArH), 128.6 (ArH), 127.7 (ArH), 127.4 (ArH), 126.7 (ArH), 68.1 
(CHN), 61.1 (CH2OSi), 44.0 (CH2N), 33.2 (CH2CH2N), 32.9 (CH2Ph), 26.9 (
tBu), 21.5 (ArCH3), 
19.0 (QtBu); m/z (ES) [M+Na]+ 622.1; C35H41NO4SiSNa requires 622.2423, found 622.2429 
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96c  
N-Tosyl-2-((3-((tert-butyldiphenylsilyl)oxy)propyl)amino)-3-methylbutanal 
 
 
Procedure F was followed using the following amounts:  
Oxalyl chloride (1.1 eq, 1.99 mmol, 0.17 mL) in DCM (0.33 M, 5.0 mL)  
DMSO (2.4 eq, 4.33 mmol, 0.31 mL)  
Alcohol 95c (1 eq, 1.81 mmol, 1.0 g) in DCM (1 M, 2.2 mL)  
Triethylamine (5 eq, 9.03 mmol, 1.25 mL)  
The product was purified by column chromatography, eluting with 20 % EtOAc in hexane, to 
yield a yellow oil (990 mg, >99 %).  
 
Rf 0.57 (20 % EtOAc in hexane); IR (cm
-1) 2923 (CHO), 1646 (Ar), 1328/1139 (SO2N), 1115 
(SiO), 1081 (CO); 1H-NMR (300 MHz, CDCl3)  9.53 (d, 1H, J = 1.0 Hz (CHO)), 7.71 (app d, 2H 
(ArH)), 7.66-7.61 (stack, 4H (Ph)), 7.54-7.34 (stack, 6H (Ph)), 7.29 (app d, 2H (ArH)), 3.94 (dd, 
1H, J = 1.0, 10.0 Hz (CH)), 3.71-3.57 (m, 2H (CH2O)), 3.30 (ddd, 2H, J = 6.0, 7.5, 10.5 Hz 
(CH2N)), 2.44 (s, 3H (ArCH3)), 2.19 (dsept, 1H, J = 6.5, 10.0 Hz (CHMe2)), 1.99- 1.76 (m, 2H 
(CH2CH2N)), 1.07 (d, 3H, J = 6.5 Hz (Me)), 1.05 (s, 9H (
tBu)), 0.92 (d, 3H, J = 6.5 Hz (Me)); 13C-
NMR (100 MHz, CDCl3) 198.9 (CHO), 143.5 (QAr), 142.6 (QAr), 137.3 (ArH), 135.5 (QAr), 
129.7 (ArH), 127.7 (ArH), 127.4 (ArH), 72.0 (CHN), 61.3 (CH2OSi), 44.3 (CH2N), 33.4 (CH2CH2N), 
27.2 (CHMe2), 26.8 (
tBu), 21.5 (ArCH3), 20.2 (Me), 19.9 (Me), 19.2 (Q
tBu); m/z (ES) [M+Na]+ 
622.1; C35H41NO4SiSNa requires 622.2423, found 622.2429 
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97a  
(S)-1-(tert-Butyldimethylsilyloxy)-3-phenylpropan-2-amine117  
 
 
To a solution of alcohol 69a (1 eq, 13.23 mmol, 2.00 g) and triethylamine (2 eq, 26.45 mmol, 
3.69 mL) in DCM (1.65 M, 8 mL), was added TBSCl (1 eq, 13.23 mmol, 1.99 g) in DCM (1.65 M, 
8 mL). The mixture stirred at RT for 48 hours then was diluted with sat. aq. ammonium 
chloride and extracted into DCM and washed with brine. Yield 3.46 g as a white solid (98 %).  
 
Rf 0.64 (5 % MeOH in DCM); IR (cm
-1) 3370 (NH2), 1251/833 (SiMe), 1093/774 (SiO); 
1H-
NMR (300 MHz, CDCl3)  7.36-7.15 (stack, 5H (ArH)), 3.58 (dd, 1H, J = 4.5, 9.5 (CHHO)), 3.43 
(dd, 1H, J = 6.5, 9.5 Hz (CHHO)), 3.15-3.03 (m, 1H (CH)), 2.79 (dd, 1H, J = 8.5, 13.5 (CHHPh)), 
2.51 (dd, 1H, J = 8.5, 13.5 (CHHPh)), 1.63 (brs, 2H (NH2)), 0.91 (s, 9H (
tBu)), 0.06 (s, 3H (Me)), 
0.06 (s, 3H (Me)) [Lit. agreement]; 13C-NMR (100 MHz, CDCl3) 138.0 (QAr), 128.8 (ArH), 
128.1 (ArH), 126.0 (ArH), 70.8 (CH2O), 54.9 (CHN), 39.6 (CH2Ph), 30.6 (Q
tBu), 25.9 (tBu), -2.3 
(Me); m/z (ES) [M+H]+ 266.1; C15H28NOSi requires 266.1940, found 266.1934 
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97b  
(S)-1-(tert-Butyldimethylsilyloxy)propan-2-amine  
 
 
To a solution of alcohol 69b (1 eq, 6.66 mmol, 500 mg) and triethylamine (2 eq, 13.31 mmol, 
1.86 mL) in DCM (1.65 M, 4.0 mL), was added TBSCl (1 eq, 6.66 mmol, 1.00 g) in DCM (1.65 
M, 4.0 mL). The mixture stirred at RT for 20 hours then was diluted with sat. aq. ammonium 
chloride and extracted into DCM and washed with brine. Yield 0.94 g as a colourless oil 
(75 %).  
 
IR (cm-1) 3321 (NH2), 1258/831 (SiMe), 1090/775 (SiO); 
1H-NMR (300 MHz, CDCl3) 3.53 
(dd, 1H, J = 4.5, 9.5 Hz (CHHO)), 3.29 (dd, 1H, J = 7.5, 9.5 (CHHO)), 3.06-2.88 (m, 1H (CH)), 
1.60 (brs, 2H (NH2)), 1.03 (d, 3H, J = 6.5 Hz (CH3)), 0.92 (s, 9H (
tBu)), 0.07 (s, 6H (MeSi)); 13C-
NMR (100 MHz, CDCl3) 69.9 (CH2), 48.6 (CH), 25.9 (
tBu), 19.3 (CH3), 18.3 (Q
tBu), -5.3 (CH3Si); 
m/z (ES) [M+H]+ 190.1; C9H24NOSi requires 190.1627, found 190.1626 
 
 
98a  
(S)-N-(1-(tert-Butyldimethylsilyloxy)-3-phenylpropan-2-yl)-3-(tert-butyldiphenylsilyloxy) 
propan-1-amine  
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Alcohol 93a (1 eq, 1.12 mmol, 500 mg) and triethylamine (2 eq, 2.23 mmol, 0.31 mL) were 
dissolved in DCM (1.67 M, 0.67 mL). tert-Butyldimethylsilyl chloride (1 eq, 1.12 mmol, 168 
mg) in DCM (1.67 M, 0.67 mL) was added and the reaction mixture stirred at RT overnight. 
The reaction was quenched with aq. ammonium chloride, the products extracted into DCM 
and washed with brine to yield a purple oil. Yield 563 mg (89 %).  
 
Rf 0.47 (20 % EtOAc in hexane); IR (cm
-1) 3071 (NH), 1590 (Ar), 1105 (SiO); 1H-NMR (300 
MHz, CDCl3) 7.68 (app dd, 4H (ArH)), 7.49-7.38 (stack, 6H (ArH)), 7.34-7.17 (stack, 5H (ArH)), 
3.71 (t, 2H, J = 6.5 Hz (CH2OTBDPS)), 3.51 (dd, 2H, J = 1.0, 4.0 Hz (CH2Ph)), 2.86 (dt, 1H, J = 4.0, 
9.5 Hz (CH)), 2.81-2.73 (stack, 4H (CH2N, CH2OTBS)), 1.73 (quin, 2H, J = 6.5 Hz (CH2 CH2N)), 
0.92 (s, 9H (tBu)), 0.06 (s, 3H (Me)), 0.04 (s, 3H (Me)); 13C-NMR (100 MHz, CDCl3) 135.6 
(QAr), 134.0 (QAr), 129.6 (ArH), 129.3 (ArH), 128.6 (ArH), 128.3 (ArH), 127.6 (ArH), 126.1 
(ArH), 63.8 (CH2Ph), 62.1 (CH2OTBDPS), 60.9 (CH), 44.3 (CH2N), 37.8 (CH2OTBS), 33.3 
(CH2CH2N), 26.9 (
tBu), 25.9 (tBu), 19.2 (QtBu), 18.3 (QtBu); m/z (ES) [M+Na]+ 584.4 
 
 
98b  
(S)-N-(1-(tert-Butyldimethylsilyloxy)propan-2-yl)-3-(tert-butyldiphenylsilyloxy)propan-1- 
amine  
 
 
Procedure G was followed using the following amounts:  
Amine 97b (1 eq, 4.96 mmol, 939 mg) in DCM (1 M, 5.00 mL)  
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Na2SO4 (1.02 eq, 5.06 mmol, 718 mg)  
3-(tert-butyldiphenylsilyloxy)propanal (1 eq, 4.96 mmol, 1.55 g) in DCM (1.75 M, 3.00 mL)  
NaBH4 (1.5 eq, 7.44 mmol, 281 mg)  
MeOH (1 M, 5.00 mL)  
Yield: 2.01 g, 91 %, yellow oil.  
 
Rf 0.05 (2.5 % MeOH in DCM); IR (cm
-1) 3071 (NH), 1088 (SiO); 1H-NMR (300 MHz, CDCl3)  
7.73-7.65 (stack, 4H (ArH)), 7.49-7.32 (stack, 6H (ArH)), 3.76 (t, 2H, J = 6.0 Hz (CH2OTBDPS)), 
3.49 (ddd, 2H, J = 6.0, 10.0, 16.5 Hz (CH2N)), 2.88-2.64 (stack, 3H (CH, CH2OTBS)), 1.89 (brs, 
1H (NH)), 1.83-1.70 (m, 2H (CH2CH2N)), 1.07 (s, 9H (
tBu)), 1.01 (d, 3H, J = 6.5 Hz (Me)), 0.91 (s, 
9H (tBu)), 0.07 (s, 6H (MeSi)); 13C-NMR (100 MHz, CDCl3) 134.1 (QAr), 130.2 (ArH), 130.0 
(ArH), 129.6 (ArH), 72.4 (CHN), 71.2 (CH2OTBS), 61.5 (CH2OTBDPS), 43.2 (CH2N), 33.9 
(CH2CH2N), 31.4 (Q
tBu), 30.4 (QtBu), 26.7 (tBu), 25.4 (tBu), 17.4 (Me), -2.1 (MeSi); m/z (ES) 
[M+Na]+ 508.3 
 
 
99  
N-Tosyl-(S)-N-(1-(tert-butyldimethylsilyloxy)-3-phenylpropan-2-yl)-3-(tert-
butyldiphenylsilyloxy)propan-1-amine  
 
 
Amine 98a (1 eq, 8.85 mmol, 5.00 g), triethylamine (2 eq, 17.70 mmol, 2.47 mL) and tosyl 
chloride (1 eq, 8.85 mmol, 1.69 g) were mixed together in DCM (0.07 M, 130 mL) and stirred 
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at RT overnight. The solvents were removed and the residue taken up into ethyl acetate. The 
white precipitate was removed by filtration under suction and the filtrate washed with 
NaHCO3 and water. The product was purified by column chromatography, eluting with 5 % 
EtOAc in hexane, to yield a pale yellow oil (4.63 g, 73 %).  
 
Rf 0.75 (25 % EtOAc in hexane); IR (cm
-1) 2929 (CH), 1733 (Ar), 1337/1154 (SO2N), 1106 (Si); 
1H-NMR (300 MHz, CDCl3)  7.71-7.10 (stack, 19H (ArH)), 4.10-4.02 (m, 1H (CH)), 3.66 (dd, 2H, 
J = 4.0, 7.5 Hz (CH2OTBDPS)), 3.59 (dd, 2H, J = 5.0, 10.5 (CH2OTBS)), 3.52-3.29 (m, 2H (CH2N)), 
2.99 (dd, 1H, J = 8.0, 13.5 (CHHPh)), 2.77 (dd, 1H, J = 6.5, 13.5 (CHHPh)), 2.40 (s, 3H (ArCH3)), 
1.96-1.84 (m, 2H (CH2CH2N)), 1.08 (s, 9H (
tBu)), 0.85 (s, 9H (tBu)), -0.03 (s, 3H (Me)), -0.04 (s, 
3H (Me)); 13C-NMR (100 MHz, CDCl3) 142.6 (QAr), 138.6 (QAr), 138.3 (QAr), 135.6 (ArH), 
133.7 (QAr), 129.7 (ArH), 129.4 (ArH), 129.2 (ArH), 128.4 (ArH), 127.7 (ArH), 127.2 (ArH), 
126.3 (ArH), 63.6 (CH2OTBDMS), 61.8 (CH2OTBDPS), 60.4 (CH), 42.6 (CH2N), 36.5 (CH2Ph), 
34.0 (CH2CH2N), 26.9 (
tBu), 25.9 (tBu), 21.4 (ArCH3), 19.2 (Q
tBu), 18.2 (QtBu), -5.6 (SiMe); m/z 
(ES) [M+Na]+ 738.1; C41H57NO4SSi2Na requires 738.3445, found 738.3442 
 
 
100a  
N-Tosyl-(S)-N-3-(tert-butyldiphenylsilyloxy)propyl-4-methyl-1-phenylpent-3-en-2-amine  
 
 
Procedure H was followed using the following amounts:  
Isopropyltriphenylphosphonium iodide (3 eq, 11.0 mmol, 4.76 g) in THF (0.05 M, 70 mL)  
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n-BuLi [1.6 M] (3 eq, 11.0 mmol, 6.88 mL)  
aldehyde 96a (1 eq, 3.67 mmol, 2.20 g) in THF (0.1 M, 40 mL)  
ylide colour: deep red  
yield: 1.94 g (84 %) orange oil after column 10 % EtOAc in heptane.  
 
Rf 0.80 (10 % EtOAc in heptane); IR (cm
-1) 1724 (Ar), 1599 (=), 1337/1156 (SO2N), 1105 
(SiO), 1089 (CO); 1H-NMR (300 MHz, CDCl3)  7.68-7.61 (stack, 6H (ArH)), 7.46-7.34 (stack, 6H 
(ArH)), 7.25-7.14 (stack, 5H (ArH)), 7.11-7.07 (stack, 2 H (ArH)), 5.05 (d, 1H, J = 9.5 Hz (=CH)), 
4.71 (dt, 1H, J = 4.5, 9.5 Hz (CH)), 3.67 (t, 2H, J = 5.5 Hz (CH2OSi)), 3.38-3.21 (m, 2H (CH2N)), 
2.91 (dd, 1H, J = 4.5, 13.0 Hz (CHHPh)), 2.67 (dd, 1H, J = 9.5, 13.0 Hz (CHHPh)), 2.39 (s, 3H 
(ArCH3)), 1.98-1.81 (m, 2H (CH2CH2N)), 1.51 (d, 3H, J = 1.0 Hz (=CH3)), 1.17 (d, 3H, J = 1.0 Hz 
(=CH3)), 1.07 (s, 9H (
tBu)); 13C-NMR (100 MHz, CDCl3) 140.2 (QAr), 137.7 (QAr), 136.9 
(=CMe2), 135.9 (QAr), 134.2 (QAr), 130.5 (ArH), 130.2 (ArH), 129.6 (ArH), 129.1 (ArH), 128.4 
(ArH), 128.1 (=CH), 128.0 (ArH), 127.5 (ArH), 125.4 (ArH), 61.2 (CH2O), 55.4 (CHN), 44.9 
(CH2N), 38.5 (CH2Ph), 31.5 (Q
tBu), 30.0 (CH2CH2N), 26.4 (
tBu), 21.3 (ArCH3), 21.5 (Me=), 15.6 
(Me=); m/z (ES) [M+Na]+ 648.2; C38H47NO3SSiNa requires 648.2944, found 648.2941 
 
 
100c  
N-Tosyl-(S)-N-3-(tert-butyldiphenylsilyloxy)propyl-2,5-dimethylhex-4-en-3-amine 
 
Procedure H was followed using the following amounts:  
Isopropyltriphenylphosphonium iodide (3 eq, 1.09 mmol, 470 mg) in THF (0.16 M, 7 mL)  
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n-BuLi [1.6 M] (3 eq, 1.09 mmol, 0.68 mL)  
aldehyde 96b (1 eq, 0.36 mmol, 200 mg) in THF (0.27 M, 4 mL)  
ylide colour: deep red  
yield: 98 mg (47 %) orange oil after column 10 % EtOAc in hexane.  
 
IR (cm-1) 1727 (Ar), 1605 (=), 1332/1151 (SO2N), 1107 (SiO), 1088 (CO); 
1H-NMR (300 MHz, 
CDCl3)  7.73-7.58 (stack, 6H (ArH)), 7.49-7.32 (stack, 6H (ArH)), 7.21 (app d, 2H (ArH)), 5.02 
(dsept, 1H, J = 1.5, 10.5 Hz (=CH)), 4.19 (t, 1H, J = 10.5 (CH)), 3.66 (t, 1H, J = 5.5 Hz (CHHO)), 
3.65 (t, 1H, J = 5.5 Hz (CHHO)), 3.27 (ddd, 1H, J = 5.5, 11.0, 22.0 (CHHN)), 3.16 (ddd, 1H, J = 
5.5, 11.0, 15.0 (CHHN)), 2.41 (s, 3H (ArCH3)), 2.07-1.90 (m, 1H (CHMe2)), 1.89-1.71 (m, 2H 
(CH2CH2N)), 1.62 (d, 3H, J = 1.5 Hz (=Me)), 1.62 (d, 3H, J = 1.5 Hz (=Me)), 1.07 (s, 9H (
tBu)), 
1.03 (d, 3H, J = 6.5 Hz (Me)), 0.82 (d, 3H, J = 6.5 Hz (Me)); 13C-NMR (100 MHz, CDCl3) 135.5 
(QAr), 134.8 (QAr), 133.7 (QAr), 132.6 (=CMe2), 129.7 (ArH), 129.0 (ArH), 127.7 (ArH), 127.4 
(ArH), 121.8 (ArH), 116.1 (=CH), 62.9 (CH), 61.8 (CH2O), 42.1 (CH2N), 33.8 (CH2CH2N), 31.7 
(CHMe2), 26.8 (
tBu), 25.8 (=Me), 21.5 (ArCH3), 20.4 (Me), 19.9 (Q
tBu), 19.5 (Me), 18.9 (=Me) 
 
 
101a  
N-Tosyl-(S)-3-((4-methyl-1-phenylpent-3-en-2-yl)amino)propan-1-ol 
 
 
To a solution of silyl ether 100a (1 eq, 7.79 mmol, 4.87 g) in THF (0.1 M, 78 mL) was added 
TBAF [1 M/THF] (1.5 eq, 11.68 mmol, 11.68 mL). The mixture was stirred at room 
140 
 
temperature overnight then water was added and the product extracted into ether. 
Purification by column chromatography, eluting with 30 % EtOAc in heptane, yielded an 
orange oil (1.98 g, 65 %).  
 
Rf 0.22 (30 % EtOAc in heptane); IR (cm
-1) 3562 (OH), 2931 (CH), 1675 (Ar), 1598 (=), 
1383/1153 (SO2N), 1322 (CO); 
1H-NMR (400 MHz, CDCl3)  7.67 (app d, 2H (ArH)), 7.27- 7.13 
(stack, 5H (ArH)), 7.10 (app d, 2H (ArH)), 5.05 (d, 1H, J = 9.5 Hz (=CH)), 4.64 (ddd, 1H, J = 4.5, 
9.5, 10.0 Hz (CH)), 3.78-3.64 (m, 2H (CH2N)), 3.36 (t, 2H, J = 7.0 Hz (CH2OH)), 2.97 (dd, 1H, J = 
4.5, 13.0 Hz (CHHPh)), 2.69 (dd, 1H, J = 10.0, 13.0 Hz (CHHPh)), 2.39 (s, 3H (ArCH3)), 2.31 (brs, 
1H (OH)), 1.82 (dt, 2H, J = 5.5, 7.0 Hz (CH2CH2N)); 
13C-NMR (100 MHz, CDCl3) 140.2 (QAr), 
137.5 (QAr), 136.5 (=CMe2), 136.1 (QAr), 129.7 (ArH), 128.4 (ArH), 128.3 (ArH), 128.1 (=CH), 
127.8 (ArH), 125.2 (ArH), 58.4 (CH2O), 55.4 (CHN), 44.7 (CH2N), 38.7 (CH2Ph), 31.5 (CH2CH2N), 
21.4 (ArCH3), 21.1 (Me=), 15.8 (Me=); m/z (ES) [M+Na]
+ 410.1; C22H29NO3SNa requires 
410.1766, found 410.1773 
 
 
101c  
N-Tosyl-(S)-3-((2,5-dimethylhex-4-en-3-yl)amino)propan-1-ol  
 
 
To a solution of silyl ether 100c (1 eq, 0.53 mmol, 305 mg) in THF (0.1 M, 5.50mL) was added 
TBAF [1 M/THF] (1.5 eq, 0.79 mmol, 0.80 mL). The mixture was stirred at room temperature 
overnight then water was added and the product extracted into ether. Purification by 
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column chromatography, eluting with 25 % EtOAc in hexane, yielded a pale yellow oil (139 
mg, 78 %).  
 
IR (cm-1) 3514 (OH), 2959 (CH), 1672 (=), 1384/1154 (SO2N), 1326 (CO); 
1H-NMR (400 MHz, 
CDCl3)  7.63 (app d, 2H (ArH)), 7.22 (app d, 2H (ArH)), 5.01 (dsept, 1H, J = 1.0, 10.5 Hz (=CH)), 
4.09 (t, 1H, J = 10.5 Hz (CH)), 3.82-3.62 (m, 2H (CH2N)), 3.26 (t, 2H, J = 7.0 Hz (CH2OH)), 2.40 
(s, 3H (ArCH3)), 2.31 (brs, 1H (OH)), 1.98-1.67 (stack, 3H (CH2CH2N, CHMe2)), 1.59 (d, 3H, J = 
1.0 Hz (=Me)), 1.53 (d, 3H, J = 1.0 Hz (=Me)), 1.26 (d, 3H, J = 7.0 Hz (Me)), 0.99 (d, 3H, J = 6.5 
Hz (Me)); 13C-NMR (100 MHz, CDCl3) 142.7 (=CMe2), 137.8 (QAr), 136.0 (QAr), 129.1 (ArH), 
127.4 (ArH), 121.4 (=CH), 63.1 (CH), 59.7 (CH2N), 41.4 (CH2OH), 33.6 (CH2CH2N), 31.9 (CHMe2), 
25.7 (=Me), 21.1 (ArCH3), 20.4 (Me), 19.6 (Me), 18.9 (=Me); m/z (ES) [M+Na]
+ 362.2  
 
 
102a  
N-Tosyl-(S)-3-((4-methyl-1-phenylpent-3-en-2-yl)amino)propanal  
 
 
Procedure F was followed using the following amounts:  
Oxalyl chloride (1.1 eq, 1.42 mmol, 0.12 mL) in DCM (0.33 M, 3.50 mL)  
DMSO (2.4 eq, 3.10 mmol, 0.22 mL)  
Alcohol 101a (1 eq, 1.29 mmol, 0.50 g) in DCM (1 M, 1.50 mL)  
Triethylamine (5 eq, 6.45 mmol, 0.90 mL)  
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The product was purified by column chromatography, eluting with 15 % EtOAc in heptane, to 
yield a yellow oil (432 mg, 87 %).  
 
Rf 0.21 (20 % EtOAc in heptane); IR (cm
-1) 3029 (CHO), 2928 (CH), 1719 (C=O), 1598 (Ar), 
1453 (=), 1330/1153 (SO2N); 
1H-NMR (300 MHz, CDCl3)  9.74 (s, 1H (CHO)), 7.64 (app d, 2H 
(ArH)), 7.26-7.15 (stack, 5H (ArH)), 7.09 (app d, 2H (ArH)), 4.97 (dt, 1H, J = 1.5, 9.5 Hz (=CH)), 
4.74 (dt, 1H, J = 5.0, 9.5 Hz (CH)), 3.50-3.31 (m, 2H (CH2N)), 2.96-2.79 (stack, 3H (CH2CHO, 
CHHPh)), 2.64 (dd, 1H, J = 9.5, 13.0 Hz (CHHPh)), 2.40 (s, 3H (ArCH3)), 1.52 (s, 3H (=CH3)), 
1.26 (s, 3H (=CH3)); 
13C-NMR (100 MHz, CDCl3) 200.7 (CHO), 143.2 (=CMe2), 137.7 (QAr), 
137.6 (QAr), 137.3 (QAr), 129.4 (ArH), 128.7 (ArH), 128.3 (ArH), 127.4 (ArH), 126.4 (ArH), 
121.0 (=CH), 57.6 (CH), 46.2 (CH2CHO), 41.0 (CH2Ph), 37.7 (CH2N), 25.6 (Me), 21.5 (ArCH3), 
18.1 (Me); m/z (ES) [M+Na]+ 408.1; C22H27NO3SNa requires 408.1609, found 408.1618 
 
 
102c  
N-Tosyl-(S)-3-((2,5-dimethylhex-4-en-3-yl)amino)propanal  
 
 
Procedure F was followed using the following amounts:  
Oxalyl chloride (1.1 eq, 0.42 mmol, 36 l) in DCM (0.4 M, 1 mL)  
DMSO (2.4 eq, 0.92 mmol, 65 l)  
Alcohol 101c (1 eq, 0.38 mmol, 130 mg) in DCM (0.75 M, 0.5 mL)  
Triethylamine (5 eq, 1.91 mmol, 266 l)  
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The product was purified by column chromatography, eluting with 15 % EtOAc in hexane, to 
yield a yellow oil (55 mg, 43 %).  
 
IR (cm-1) 2921 (CH), 1720 (C=O), 1598 (=), 1330/1156 (SO2N); 
1H-NMR (300 MHz, CDCl3)  
9.78 (s, 1H (CHO)), 7.63 (app d, 2H (ArH)), 7.25 (app d, 2H (ArH)), 4.95 (d, 1H, J = 10.0 Hz 
(=CH)), 4.19 (t, 1H, J = 10.0 Hz (CH)), 3.43 (ddd, 1H, J = 5.0, 9.5, 13.5 (CHHCHO)), 3.38 (ddd, 
1H, J = 5.0, 9.5, 15.5 Hz (CHHCHO)), 3.10 (ddd, 1H, J = 5.0, 9.5, 18.5 (CHHN)), 2.89 (ddd, 1H, J 
= 5.0, 9.5, 18.5 (CHHN)), 2.42 (s, 3H (=Me)), 1.59 (s, 3H (=Me)), 0.99 (d, 3H, J = 6.5 Hz (Me)), 
0.81 (d, 3H, J = 6.5 Hz (Me)); 13C-NMR (100 MHz, CDCl3) 200.6 (CHO), 143.0 (=CMe2), 137.2 
(QAr), 136.4 (QAr), 129.2 (ArH), 127.5 (ArH), 121.0 (=CH), 62.9 (CHN), 45.8 (CH2CHO), 37.4 
(CH2N), 31.6 (CHMe2), 25.7 (=Me), 21.5 (ArCH3), 20.3 (Me) 19.4 (Me), 19.0 (=Me); m/z (ES) 
[M+Na]+ 360.2; C18H27NO3SNa requires 360.1609, found 360.1613 
 
 
112a  
(E)-2-Methyl-N-(2-methylpropylidene)propane-2-sulfinamide80  
 
 
(R)-t-butanesulfinamide (1 eq, 16.50 mmol, 2.00 g) was dissolved in DCM (1.7 M, 28 mL), 
then pyridinium tosylate (5 mol%, 0.83 mmol, 207 mg), anhydrous magnesium sulfate (5 eq, 
82.51 mmol, 9.93 g) isobutyraldehyde (2 eq, 33.00 mmol, 3.0 mL) and 3 Å molecular sieves 
were added. The reaction mixture stirred at RT overnight then was filtered through Celite® 
and washed with DCM. The filtrate was concentrated and purified by column 
chromatography, eluting with 5 % hexane in DCM, to yield a yellow liquid (2.77 g, 95 %).  
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IR (cm-1) 2969 (CH), 1704/1621 (C=N), 1063 (S=O); 1H-NMR (300 MHz, CDCl3)  7.93 (d, 1H, 
J = 4.5 Hz (N=CH)), 2.67 (dsept, 1H, J = 4.5, 7.0 Hz (CHMe2)), 1.17 (s, 9H, (
tBu)), 1.12 (s, 6H 
(Me)) [lit. agreement] ; 13C-NMR (100 MHz, CDCl3) 163.7 (C=N), 59.8 (Q
tBu), 32.4 (CHMe2), 
27.1 (tBu), 19.4 (Me); m/z (ES) [M+Na]+ 198.1; C8H17NOSNa requires 198.0929, found 
198.0936 
 
 
112b  
(E)-N-Ethylidene-2-methylpropane-2-sulfinamide118 
 
 
(R)-t-butanesulfinamide (1 eq, 8.25 mmol, 1.00 g) was dissolved in DCM (1.7 M, 14 mL), then 
pyridinium tosylate (5 mol%, 0.41 mmol, 104 mg), anhydrous magnesium sulfate (5 eq, 41.25 
mmol, 4.97 g) acetaldehyde (2 eq, 16.50 mmol, 0.92 mL) and 3 Å molecular sieves were 
added. The reaction mixture stirred at RT overnight then was filtered through Celite® and 
washed with DCM. The filtrate was concentrated and purified by column chromatography, 
eluting with 5 % hexane in DCM, to yield a yellow liquid (1.95 g, 95 %). 
  
IR (cm-1) 3233 (N=C), 2977 (CH), 1413/1030 (S=O), 886 (SN); 1H-NMR (300 MHz, CDCl3)  
8.08 (q, 1H J = 5.1 Hz (N=CH)), 2.24 (d, 3H, J = 5.1 Hz (Me)), 1.18 (s, 9H, (tBu)) [Lit. agreement]; 
13C-NMR (100 MHz, CDCl3) 162.2 (N=CH), 59.8 (Q
tBu), 25.6 (tBu), 14.9 (Me); m/z (ES) 
[M+Na]+ 170.1 
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112c  
(E)-N-Benzylidene-2-methylpropane-2-sulfinamide80  
 
 
To a solution of (R)-t-butanesulfinamide (1 eq, 8.25 mmol, 1.00 g) in DCM (0.5 M, 16.5 mL) 
was added freshly dried and ground copper sulfate (2.2 eq, 18.15 mmol, 2.90 g) followed by 
benzaldehyde (1.1 eq, 9.08 mmol, 1.68 mL). The reaction mixture stirred at RT overnight 
before filtering through Celite® and washing with DCM. The filtrate was reduced to half its 
volume then dried with MgSO4 and concentrated fully, the product was purified by column 
chromatography, eluting with DCM, to yield a clear oil (1.09 g, 63 %).  
 
IR (cm-1) 1605 (N=C), 1572 (Ar), 1082 (S=O); 1H-NMR (400 MHz, CDCl3)  8.60 (s, 1H 
(N=CH)), 7.87 (app dd, 2H (ArH)), 7.56-7.45 (stack, 3H (ArH)), 1.27 (s, 9H (tBu)) [lit. 
agreement]; 13C-NMR (100 MHz, CDCl3) 162.8 (N=CH), 134.1 (QAr), 132.4 (ArH), 129.4 
(ArH), 128.9 (ArH), 57.8 (QtBu), 22.6 (tBu); m/z (ES) [M+Na]+ 232.0; C11H15NOSNa requires 
232.0772, found 232.0773 
 
 
114a  
N-((R)-2,5-Dimethylhex-4-en-3-yl)-2-methylpropane-2-sulfinamide  
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Procedure I was followed using the following amounts:  
Imine 112a (1 eq, 5.67 mmol, 1.00 g)  
DCM (0.2 M, 28 mL)  
2-Methyl-1-propenylmagnesium bromide [0.5 M/THF] (2 eq, 11.34 mmol, 22.70 mL)  
Yield: 1.11 g, 85 %, yellow liquid [31:69 isomers]  
 
Rf 0.32 (1 % MeOH in DCM); IR (cm
-1) 3228 (NH), 2959 (CH), 1674 (=), 1039 (S=O); 1H-NMR 
(300 MHz, CDCl3)  5.06 [4.90] (dsept, 1H, J = 1.5, 9.5 Hz (=CH)), 3.75 [3.83] (ddd, 1H, J = 1.0, 
5.5, 9.5 Hz (CH)), 2.90 [3.15] (d, 1H, J = 5.5 Hz (NH)), 1.78 (dsept, 1H, J = 1.0, 7.0 Hz (CHMe2)), 
1.69 [1.72] (d, 3H J = 1.5 Hz (Me)), 1.66 [1.66] (d, 3H J = 1.5 Hz (Me)), 1.16 [1.15] (s, 9H (tBu)), 
0.87 [0.88] (d, 3H, J = 7.0 Hz (Me)), 0.84 [0.86] (d, 3H, J = 7.0 Hz (Me)); 13C-NMR (100 MHz, 
CDCl3) 135.8 (=CMe2), 123.8 (=CH), 58.8 (CH), 55.7 (Q
tBu), 33.0 (CH), 26.0 (Me), 22.7 (tBu), 
19.0 (Me), 18.5 (Me), 17.5 (Me); m/z (EI) [M]+ 231.2; C12H25NOS requires 231.1657 found 
231.1658 
 
 
114b  
2-Methyl-N-((R)-4-methylpent-3-en-2-yl)propane-2-sulfinamide  
 
 
Procedure I was followed using the following amounts:  
Imine 112b (1 eq, 8.15 mmol, 1.20 g)  
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DCM (0.2 M, 40 mL)  
2-Methyl-1-propenylmagnesium bromide [0.5 M/THF] (2 eq, 16.30 mmol, 32.6 mL)  
Yield: 1.13 g, 68 %, yellow oil [25:75 isomers]  
 
IR (cm-1) 3430 (NH), 2977 (CH), 1626 (=), 1026 (S=O), 870 (SN); 1H-NMR (300 MHz, CDCl3) 
5.09 [4.97] (dsept, 1H, J = 1.5, 9.0 Hz (=CH)), 4.18-4.06 (m, 1H (CH)), 2.92 [2.97] (brs, 1H, 
(NH)) 1.67 (s, 3H (=Me)), 1.63 (s, 3H (=Me)), 1.15 (s, 3H (Me)), 1.10 (s, 9H (tBu)); 13C-NMR 
(100 MHz, CDCl3) 180.0 (=CMe2), 127.7 (=CH), 48.3 (CH), 55.7 (Q
tBu), 25.7 (=Me), 22.5 (tBu), 
21.8 (Me), 18.2 (=Me); m/z (ES) [M+Na]+ 226.2; C10H21NOSNa requires 226.1242 found 
226.1228 
 
 
114c  
2-Methyl-N-((S)-3-methyl-1-phenylbut-2-en-1-yl)propane-2-sulfinamide  
 
Procedure I was followed using the following amounts:  
Imine 112c (1 eq, 0.96 mmol, 200 mg)  
DCM (0.2 M, 4.8 mL)  
2-Methyl-1-propenylmagnesium bromide [0.5 M/THF] (2 eq, 1.91 mmol, 3.82 mL)  
Yield: 208 mg, 82 %, yellow oil [10:90 isomers]  
 
IR (cm-1) 3398 (NH), 29.59 (CH), 1453 (=), 1052 (S=O); 1H-NMR (300 MHz, CDCl3)  7.40- 
7.24 (stack, 5H (ArH)), 5.37 (dsept, 1H, J = 1.5, 9.0 Hz (=CH)), 5.21 (dd, 1H, J = 2.5, 9.0 Hz 
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(CH)), 3.34 (brs, 1H, (NH)) 1.82 (d, 3H, J = 1.5 Hz (=Me)), 1.74 (d, 3H, J = 1.5 Hz (=Me)), 1.22 (s, 
9H (tBu)); 13C-NMR (100 MHz, CDCl3) 142.2 (=CMe2), 135.4 (QAr), 128.6 (ArH), 127.4 (ArH), 
126.9 (ArH), 126.3 (=CH), 56.6 (CH), 55.6 (QtBu), 25.8 (=Me), 22.6 (tBu), 18.4 (=Me); m/z (ES) 
[M+Na]+ 288.2; C15H23NOSNa requires 288.1398, found 288.1386 
 
 
(R)-2,5-Dimethylhex-4-en-3-amine  
 
 
To a solution of 114a (1 eq, 4.32 mmol, 1.00 g) in methanol (2 M, 2.20 mL) at 0 °C, was 
added anhydrous HCl [1 M/Et2O] (2 eq, 8.64 mmol, 8.60 mL). The mixture was stirred at 
room temperature for 30 minutes then was reduced in volume by half. Anhydrous ether was 
added and the white precipitate collected. The filtrate was concentrated then further 
triturated with ether. Yield 348 mg, off-white solid (49 %).  
 
IR (cm-1) 2890 (br) (NH), 2032 (NH3
+), 1600 (=); 1H-NMR (300 MHz, MeOD)  5.15 (dt, 1H, J 
= 1.5, 10.0 Hz (=CH)), 3.77 (dd, J = 7.0, 10.0 Hz (CH)), 1.91 (sept, 1H, J = 7.0 Hz (CHMe2)), 1.84 
(d, 3H, J = 1.5 Hz (Me)), 1.77 (d, 3H, J = 1.5 Hz (Me)), 1.02 (d, 3H, J = 7.0 Hz (Me)), 0.96 (d, 3H, 
J = 7.0 Hz (Me)); 13C-NMR (100 MHz, CDCl3) 135.8 (=CMe2), 119.9 (=CH), 56.2 (CHN), 33.1 
(CHMe2), 26.1 (Me), 19.3 (Me), 18.7 (Me), 17.9 (Me); m/z (ES) [M+Na]
+ 150.1 
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(R)-4-Methylpent-3-en-2-amine  
 
 
To a solution of 114b (1 eq, 5.55 mmol, 1.13 g) in methanol (2 M, 3.0 mL) at 0 °C, was added 
anhydrous HCl [1 M/Et2O] (2 eq, 11.11 mmol, 11.1 mL). The mixture stirred at room 
temperature for 30 minutes then was concentrated to a brown oil. Anhydrous ether was 
added and the white precipitate collected. The filtrate was concentrated then further 
triturated with ether. Yield 279 mg, white solid (37 %).  
 
IR (cm-1) 3118/3025/2806 (NH3
+), 1756 (=), 1392 (CH); 1H-NMR (300 MHz, MeOD)  5.17 
(dsept, 1H, J = 1.5, 9.5 Hz (=CH)), 4.14 (dq, 1H, J = 6.5, 9.5 Hz (CH)), 1.80 (d, 3H, J = 1.5 Hz 
(=Me)), 1.77 (d, 3H, J = 1.5 Hz (=Me)), 1.33 (d, 3H, J = 6.5 Hz (Me)); 13C-NMR (100 MHz, CDCl3) 
136.8 (=CMe2), 125.9 (=CH), 53.2 (CHN), 26.2 (Me), 21.3 (=Me), 15.9 (=Me); m/z (ES) [M]
+ 
100.1; C6H14N requires 100.1126, found 100.1125 
 
 
115  
(E)-2-Methyl-N-(3-methylbut-2-en-1-ylidene)propane-2-sulfinamide  
 
 
(R)-t-butanesulfinamde (1 eq, 4.13 mmol, 500 mg) and 3-methylbut-2-enal (2 eq, 8.25 mmol, 
0.79 mL) were dissolved in toluene (0.1 M, 40 mL) and potassium bisulfate (2 eq, 8.25 mmol, 
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1.12 g) was added. The reagents were stirred at 45 °C for 24 hours then the solids were 
removed and the filtrate concentrated to yield a yellow liquid in quantitative yield. The 
product required no further purification.  
 
IR (cm-1) 2868 (CH), 1639 (N=C), 1570 (C=), 1078 (S=O); 1H-NMR (300 MHz, CDCl3)  8.54 (d, 
1H, J = 10.0 Hz (N=CH)), 6.26 (dsept, 1H, J = 1.5, 10.0 Hz (=CH)), 2.07 (d, 3H, J = 1.5 Hz (=Me)), 
1.99 (d, 3H, J = 1.5 Hz (=Me)), 1.22 (s, 9H (tBu)); 13C-NMR (100 MHz, CDCl3) 160.5 (N=CH), 
153.7 (=CMe2), 124.1 (C=CH), 57.1 (Q
tBu), 27.0 (=Me), 22.5 (tBu), 19.3 (=Me); m/z (ES) 
[M+Na]+ 210.1; C9H17NOSNa requires 210.0929, found 210.0926 
 
 
116a  
2-Methyl-N-((S)-4-methylpent-3-en-2-yl)propane-2-sulfinamide  
 
 
Procedure I was followed using the following amounts:  
Imine 115 (1 eq, 13.24 mmol, 2.48 g)  
DCM (0.2 M, 65 mL)  
Methylmagnesium bromide [3 M/Et2O] (2 eq, 26.48 mmol, 8.83 mL)  
Yield: 2.01 g, 75 %, yellow liquid [13:87 isomers]  
 
IR (cm-1) 3215 (NH), 2928 (CH), 1673 (=), 1028 (S=O); 1H-NMR (300 MHz, CDCl3)  4.91 
[5.03] (dsept, 1H, J = 1.5, 9.0 Hz (=CH)), 4.21 (m, 1H (CH)), 2.98 [2.93] (d, 1H, J = 2.0 Hz (NH)), 
1.65 (d, 3H, J = 1.5 Hz (=Me)), 1.63 (d, 3H, J = 1.5 Hz (=Me)), 1.15 (d, 3H, J = 6.5 Hz (Me)), 1.13 
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(s, 9H (tBu)); 13C-NMR (400 MHz, CDCl3) 134.7 (=CMe2), 127.7 (=CH), 55.1 (Q
tBu), 48.5 (CH), 
25.7 (Me), 23.2 (Me), 22.6 (tBu), 18.2 (Me); m/z (EI) [M]+ 203.1; C10H21NOS requires 203.1344, 
found 203.1342 
 
 
116b  
N-((S)-2,5-Dimethylhex-4-en-3-yl)-2-methylpropane-2-sulfinamide  
 
 
Isopropylmagnesium bromide was produced following the procedure set out by Harwood 
and Moody.83  
Procedure I was followed using the following amounts:  
Imine 115 (1 eq, 2.67 mmol, 0.50 g)  
DCM (0.2 M, 10 mL)  
Isopropylmagnesium bromide [1.25 M/Et2O] (2 eq, 5.34 mmol, 4.27 mL)  
Yield: 468 mg, 76 %, yellow oil [20:80 isomers]  
 
IR (cm-1) 3209 (NH), 2935 (CH), 1457 (=), 1049 (S=O); 1H-NMR (300 MHz, CDCl3)  4.88 
[5.04] (dsept, 1H, J = 1.5, 9.0 Hz (=CH)), 3.81 [3.73] (ddd, 1H, J = 3.0, 6.0, 9.0 Hz (CH)), 3.12 
[2.86] (brs, 1H (NH)), 1.70 (d, 3H, J = 1.5 Hz (=Me)), 1.68-1.65 (m, 1H (CHMe2)), 1.64 (d, 3H, J 
= 1.5 Hz (=Me)), 1.13 (s, 9H (tBu)), 0.85 (d, 3H, J = 6.0 Hz (Me)), 0.82 (d, 3H, J = 6.0 Hz (Me)); 
13C-NMR (100 MHz, CDCl3) 136.8 (=CMe2), 122.7 (=CH), 57.3 (CH), 55.4 (Q
tBu), 34.1 
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(CHMe2), 26.0 (=Me), 22.7 (
tBu), 19.1 (Me), 18.6 (=Me), 17.5 (Me); m/z (EI) [M]+ 231.2; 
C12H25NOS requires 231.1657, found 231.1660 
 
 
116c  
2-Methyl-N-((S)-4-methyl-1-phenylpent-3-en-2-yl)propane-2-sulfinamide  
 
 
Benzylmagnesium bromide was produced following the procedure set out by Harwood and 
Moody.83  
Procedure I was followed using the following amounts:  
Imine 115 (1 eq, 50.34 mmol, 9.43 g)  
DCM (0.2 M, 250 mL)  
Benzylmagnesium bromide [1.25 M/Et2O] (2 eq, 100.69 mmol, 80.6 mL)  
Yield: 7.83 g, 59 %, yellow oil after column chromatography (10 % EtOAc in Hexane).  
 
IR (cm-1) 3212 (NH), 2975 (CH), 1454 (=), 1049 (S=O), 749/698 (Ph); 1H-NMR (300 MHz, 
CDCl3)  7.36-7.12 (stack, 5H (ArH)), 5.00 (dsept, 1H, J = 1.0, 9.0 Hz (=CH)), 4.28 (dddd, 1H, J = 
1.5, 6.0, 7.5, 9.0 Hz (CH)), 3.27 (d, 1H, J = 1.5 Hz (NH)), 2.85 (dd, 1H, J = 6.0, 13.0 Hz (CHHPh)), 
2.75 (dd, 1H, J = 7.5, 13.0 Hz (CHHPh)), 1.74 (d, 3H, J = 1.0 Hz (=Me)), 1.59 (d, 3H, J = 1.0 Hz 
(=Me)), 1.15 (s, 9H (tBu)); 13C-NMR (400 MHz, CDCl3) 136.7 (=CMe2), 136.5 (QAr), 128.7 
(=CH), 128.6 (ArH), 127.4 (ArH), 125.4 (ArH), 61.1 (QtBu), 52.5 (CHN), 41.8 (CH2Ph), 26.6 (
tBu), 
21.6 (=Me), 15.2 (=Me); m/z (ES) [M+Na]+ 302.2 
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116d  
2-Methyl-N-((S)-6-methylhepta-1,5-dien-4-yl)propane-2-sulfinamide  
 
 
Allylmagnesium bromide was produced following the procedure set out by Harwood and 
Moody.83  
Procedure I was followed using the following amounts:  
Imine 115 (1 eq, 5.34 mmol, 1.00 g)  
DCM (0.2 M, 16 mL)  
Allylmagnesium bromide [1.25 M/Et2O] (3 eq, 16.02 mmol, 12.80 mL)  
Yield: 862 mg, 71 %, yellow oil after column chromatography (10 % EtOAc in Hexane).  
 
Rf 0.10 (25 % EtOAc in hexane); IR (cm-1) 3215 (NH), 2979 (CH), 1640 (=), 1572 (=), 1050 
(S=O); 1H-NMR (300 MHz, CDCl3)  5.77 (dddd, 1H, J = 6.0, 8.5, 11.0, 17.0 Hz (=CHCH2)), 5.14 
(d, 1H, J = 17.0 Hz (=CHH)), 5.13 (d, 1H, J = 11.0 Hz (=CHH)), 4.96 (dsept, 1H, J = 1.5, 8.0 Hz 
(=CHCH)), 4.17-4.06 (m, 1H (CH)), 3.36 (brs, 1H (NH)), 2.33 (ddd, 1H, J = 6.0, 8.5, 14.0 Hz 
(CHHCH)), 2.22 (ddd, 1H, J = 7.5, 8.5, 14.0 Hz (CHHCH)), 1.76 (d, 3H, J = 1.5 Hz (=Me)), 1.73 (d, 
3H, J = 1.5 Hz (=Me)), 1.20 (s, 9H (tBu)); 13C-NMR (400 MHz, CDCl3) 135.7 (=CMe2), 132.7 
(=CHCH2), 128.4 (=CHCH), 116.7 (=CH2), 60.1 (Q
tBu), 51.5 (CHN), 40.9 (CH2), 26.7 (
tBu), 21.2 
(=Me), 15.8 (=Me); m/z (ES) [M+Na]+ 252.2 
 
 
 
154 
 
116e  
N-((S)-2,7-Dimethylocta-2,6-dien-4-yl)-2-methylpropane-2-sulfinamide  
 
 
Prenylmagnesium bromide was produced following the procedure set out by Harwood and 
Moody.83  
Procedure I was followed using the following amounts:  
Imine 115 (1 eq, 2.67 mmol, 500 mg)  
DCM (0.2 M, 14 mL)  
Prenylmagnesium bromide [1 M/Et2O] (3 eq, 8.01 mmol, 8.01 mL)  
Yield: 12 mg, <2 % after column chromatography (10 % EtOAc in Hexane).  
 
Rf 0.05 (10 % EtOAc in hexane); 
1H-NMR (300 MHz, CDCl3)  5.86 (t, 1H, J = 8.5 Hz (=CHCH2)), 
4.14-3.89 (m, 1H (=CHCH)), 3.26 (t, 1H, J = 12.5 Hz (CH)), 1.93 (d, 3H, J = 1.0 Hz (Me)), 1.85 (d, 
3H, J = 1.0 Hz (Me)), 1.71 (dt, 2H, J = 8.5, 12.5 Hz (CH2)), 1.67 (brs, 1H (NH)), 1.33 (s, 3H (Me)), 
1.29 (s, 9H (tBu)), 1.29 (s, 3H (Me)); 13C-NMR (400 MHz, CDCl3) 136.7 (=CMe2), 132.0 
(=CMe2), 127.9 (=CHCH), 123.8 (=CHCH2), 60.1 (Q
tBu), 51.5 (CHN), 34.1 (CH2), 27.1 (
tBu), 24.1 
(=Me), 21.5 (=Me), 18.2 (=Me), 15.1 (=Me); m/z (ES) [M+Na]+ 280.2 
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117a  
(S)-4-Methylpent-3-en-2-aminium chloride128 
 
 
Sulfinamide 116a (1 eq, 68.9 mmol, 14.0 g) was dissolved in methanol (2 M, 35 mL) and 
chilled to 0 °C. HCl [4 M/dioxane] (2 eq, 137.7 mmol, 34 mL) was added slowly before the 
reaction mixture stirred at RT for 30 minutes. The solvents were removed and the product 
used without further purification. NB full data not collected.  
 
IR (cm-1) 3412/2973 (br) (NH3
+), 2917 (CH), 1613 (=); 1H-NMR (300 MHz, CDCl3)  8.21 (brs, 
3H (NH3
+)), 5.24 (d, 1H, J = 9.5 Hz (=CH)), 4.18-4.03 (m, 1H (CH)), 1.72 (d, 6H, J = 2.0 Hz 
(=Me)), 1.42 (d, 3H, J = 6.5 Hz (Me)). 
 
 
117b  
(S)-2,5-Dimethylhex-4-en-3-aminium chloride  
 
 
Sulfinamide 116b (1 eq, 25.06 mmol, 5.8 g) was dissolved in methanol (2 M, 12.5 mL) and 
chilled to 0 °C. HCl [4 M/dioxane] (2 eq, 50.13 mmol, 12.5 mL) was added slowly before the 
reaction mixture stirred at RT for 30 minutes. The solvents were removed and the product 
used without further purification. NB data not collected.  
 
156 
 
117c  
(S)-4-Methyl-1-phenylpent-3-en-2-aminium chloride  
 
 
Sulfinamide 116c (1 eq, 29.50 mmol, 7.83 g) was dissolved in methanol (2 M, 14.80 mL) and 
chilled to 0 °C. HCl [4 M/dioxane] (2 eq, 59.00 mmol, 14.80 mL) was added slowly before the 
reaction mixture stirred at RT for 30 minutes. The solvents were removed and the product 
used without further purification. NB data not collected.  
 
 
117d  
(S)-6-Methylhepta-1,5-dien-4-aminium chloride  
 
 
Sulfinamide 116d (1 eq, 25.07 mmol, 5.75 g) was dissolved in methanol (2 M, 12.5 mL) and 
chilled to 0 °C. HCl [4 M/dioxane] (2 eq, 50.14 mmol, 12.5 mL) was added slowly before the 
reaction mixture stirred at RT for 30 minutes. The solvents were removed and the product 
used without further purification. NB data not collected. 
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118a  
(S)-2-Toluenesulfonamid-4-methylpent-3-ene  
 
 
General procedure B was followed with the following amounts used:  
Amine 117a hydrochloride (1 eq, 28.89 mmol, 3.92 g)  
DCM (0.1 M, 290 mL)  
Triethylamine (3 eq, 86.67 mmol, 12.08 mL)  
p-Toluene sulfonyl chloride (3 eq, 86.67 mmol, 16.52 g)  
DMAP (10 mol%, 2.89 mmol, 353 mg)  
Heated at reflux for 20 hours  
Crude product was purified by column chromatography, eluting with 5 % EtOAc in hexane, 
yielding a yellow liquid (5.27 g, 72 %).  
 
Rf 0.09 (10 % EtOAc in hexane); IR (cm
-1) 3267 (NH), 2973 (CH), 1598 (Ph), 1321/1149 
(SO2N); 
1H-NMR (300 MHz, CDCl3)  7.73 (app d, 2H (ArH)), 7.27 (app d, 2H (ArH)), 4.78 
(dsept, 1H, J = 1.0, 9.0 Hz (=CH)), 4.66 (d, 1H, J = 6.5 Hz (NH)), 4.08 (dp, 1H, J = 6.5, 9.0 Hz 
(CH)), 2.41 (s, 3H (ArCH3)), 1.48 (d, 3H, J = 1.0 Hz (=Me)), 1.43 (d, 3H, J = 1.0 Hz (=Me)), 1.14 
(d, 3H, J = 6.5 Hz (Me)); 13C-NMR (100 MHz, CDCl3) 143.0 (QAr), 138.3 (QAr), 134.1 (=CMe2), 
129.3 (ArH), 127.2 (ArH), 126.2 (=CH), 48.2 (CH), 24.5 (ArCH3), 22.5 (=Me), 21.5 (Me), 17.8 
(=Me); m/z (ES) [M+Na]+ 276.1 
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118b  
N-Tosyl-(S)-2,5-dimethylhex-4-en-3-amine  
 
 
General procedure B was followed with the following amounts used:  
Amine 117b hydrochloride (1 eq, 25.04 mmol, 4.10 g)  
DCM (0.1 M, 250 mL)  
Triethylamine (3 eq, 75.12 mmol, 10.50 mL)  
p-Toluene sulfonyl chloride (3 eq, 75.12 mmol, 14.32 g)  
DMAP (10 mol%, 2.50 mmol, 306 mg)  
Heated at reflux for 20 hours  
Crude product was purified by column chromatography, eluting with 5 % EtOAc in hexane, to 
give a white solid.  
 
Rf 0.20 (10 % EtOAc in hexane); IR (cm
-1) 3262 (NH), 2973 (CH), 1716 (Ar), 1597 (=), 
1331/1154 (SO2N); 
1H-NMR (300 MHz, CDCl3) 7.61 (app d, 2H (ArH)), 7.17 (app d, 2H (ArH)), 
4.60 (dsept, 1H, J = 1.5, 10.0 Hz (=CH)), 4.30 (d, 1H, J = 7.5 Hz (NH)), 3.69 (ddd, 1H, J = 7.5, 
10.0, 13.5 Hz (CHN)), 2.34 (s, 3H (ArCH3)), 1.64 (dsept, 1H, J = 7.0, 13.5 Hz (CHMe2)), 1.38 (s, 
3H (=Me)), 1.31 (s, 3H (=Me)), 0.79 (d, 3H, J = 7.0 Hz (Me)), 0.76 (d, 3H, J = 7.0 Hz (Me)); 13C-
NMR (100 MHz, CDCl3) 142.0 (QAr), 137.9 (QAr), 135.1 (=CMe2), 129.7 (ArH), 128.2 (ArH), 
128.1 (=CH), 50.2 (CHN), 35.4 (CHMe2), 22.5 (ArCH3), 22.3 (=Me), 19.5 (Me), 15.8 (=Me); m/z 
(ES) [M+Na]+ 304.1; C15H23NO2SNa requires 304.1347, found 304.1342 
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118c  
N-Tosyl-(S)-4-methyl-1-phenylpent-3-en-2-amine  
 
 
General procedure B was followed with the following amounts used:  
Amine 117c hydrochloride (1 eq, 29.48 mmol, 6.24 g)  
DCM (0.1 M, 290 mL)  
Triethylamine (3 eq, 88.44 mmol, 12.30 mL)  
p-Toluene sulfonyl chloride (3 eq, 88.44 mmol, 16.86 g)  
DMAP (10 mol%, 2.95 mmol, 360 mg)  
Heated at reflux for 20 hours  
Crude product was purified by column chromatography, eluting with 5 % EtOAc in hexane, to 
give a white solid (9.13 g, 94 %).  
 
IR (cm-1) 3253 (NH), 2978 (CH), 1716 (Ar), 1598 (=), 1331/1157 (SO2N); 
1H-NMR (300 MHz, 
CDCl3)  7.65-7.60 (stack, 2H (ArH)), 7.28-7.07 (stack, 5H (ArH)), 7.10-7.04 (stack, 2H (ArH)), 
4.76 (dsept, 1H, J = 1.5, 9.5 Hz (=CH)), 4.37 (d, 1H, J = 6.5 Hz (NH)), 4.22-4.14 (m, 1H (CH)), 
2.82 (dd, 1H, J = 6.0, 13.5 Hz (CHHPh)), 2.69 (dd, 1H, J = 7.0, 13.5 Hz (CHHPh)), 2.40 (s, 3H 
(ArCH3)), 1.47 (s, 3H (Me)), 1.26 (s, 3H (Me)); 
13C-NMR (100 MHz, CDCl3) 143.0 (QAr), 136.8 
(QAr), 135.3 (QAr), 134.6 (=CMe2), 129.6 (ArH), 129.3 (ArH), 128.4 (ArH), 126.6 (=CH), 124.0 
(ArH), 53.2 (CHN), 42.5 (CH2Ph), 25.4 (ArCH3), 21.5 (=Me), 17.8 (=Me); m/z (ES) [M+Na]
+ 
352.1; C19H23NO2SNa requires 352.1347, found 352.1358 
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118d  
N-Tosyl-(S)-6-methylhepta-1,5-dien-4-amine  
 
 
General procedure B was followed with the following amounts used:  
Amine 111d hydrochloride (1 eq, 25.05 mmol, 4.05 g)  
DCM (0.1 M, 250 mL)  
Triethylamine (2 eq, 50.10 mmol, 7.00 mL)  
p-Toluene sulfonyl chloride (2 eq, 50.10 mmol, 9.55 g)  
DMAP (10 mol%, 2.51 mmol, 306 mg)  
Heated at reflux for 20 hours  
Crude product was purified by column chromatography, eluting with 5 % EtOAc in hexane, to 
give a colourless crystalline solid (6.35 g, 91 %).  
 
Rf 0.22 (10 % EtOAc in hexane); IR (cm
-1) 3270 (NH), 2980 (CH), 1641 (Ar), 1599(=), 1496 (=), 
1323/1157 (SO2N); 
1H-NMR (300 MHz, CDCl3)  7.72 (app d, 2H (ArH)), 7.28 (app d, 2H (ArH)), 
5.65 (ddt, 1H, J = 6.5, 10.5, 17.5 Hz (=CHCH2)), 5.12-5.07 (m, 1H (=CHH)), 5.12-5.04 (m, 1H 
(=CHH)), 4.78 (dsept, 1H, J = 1.5, 9.5 Hz (=CHCH)), 4.38 (d, 1H, J = 6.5 Hz (NH)), 4.06 (dq, 1H, J 
= 6.5, 9.5 Hz (CH)), 2.44 (s, 3H (ArCH3)), 2.31-2.15 (m, 2H (CH2)), 1.52 (d, 3H, J = 1.5 Hz (Me)), 
1.48 (d, 3H, J = 1.5 Hz (Me)) ; 13C-NMR (100 MHz, CDCl3) 143.1 (QAr), 138.2 (QAr), 135.2 
(=CMe2), 133.3 (RHC=CH2), 129.3 (ArH), 127.3 (ArH), 124.2 (RHC=CMe2), 118.7 (=CH2), 51.5 
(CH), 40.5 (CH2), 25.5 (Me), 21.5 (ArCH3), 18.0 (Me) 
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tert-Butyl(3-chloropropoxy)dimethylsilane119 
 
 
3-Chloro-1-propanol (1 eq, 52.92 mmol, 5.00g) was dissolved in DMF (1 M, 50 mL), before 
imidazole (1.1 eq, 58.21 mmol, 3.96 g) and tert-butylsilyl chloride (1.1 eq, 58.21 mmol, 8.77 g) 
were added. The mixture was stirred at room temperature overnight before quenching with 
sat. aq. ammonium chloride. The product was extracted into ether and washed with water 
and brine to yield a clear oil (10.35 g, 94 %).  
 
Rf 0.60 (10 % MeOH in DCM); IR (cm
-1) 2955/2858 (CH), 1255/833 (SiMe), 1101/774 (SiO); 
1H-NMR (300 MHz, CDCl3)  3.68 (t, 2H, J = 6.0 Hz (CH2Cl)), 3.59 (t, 2H, J = 6.0 Hz (CH2OSi)), 
1.88 (quin, 2H, J = 6.0 Hz (CH2CH2)), 0.83 (s, 9H (
tBu)), 0.00 (s, 6H (Me)) [Lit. agreement]; 13C-
NMR (100 MHz, CDCl3) 59.4 (CH2OSi), 41.8 (CH2Cl), 35.4 (CH2CH2), 25.9 (
tBu), 18.3 (QtBu), -
5.4 (Me); m/z (EI) [35Cl] [M-H]+ 207 
 
 
tert-Butyl(3-iodopropoxy)dimethylsilane120 
 
 
tert-Butyl(3-chloropropoxy)dimethylsilane (1 eq, 49.58 mmol, 10.35 g) was dissolved in 
freshly distilled acetone (1 M, 50 mL). Sodium iodide (2.5 eq, 123.95 mmol, 18.58 g) was 
added and stirred until completely dissolved. The apparatus was covered to exclude all light 
and the reaction mixture heated at reflux overnight. The mixture was diluted with ether and 
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the precipitate removed. The solvents were removed to yield a yellow oil in quantitative 
yield that was used without further purification. NB. Product requires dark storage.  
 
Rf 0.54 (40 % EtOAc in hexane); IR (cm
-1) 2953/2884 (CH), 1252/856 (SiMe), 1050/832 (SiO); 
1H-NMR (300 MHz, CDCl3)  3.68 (t, 2H, J = 5.5 Hz (CH2O)), 3.30 (t, 2H, J = 6.5 Hz (CH2I)), 2.06-
1.95 (m, 2H, (CH2CH2)), 0.91 (s, 9H (
tBu)), 0.09 (s, 6H (Me)) [Lit. agreement]; 13C-NMR (100 
MHz, CDCl3) 62.3 (CH2OSi), 36.2 (CH2CH2), 25.9 (
tBu), 18.3 (QtBu), 3.6 (CH2I), -5.3 (Me); m/z 
(EI) [M-tBu]+ 243.0; C5H12OSi127I requires 242.9702, found 242.9703 
 
 
119a  
N-Tosyl-(S)-3-((4-methylpent-3-en-2-yl)amino)propan-1-ol 
 
 
Procedure E was followed using the following amounts:  
Amine 118a (1 eq, 8.88 mmol, 2.25 g) in DMF (0.1 M, 90 mL)  
Cesium carbonate (1.5 eq, 13.32 mmol, 4.34 g)  
tert-Butyl(3-iodopropoxy)dimethylsilane (1.5 eq, 13.32 mmol, 4.00 g)  
yield: pale yellow oil (1.97 g, 71 %)  
 
Rf 0.06 (25 % EtOAc in hexane); IR (cm
-1) 2954/2856 (CH), 1471 (=), 1462/1153 (NSO2); 
1H-
NMR (300 MHz, CDCl3)  7.67 (app d, 2H (ArH)), 7.26 (app d, 2H (ArH)), 4.98 (dsept, 1H, J = 
1.5, 9.0 Hz (=CH)), 4.66 (dq, 1H, J = 7.0, 9.0 Hz (CH)), 3.75 (m, 2H (CH2N)), 3.29 (t, 2H, J = 6.5 
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Hz (CH2O)), 2.41 (s, 3H (ArCH3)), 1.81 (dt, 2H, J = 6.5, 13.5 (CH2CH2N)), 1.70 (brs, 1H (OH)), 
1.59 (d, 3H, J = 1.5 Hz (=Me)), 1.55 (d, 3H, J = 1.5 Hz (=Me)), 1.12 (d, 3H, J = 7.0 Hz (Me)); 13C-
NMR (100 MHz, CDCl3) 140.5 (QAr), 137.4 (QAr), 136.4 (=CMe2), 129.4 (ArH), 128.4 (ArH), 
128.2 (=CH), 58.9 (CH2O), 49.5 (CHN), 44.7 (CH2N), 31.4 (CH2CH2N), 21.8 (ArCH3), 21.5 (=Me), 
19.2 (Me), 15.4 (=Me); m/z (ES) [M+Na]+ 334.3; C16H25NO3SNa requires 334.1453, found 
334.1443 
 
 
119b  
N-Tosyl-(S)-3-((2,5-dimethylhex-4-en-3-yl)amino)propan-1-ol  
 
 
Procedure E was followed using the following amounts:  
Amine 118b (1 eq, 0.89 mmol, 250 mg) in DMF (0.1 M, 9 mL)  
Cesium carbonate (1.5 eq, 1.33 mmol, 434 mg)  
tert-Butyl(3-iodopropoxy)dimethylsilane (1.5 eq, 1.33 mmol, 400 mg)  
yield: pale yellow oil (116 mg, 38 %)  
 
Rf 0.08 (20 % EtOAc in hexane); IR (cm
-1) 3520 (OH), 2872 (CH), 1725 (Ar), 1673 (=), 
1327/1154 (SO2N); 
1H-NMR (300 MHz, CDCl3)  7.66-7.60 (m, 2H (ArH)), 7.25-7.19 (m, 2H 
(ArH)), 5.01 (dsept, 1H, J = 1.5, 10.5 Hz (=CH)), 4.09 (t, 1H, J = 10.5 Hz (CH)), 3.82-3.65 (m, 2H 
(CH2N)), 3.26 (t, 2H, J = 7.0 Hz (CH2O)), 2.40 (s, 3H (ArCH3)), 1.93-1.70 (stack, 3H (CHMe2, 
CH2CH2N)), 1.63 (brs, 1H (OH)), 1.57 (d, 3H, J = 1.5 Hz (=Me)), 1.54 (d, 3H, J = 1.5 Hz (=Me)), 
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0.99 (d, 3H, J = 6.5 Hz (Me)), 0.79 (d, 3H, J = 6.5 Hz (Me)); 13C-NMR (100 MHz, CDCl3) 140.5 
(QAr), 137.4 (QAr), 136.4 (=CMe2), 129.4 (ArH), 128.4 (ArH), 132.2 (=CH), 58.9 (CH2O), 59.5 
(CHN), 45.7 (CH2N), 32.6 (CHMe2), 31.4 (CH2CH2N), 21.8 (ArCH3), 21.5 (=Me), 19.2 (Me), 15.4 
(=Me); m/z (ES) [M+Na]+ 362.2 
 
 
119c  
N-Tosyl-(S)-3-((4-methyl-1-phenylpent-3-en-2-yl)amino)propan-1-ol  
 
 
Procedure E was followed using the following amounts:  
Amine 118c (1 eq, 15.17 mmol, 5.00 g) in DMF (0.1 M, 150 mL)  
Cesium carbonate (1.5 eq, 22.75 mmol, 7.41 g)  
tert-Butyl(3-iodopropoxy)dimethylsilane (1.5 eq, 22.75 mmol, 6.83 g)  
yield: pale yellow oil (2.66 g, 45 %)  
IR (cm-1) 3515 (OH), 2929 (CH), 1742 (Ar), 1598 (=), 1327/1154 (SO2N), 1256 (CO); 
1H-NMR 
(300 MHz, CDCl3)  7.70-7.63 (stack, 2H (ArH)), 7.27-7.13 (stack, 5H (ArH)), 7.12-7.08 (stack, 
2H (ArH)), 5.05 (dsept, 1H, J = 1.5, 9.5 Hz (=CH)), 4.64 (dt, 1H, J = 4.5, 9.5 Hz (CH)), 3.72 (ddd, 
1H, J = 5.5, 11.5, 17.0 Hz (CHHN)), 3.70 (ddd, 1H, J = 5.5, 11.5, 17.0 Hz (CHHN)), 3.36 (t, 2H, J 
= 7.0 Hz (CH2O)), 2.96 (dd, 1H, J = 4.5, 13.0 Hz (CHHPh)), 2.69 (dd, 1H, J = 4.5, 13.0 Hz 
(CHHPh)), 2.52 (brs, 1H (OH)), 2.39 (s, 3H (ArCH3)), 1.83 (dt, 2H, J = 5.5, 7.0 Hz (CH2CH2N)), 
1.50 (d, 3H, J = 1.5 Hz (Me)), 1.12 (d, 3H, J = 1.5 Hz (Me)); 13C-NMR (100 MHz, CDCl3) 143.1 
(QAr), 138.0 (QAr), 137.7 (QAr), 137.5 (=CMe2), 59.1 (CH2N), 58.0 (CH), 42.0 (CH2Ph), 41.4 
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(CH2O), 33.7 (CH2CH2N), 25.6 (Me), 21.5 (ArCH3), 17.9 (Me); m/z (ES) [M+Na]
+ 410.1; 
C22H29NO3SNa requires 410.1766, found 410.1765 
 
 
119d(i)  
N-Tosyl-(S)-N-(3-(tert-butyldimethylsilyloxy)propyl)-6-methylhepta-1,5-dien-4-amine  
 
 
Procedure E was followed using the following amounts:  
Amine 118d (1 eq, 21.47 mmol, 6.0 g) in DMF (0.1 M, 215 mL)  
Cesium carbonate (1.5 eq, 32.21 mmol, 10.50 g)  
tert-Butyl(3-iodopropoxy)dimethylsilane (1.5 eq, 32.21 mmol, 9.67 g)  
yield: pale yellow oil (9.04 g, 93 %)  
 
IR (cm-1) 2928 (CH), 1641 (=), 1599 (=), 1339/1159 (SO2N), 1254 (CO); 
1H-NMR (300 MHz, 
CDCl3)  7.68 (app d, 2H (ArH)), 7.25 (app d, 2H (ArH)), 5.65 (dsept, 1H, J = 1.0, 9.0 Hz (=CH)), 
5.15-4.94 (stack, 3H (=CH)), 4.58 (td, 1H, J = 6.0, 9.0 Hz (CH)), 3.63 (t, 1H, J = 5.5 Hz (CHHN)), 
3.59 (t, 1H, J = 5.5 Hz (CHHN)), 3.22 (dd, 1H, J = 6.5, 9.5 Hz (CHHO)), 3.15 (dd, 1H, J = 6.0, 15.0 
Hz (CHHO)), 2.42 (s, 3H (ArCH3)), 2.36-2.16 (stack, 2H (CH2C=)), 1.96-1.75 (stack, 2H 
(CH2CH2O)), 1.63 (d, 3H, J = 1.0 Hz (=Me)), 1.59 (d, 3H, J = 1.0 Hz (=Me)), 0.91 (s, 9H (
tBu)), 
0.09 (s, 3H (SiMe)), 0.06 (s, 3H (SiMe)); 13C-NMR (100 MHz, CDCl3) 142.7 (QAr), 138.1 (QAr), 
136.3 (=CMe2), 134.6 (HC=CH2), 129.2 (ArH), 127.4 (ArH), 122.3 (HC=Me2), 117.1 (=CH2), 60.7 
(CH2N), 56.1 (CH), 41.9 (CH2O), 39.2 (CH2CH), 34.4 (CH2CH2N), 25.9 (
tBu), 25.7 (=Me), 21.5 
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(ArCH3), 18.5 (=Me), 18.2 (Q
tBu), -5.4 (SiMe); m/z (ES) [M+Na]+ 475.4; C24H41NO3SSiNa 
requires 474.2474, found 474.2459 
 
 
119d(ii)  
N-Tosyl-(S)-3-(6-methylhepta-1,5-dien-4-yl)aminopropan-1-ol 
 
 
Silyl ether 119d(i) (1 eq, 1.42 mmol, 640 mg) was dissolved in THF (0.1 M, 14 mL) and TBAF 
[1 M] (1.5 eq, 2.13 mmol, 2.20 mL) added slowly. The mixture was stirred at room 
temperature overnight then diluted with water and the products extracted into ether. 
Purification by column chromatography, eluting with 20 % EtOAc in hexane yielded a yellow 
oil.  
 
IR (cm-1) 3418 (OH), 2931 (CH), 1663 (Ar), 1598 (=), 1331/155 (SO2N); 
1H-NMR (300 MHz, 
CDCl3)  7.63 (app d, 2H (ArH)), 7.21 (app d, 2H (ArH)), 5.60 (dsept, 1H, J = 1.0, 8.5 Hz (=CH)), 
5.24-4.86 (stack, 3H (=CH)), 4.46 (dt, 1H, J = 6.0, 8.5 Hz (CH)), 3.52 (t, 1H, J = 6.0 Hz (CHHN)), 
3.62 (t, 1H, J = 6.0 Hz (CHHN)), 3.51 (brs, 1H (OH)), 3.13 (dd, 1H, J = 6.5, 9.5 Hz (CHHO)), 3.10 
(dd, 1H, J = 6.5, 15.0 Hz (CHHO)), 2.40 (s, 3H (ArCH3)), 2.31-2.11 (stack, 2H (CH2C=)), 1.87-
1.69 (stack, 2H (CH2CH2O)), 1.58 (d, 3H, J = 1.0 Hz (=Me)), 1.56 (d, 3H, J = 1.0 Hz (=Me)); 
13C-
NMR (100 MHz, CDCl3) 142.7 (QAr), 138.1 (QAr), 136.3 (=CMe2), 134.6 (HC=CH2), 129.2 
(ArH), 127.4 (ArH), 122.3 (HC=Me2), 117.1 (=CH2), 60.7 (CH2N), 56.1 (CH), 39.9 (CH2O), 39.2 
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(CH2CH), 35.4 (CH2CH2N), 25.7 (=Me), 21.5 (ArCH3), 18.5 (=Me); m/z (ES) [M+Na]
+ 360.3; 
C18H27NO3SNa requires 360.1609, found 360.1599 
 
 
120a  
N-Tosyl-(S)-3-(4-methylpent-3-en-2-yl)aminopropanal 
 
 
Procedure F was followed using the following amounts:  
Oxalyl chloride (1.1 eq, 1.77 mmol, 149 l) in DCM (0.4 M, 4.50 mL)  
DMSO (2.4 eq, 3.85 mmol, 274 l)  
Alcohol 119a (1 eq, 1.61 mmol, 500 mg) in DCM (0.75 M, 2.00 mL)  
Triethylamine (5 eq, 8.03 mmol, 1.12 mL)  
The product was purified by column chromatography, eluting with 15 % EtOAc in hexane, to 
yield a pale yellow oil (418 mg, 84 %).  
 
Rf 0.71 (50 % EtOAc in hexane); IR (cm
-1) 2930 (CHO), 1721 (C=O), 1648 (=), 1597 (Ar), 
1329/1152 (SO2N); 
1H-NMR (300 MHz, CDCl3) 9.79 (s, 1H (CHO)), 7.69 (app d, 2H (ArH)), 
7.28 (app d, 2H (ArH)), 4.92 (dsept, 1H, J = 1.5, 8.5 Hz (=CH)), 4.74 (dq, 1H, J = 7.0, 8.5 Hz 
(CHN)), 3.53-3.28 (m, 2H (CH2N)), 2.95 (t, 2H, J = 7.5 Hz (CH2CHO)), 2.43 (s, 3H (ArCH3)), 1.64 
(d, 3H, J = 1.5 Hz (=Me)), 1.62 (d, 3H, J = 1.5 Hz (=Me)), 1.06 (d, 3H, J = 7.0 Hz (Me)); 13C-NMR 
(100 MHz, CDCl3) 199.7 (CHO), 141.2 (QAr), 137.7 (QAr), 136.3 (=CMe2), 129.4 (ArH), 128.4 
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(ArH), 128.0 (=CH), 49.6 (CHN), 43.2 (CH2N), 39.4 (CH2CH2N), 21.5 (ArCH3), 21.4 (=Me), 18.5 
(Me), 15.4 (=Me); m/z (ES) [M+Na]+ 332.1 
 
 
120c  
N-Tosyl-(S)-3-(4-methyl-1-phenylpent-3-en-2-yl)aminopropanal  
 
 
Procedure F was followed using the following amounts:  
Oxalyl chloride (1.1 eq, 7.10 mmol, 600 l) in DCM (0.4 M, 18.00 mL)  
DMSO (2.4 eq, 15.48 mmol, 1.10 mL)  
Alcohol 119c (1 eq, 6.45 mmol, 2.50 g) in DCM (0.75 M, 8.00 mL)  
Triethylamine (5 eq, 32.25 mmol, 4.50 mL)  
The product was purified by column chromatography, eluting with 25 % EtOAc in hexane, to 
yield a pale yellow liquid (1.67 g, 67 %).  
 
IR (cm-1) 2932 (CHO), 1723 (C=O), 1639 (=), 1592 (Ar), 1336/1149 (SO2N); 
1H-NMR (300 
MHz, CDCl3)  9.77 (s, 1H (CHO)), 7.66 (app d, 2H (ArH)), 7.32-7.17 (stack, 5H (Ph)), 7.11 (app 
d, 2H (ArH)), 4.98 (dsept, 1H, J = 1.0, 9.0 Hz (=CH)), 4.77 (dt, 1H, J = 9.0, 9.5 Hz (CH)), 3.54 
(ddd, 1H, J = 5.0, 9.5, 12.5 Hz (CHHN)), 3.42 (ddd, 1H, J = 5.0, 9.5, 12.5 Hz (CHHN)), 3.03-2.78 
(stack, 3H (CH2CHO, CHHPh)), 2.65 (dd, 1H, J = 9.5, 13.0 (CHHPh)), 2.42 (s, 3H (ArCH3)), 1.53 
(d, 3H, J = 1.0 Hz (=Me)), 1.28 (d, 3H, J = 1.0 Hz (=Me)); 13C-NMR (100 MHz, CDCl3) 200.7 
(CHO), 143.2 (QAr), 137.7 (QAr), 137.6 (QAr), 137.3 (=CMe2), 129.4 (ArH), 129.4 (ArH), 128.3 
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(ArH), 127.4 (ArH), 126.4 (ArH), 121.0 (=CH), 57.6 (CH), 46.2 (CH2O), 41.0 (CH2Ph), 37.7 
(CH2N), 25.6 (Me), 21.5 (ArCH3), 18.1 (Me); m/z (ES) [M+Na]
+ 408.2 
 
 
120d  
N-Tosyl-(S)-3-(6-methylhepta-1,5-dien-4-yl)aminopropanal 
 
 
Procedure F was followed using the following amounts:  
Oxalyl chloride (1.1 eq, 6.52 mmol, 552 l) in DCM (0.4 M, 16.50 mL)  
DMSO (2.4 eq, 14.22 mmol, 1.00 mL)  
Alcohol 119d(ii) (1 eq, 5.93 mmol, 2.00 g) in DCM (0.75 M, 7.00 mL)  
Triethylamine (5 eq, 29.63 mmol, 4.10 mL)  
The product was purified by column chromatography, eluting with 15 % EtOAc in hexane, to 
yield a pale yellow oil (1.12 g, 56 %). 
  
Rf 0.21 (15 % EtOAc in hexane); IR (cm
-1) 2916 (CHO), 1730 (C=O), 1646 (=), 1598 (Ar), 
1324/1157 (SO2N); 
1H-NMR (400 MHz, CDCl3) 9.75 (s, 1H (CHO)), 7.65 (app d, 2H (ArH)), 
7.25 (app d, 2H (ArH)), 5.66-5.53 (m, 1H (=CHCH2)), 5.03-4.95 (stack, 2H (=CH2)), 4.91 (dsept, 
1H, J = 1.5, 9.0 Hz (=CHCH)), 4.58 (dt, 1H, J = 6.5, 9.0 Hz (CH)), 3.43 (ddd, 1H, J = 6.0, 8.5, 15.5 
Hz (CHHN)), 3.36 (ddd, 1H, J = 6.0, 8.5, 15.5 Hz (CHHN)), 2.96 (ddd, 1H, J = 6.0, 8.5, 18.5 Hz 
(CHHCHO)), 2.89 (ddd, 1H, J = 6.0, 8.5, 18.5 Hz (CHHCHO)), 2.39 (s, 3H (ArCH3)), 2.22-2.09 (m, 
2H (CH2CH)), 1.59 (d, 6H, J = 1.5 Hz (Me)); 
13C-NMR (100 MHz, CDCl3) 200.7 (CHO), 143.2 
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(QAr), 137.3 (QAr), 134.2 (=CH), 129.4 (ArH), 127.4 (ArH), 121.6 (=CH), 117.4 (=CH2), 117.3 
(Q=CMe2), 55.9 (CH), 46.2 (CH2CHO), 38.7 (CH2CH), 37.4 (CH2N), 25.6 (Me), 21.4 (ArCH3), 18.5 
(Me); m/z (ES) [M+Na]+ 358.2 
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Data from cyclisations  
 
Where protons and carbons have been assigned as numbered atoms, they refer to those in 
the piperidine ring, numbered as follows:  
 
 
121  
N-Tosyl-3-amino-3-chloropropan-1-ol 
 
 
Produced from the reaction of compounds 114a-c with HCl gas as a pale yellow residue. 
 
Rf 0.80 (25 % EtOAc in hexane); 
1H-NMR (300 MHz, CDCl3)  7.61 (app d, 2H (ArH)), 7.30 (app 
dd, 2H (ArH)), 5.21 (t, 1H, J = 4.5 Hz (CHCl)), 3.70 (dt, 1H, J = 5.5, 14.0 Hz (CHHOH), 3.31 (dt, 
1H, J = 5.5, 14.0 Hz (CHHOH)), 2.31 (s, 3H (ArCH3)), 1.92 (m, 2H (OH, NH)), 1.85 (ddt, 1H, J = 
4.5, 5.5, 14.0 Hz (CHHCH)), 1.64 (ddt, 1H, J = 4.5, 5.5, 14.0 Hz (CHHCH)); 13C-NMR (100 MHz, 
CDCl3) 144.0 (QAr), 135.7 (QAr), 129.9 (ArH), 127.5 (ArH), 77.1 (CH), 37.8 (CH2), 28.9 (CH2), 
21.6 (ArCH3); m/z (ES) [
35Cl] [M+Na]+ 286.0 
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122a  
(2S,3S,4R)-2-Methyl-3-(prop-1-en-2-yl)-1-tosylpiperidin-4-ol  
 
 
Formed as the major product from the reaction of precursor 120a in procedure K as a yellow 
oil. 
 
1H-NMR (300 MHz, CDCl3)  7.62 (app d, 2H (ArH)), 7.22 (app d, 2H (ArH)), 4.99 (d, 1H, J = 1.0 
Hz (=CH)), 4.85 (d, 1H, J = 1.0 Hz (=CH)), 4.09 (dq, 1H, J = 4.5, 7.0 Hz (H2)), 3.89 (q, 1H, J = 7.0 
Hz (H4)), 3.59 (dt, 1H, J = 4.5, 9.5 Hz (H6e)), 3.09 (dt, 1H, J = 7.0, 13.0 Hz (H6a)), 2.35 (s, 3H 
(ArCH3)), 2.28 (dd, 1H, J = 4.5, 7.0 Hz (H3)), 1.84 (s, 3H (Me)), 1.82-1.74 (m, 2H (H5e, H5a)), 
1.00 (d, 3H, J = 7.0 Hz (Me)) 
 
 
122c  
(2S,3S,4R)-2-Benzyl-3-(prop-1-en-2-yl)-1-tosylpiperidin-4-ol  
 
 
Formed as the major product from the reaction of precursor 120c in procedure K as a 
colourless crystalline solid. 
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1H-NMR (300 MHz, CDCl3)  7.58 (app d, 2H (ArH)), 7.28-7.11 (stack, 7H (ArH)), 4.90 (t, 1H, J = 
1.5 (=CH)), 4.85 (app s, 1H (=CH)), 4.69 (brs, 1H (OH)), 4.17 (ddd, 1H, J = 4.5, 7.0, 8.0 Hz (H2)), 
3.53 (ddd, 1H, J = 2.0, 7.5, 14.0 Hz (H6e)), 3.47 (ddd, 1H, J = 2.0, 7.0, 7.5 Hz (H4)), 3.11 (dd, 1H, 
J = 8.0, 13.5 Hz (CHHPh)), 2.92 (ddd, 1H, J = 5.5, 11.0, 14.0 Hz (H6a)), 2.64 (dd, 1H, J = 4.5, 
13.5 Hz (CHHPh)), 2.33 (s, 3H (ArCH3)), 2.13 (t, 1H, J = 7.0 Hz (H3)), 2.08-1.95 (m, 1H (H5e)), 
1.57 (s, 3H (Me)), 1.36-1.25 (m, 1H (H5a)); 
13C-NMR (100 MHz, CDCl3) 142.6 (QAr), 142.2 
(QAr), 138.0 (QAr), 136.6 (C=), 128.8 (ArH), 128.3 (ArH), 127.6 (ArH), 126.1 (ArH), 125.4 (ArH), 
114.9 (=CH2), 65.0 (C4), 55.3 (C2), 49.0 (C3), 37.3 (CH2Ph), 36.7 (C6), 28.7 (C5), 20.5 (ArCH3), 
19.5 (Me) 
 
 
122d  
(2S,3S,4R)-2-Allyl-3-(prop-1-en-2-yl)-1-tosylpiperidin-4-ol  
 
 
Formed as the major product from the reaction of precursor 120d in procedure K as a yellow 
residue.  
 
1H-NMR (300 MHz, CDCl3)  7.64 (app d, 2H (ArH)), 7.22 (app d, 2H (ArH)), 5.62 (dddd, 1H, J = 
6.0, 8.0, 10.0, 16.5 Hz (=CH)), 5.02-4.89 (stack, 4H (4x =CHH)), 4.15 (dt, 1H, J = 3.5, 10.5 Hz 
(H2)), 3.90 (dd, 1H, J = 6.0, 13.5 Hz (H4)), 3.72 (ddt, 1H, J = 1.0, 4.0, 14.0 Hz (H6e)), 2.90 (ddd, 
1H, J = 6.0, 7.5, 14.0 Hz (H6a)), 2.51 (dd, 1H, J = 3.5, 6.0 Hz (H3)), 2.35 (s, 3H (ArCH3)), 2.31-
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2.18 (m, 1H (H5a)), 1.99-1.88 (m, 1H (H5e)), 1.84 (s, 3H (Me)), 1.82-1.73 (m, 1H (CHHCH=)), 
1.63-1.47 (m, 1H (CHHCH=)) 
 
 
der-122d  
(2S,3S,4R)-2-Allyl-3-(prop-1-en-2-yl)-1-tosylpiperidin-4-yl 4-bromobenzoate  
 
 
Piperidine 122d (1 eq, 1.40 mmol, 470 mg), DMAP (0.5 eq, 0.70 mmol, 86 mg) and 
triethylamine (2 eq, 2.80 mmol, 0.39 mL) were dissolved in DCM (0.1 M, 14 mL) at 0 °C. 4- 
bromobenzoyl chloride (1 eq, 1.40 mmol, 308 mg) in minimal DCM was added dropwise and 
the reaction stirred at RT for 6 hours. After aqueous workup the product was purified by 
column chromatography, eluting with 20 % ethyl acetate in hexane to give a white crystalline 
solid, 580 mg (80 %).  
 
Rf 0.70 (30 % EtOAc in hexane); 
1H-NMR (300 MHz, CDCl3)  7.87 (app d, 2H (ArH)), 7.73 
(app d, 2H (ArHTs)), 7.59 (app d, 2H (ArH)), 7.28 (app d, 2H ((ArHTs)), 5.82-5.63 (m, 1H (=CH)), 
5.40 (dt, 1H, J = 5.0, 10.0 Hz (H4)), 5.16-5.06 (stack, 2H (=CH2)), 5.09- 4.99 (stack, 2H (=CH2)), 
4.38 (dt, 1H, J = 3.5, 9.5 Hz (H2)), 3.89 (dd, 1H, J = 5.0, 13.5 Hz (H6e)), 3.08 (dt, 1H, J = 3.5, 13.0 
Hz (H6a)), 2.79 (dd, 1H, J = 3.5, 5.0 Hz (H3)), 2.49-2.37 (m, 1H (H5e)), 2.42 (s, 3H (ArCH3)), 2.22 
(tdd, 1H, J = 6.0, 10.0, 13.0 Hz (CHHC=)), 2.13-2.01 (m, 1H (H5a)), 2.01- 1.91 (m, 1H (CHHC=)), 
1.86 (s, 3H (Me)); 13C-NMR (100 MHz, CDCl3) 165.1 (C=O), 143.3 (=CR2), 142.8 (QTs), 138.0 
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(QTs), 133.8 (=CH), 131.8 (ArH), 131.2 (ArH), 129.7 (ArHTs), 129.1 (Q), 128.2 (Q), 127.1 
(ArHTs), 118.7 (=CH2), 115.4 (=CH2), 69.8 (C2), 56.3 (C4), 44.2 (C3), 39.7 (C6), 35.1 (C5), 27.6 
(CH2C=), 24.4 (Me), 21.5 (ArCH3) 
 
 
123c  
(2S,3S,4S)-2-Benzyl-3-(prop-1-en-2-yl)-1-tosylpiperidin-4-ol  
 
 
Formed as the minor product from the reaction of precursor 120c in procedure K as a white 
solid.  
 
1H-NMR (300 MHz, CDCl3)  7.68 (app d, 2H (ArH)), 7.29-7.17 (stack, 5H (ArH)), 7.12 (app d, 
2H (ArH)), 4.95 (t, 1H, J = 1.5 Hz (=CH)), 4.83 (s, 1H (=CH)), 4.44 (dt, 1H, J = 3.0, 10.5 Hz (H2)), 
4.03 (dt, 1H, J = 5.5, 7.5 Hz (H4)), 3.80 (dt, 1H, J = 3.0, 13.5 Hz (H6e)), 2.93 (ddd, 1H, J = 7.5, 
13.0, 13.5 Hz (H6a)), 2.76 (dd, 1H, J = 10.5, 13.5 Hz (CHHPh)), 2.57 (dd, 1H, J = 3.0, 13.5 Hz 
(CHHPh)), 2.38 (dd, 1H, J = 3.0, 5.5 Hz (H3)), 2.37 (s, 3H (ArCH3)), 1.84-1.79 (stack, 2H (H5e, 
H5a)), 1.74 (s, 3H (Me)), 1.67 (brs, 1H (OH)); 
13C-NMR (100 MHz, CDCl3) 143.6 (QAr), 143.3 
(QAr), 143.2 (QAr), 137.7 (C=), 130.9 (ArH), 129.8 (ArH), 128.7 (ArH), 127.0 (ArH), 126.7 (ArH), 
115.9 (=CH2), 65.5 (C4), 57.6 (C2), 45.8 (C3), 39.1 (C6), 36.2 (CH2Ph), 30.3 (C5), 24.6 (Me), 21.5 
(ArCH3) 
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123d  
(2S,3S,4S)-2-Allyl-3-(prop-1-en-2-yl)-1-tosylpiperidin-4-ol  
 
 
Formed as the trace product from the reaction of precursor 120d in procedure K as a yellow 
residue.  
 
1H-NMR (300 MHz, CDCl3)  7.73 (app d, 2H (ArH)), 7.31 (app d, 2H (ArH)), 5.72 (ddt, 1H, J = 
6.0, 8.5, 12.0 Hz (=CH)), 5.25 (dt, 1H, J = 5.0, 10.0 Hz (H2)), 5.14-4.98 (stack, 4H (4x =CH)), 
4.25 (dt, 1H, J = 3.5, 9.5 Hz (H4)), 3.88 (dd, 1H, J = 5.5, 13.0 Hz (H6e)), 3.06 (dd, 1H, J = 4.0, 
12.5 Hz (H6a)), 2.68 (dd, 1H, J = 3.5, 5.0 Hz (H3)), 2.51-2.34 (m, 1H (H5a)), 2.44 (s, 3H (ArCH3)), 
2.12-1.98 (m, 1H (H5e)), 1.95-1.85 (m, 1H (CHHCH=)), 1.84 (s, 3H (Me)), 1.79-1.57 (m, 1H 
(CHHCH=)) 
 
 
der-123c  
(2S,3S,4S)-2-Benzyl-3-(prop-1-en-2-yl)-1-tosylpiperidin-4-yl 4-bromobenzoate  
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Piperidine 123c (1 eq, 0.31 mmol, 120 mg), DMAP (0.5 eq, 0.16 mmol, 19 mg) and 
triethylamine (2 eq, 0.62 mmol, 87 l) were dissolved in DCM (0.1 M, 3 mL) at 0 °C. 4- 
bromobenzoyl chloride (1 eq, 0.31 mmol, 68 mg) in minimal DCM was added dropwise and 
the reaction stirred at RT for 2 ½ hours. After aqueous workup the product was purified by 
column chromatography, eluting with 20 % ethyl acetate in hexane to give a white solid, 151 
mg (86 %).  
 
Rf 0.75 (30 % EtOAc in hexane); 
1H-NMR (300 MHz, CDCl3)  7.94 (app d, 2H (ArH)), 7.74 (app 
d, 2H (ArH)), 7.63 (app d, 2H (ArH)), 7.31 (app d, 2H (ArH)), 7.25-7.13 (stack, 5H (Ph)), 5.26 (q, 
1H, J = 4.0 Hz (H4)), 5.03 (s, 1H (=CHH)), 4.93 (s, 1H (=CHH)), 4.49 (ddd, 1H, J = 3.0, 3.5, 10.5 
Hz (H2)), 3.75 (ddd, 1H, J = 2.0, 5.5, 13.5 Hz (H6a)), 3.30 (dt, 1H, J = 3.5, 13.0 Hz (H6e)), 3.19 (dd, 
1H, J = 10.5, 13.5 Hz (CHHPh)), 2.83 (dd, 1H, J = 3.5, 13.5 Hz (CHHPh)), 2.49-2.42 (m, 1H (H3)), 
2.44 (s, 3H (ArCH3)), 2.27-2.11 (m, 1H (H5e)), 1.79 (dddd, 1H, J = 2.0, 3.5, 4.0, 14.5 Hz (H5a)), 
1.66 (s, 3H (Me)) 
 
 
124a  
(2S,3R,4R)-2-Methyl-3-(prop-1-en-2-yl)-1-tosylpiperidin-4-ol  
 
 
Formed as the minor product from the reaction of precursor 120a in procedure K as a yellow 
residue.  
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1H-NMR (300 MHz, CDCl3)  7.72 (app d, 2H (ArH)), 7.30 (app d, 2H (ArH)), 5.08 (s, 1H (=CH)), 
4.83 (d, 1H, J = 1.0 Hz (=CH)), 4.29 (dq, 1H, J = 5.0, 7.0 Hz (H2)), 3.97 (td, 1H, J = 5.0, 11.0 Hz 
(H4)), 3.86 (dt, 1H, J = 5.0, 14.0 Hz (H6e)), 3.07 (dt, 1H, J = 2.5, 14.0 Hz (H6a)), 2.42 (s, 3H 
(ArCH3)), 2.03 (dd, 1H, J = 5.0, 11.0 Hz (H3)), 1.96 (ddt, 1H, J = 2.5, 5.0, 12.5 (H5e)), 1.76 (s, 3H 
(Me)), 1.39 (m, 2H (H5a)), 0.95 (d, 3H, J = 7.0 Hz (Me)); 
13C-NMR (100 MHz, CDCl3) 143.3 
(QAr), 142.3 (QAr), 138.1 (C=), 129.8 (ArH), 126.9 (ArH), 113.0 (=CH2), 64.8 (C4), 54.3 (C2), 
50.8 (C3), 38.8 (C6), 32.9 (C5), 23.1 (Me=), 21.5 (ArCH3), 12.3 (Me) 
 
 
124d  
(2S,3R,4R)-2-Allyl-3-(prop-1-en-2-yl)-1-tosylpiperidin-4-ol  
 
 
Formed as the minor product from the reaction of precursor 120d in procedure K as a yellow 
residue.  
 
1H-NMR (300 MHz, CDCl3)  7.75 (app d, 2H (ArH)), 7.31 (app d, 2H (ArH)), 5.79 (ddt, 1H, J = 
7.0, 11.0, 16.5 Hz (=CH)), 5.12-5.05 (stack, 2H (2x =CHH)), 5.04-4.95 (stack, 2H (2x =CHH)), 
3.92 (dt, 1H, J = 5.0, 7.0 Hz (H2)), 3.64 (dddd, 1H, J = 0.5, 3.0, 7.5, 14.0 Hz (H4)), 3.48 (dt, 1H, J 
= 7.0, 9.0 Hz (H6e)), 3.32 (ddd, 1H, J = 6.0, 9.0, 14.0 Hz (H6a)), 2.64 (dd, 1H, J = 7.0, 14.0 Hz 
(H3)), 2.44 (s, 3H (ArCH3)), 2.33-2.06 (stack, 3H (1 of H5, CH2CH=)), 1.74 (s, 3H (Me)), 1.50-
1.39 (m, 1H (1 of H5, CH2CH=)) 
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126  
(4R,4aS,10aS)-5,5-Dimethyl-1-tosyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-4-ol  
 
 
Formed as a by-product during derivatization of piperidine 122c, or during extended reaction 
of precursor 120c in procedure K as a white solid. (NB piperidine stereochemistry: 2S,3S,4R).  
 
IR (cm-1) 3612 (OH), 1593 (Ar), 1363/1181 (SO2N); 
1H-NMR (400 MHz, CDCl3)  7.93-7.73 
(m, 2H (ArH)), 7.36 (app dd, 1H (ArHA)), 7.37-7.32 (m, 2H (ArH)), 7.20 (app dt, 1H (ArHC)), 
7.12 (app dt, 1H (ArHB)), 7.00 (app dd, 1H (ArHD)), 4.42-4.28 (stack, 2H (H2, H4)), 3.78 (app dt, 
1H, J = 5.0, 14.5 Hz (H6e)), 3.22 (dt, 1H, J= 9.0, 14.5 Hz (H6a)), 3.04 (dd, 1H, J = 5.5, 15.5 Hz 
(CHHAr)), 2.97 (dd, 1H, J = 10.0, 15.5 Hz (CHHAr)), 2.46 (s, 3H (ArCH3)), 2.05-1.98 (stack, 2H 
(H5)), 1.85 (d, 1H, J = 8.5 Hz (OH)), 1.65 (d, 1H, J = 11.5 Hz (H3)), 1.42 (s, 3H (Me)), 1.39 (s, 3H 
(Me)); 13C-NMR (100 MHz, CDCl3) 145.7 (QAr), 143.6 (QAr), 137.7 (QAr), 132.9 (QAr), 129.8 
(ArH), 129.5 (ArHD), 127.3 (ArH), 126.6 (ArHA), 126.5 (ArHC), 125.6 (ArHB), 63.6 (C4), 50.1 (C3), 
48.3 (C2), 39.3 (CMe2), 36.5 (C6), 36.0 (CH2Ar), 35.2 (C5), 29.5 (Me), 28.5 (Me), 21.6 (ArCH3); 
m/z (ES) [M+Na]+ 408.2; C22H27NO3SNa requires 408.1609, found 408.1622 
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Unknown stereochemistry iPr piperidine isomers  
 
Isomer A  
Rf 0.37 (40 % EtOAc in hexane); 
1H-NMR (300 MHz, CDCl3)  7.74 (app d, 2H (ArH)), 7.27 (app 
d, 2H (ArH)), 4.95 (quin, 1H, J = 1.5 Hz (=CHH)), 4.82 (s, 1H (=CHH)), 3.77 (dt, 1H, J = 1.0, 7.0 
Hz (H2)), 3.68 (dddd, 1H, J = 1.0, 3.5, 9.0, 14.5 Hz (H6e)), 3.38 (tt, 1H, J = 5.5, 8.5 Hz (H4)), 3.24 
(ddd, 1H, J = 7.5, 8.5, 14.5 Hz (H6a)), 2.41 (s, 3H (ArCH3)), 2.22 (dd, 1H, J = 7.0, 8.5 Hz (H3)), 
2.16-2.00 (stack, 2H (H5e, CHMe2)), 1.78 (d, 3H, J = 0.5 Hz (MeC=)), 1.37 (dddd, 1H, J = 5.5, 7.5, 
9.0, 13.5 Hz (H5a)), 1.01 (d, 3H, J = 7.0 Hz (Me)), 0.91 (d, 3H, J = 7.0 Hz (Me)); 
13C-NMR (100 
MHz, CDCl3) 144.4 (QAr), 143.1 (QAr), 138.0 (C=), 129.5 (ArH), 127.4 (ArH), 115.7 (H2C=), 
66.0 (C4), 61.0 (C2), 52.8 (C3), 38.4 (C6), 32.9 (CHMe2), 29.1 (C5), 21.5 (ArCH3), 20.3 (Me), 20.1 
(Me=), 19.5 (Me).  
 
Isomer B  
Rf 0.29 (15 % EtOAc in hexane); 
1H-NMR (300 MHz, CDCl3)  7.71 (app d, 2H (ArH)), 7.25 (app 
d, 2H (ArH)), 4.93 (quin, 1H, J = 1.0 Hz (=CHH)), 4.84 (s, 1H (=CHH)), 4.06-3.96 (m, 1H (H4)), 
3.93 (dt, 1H, J = 2.5, 9.5 Hz (H2)), 3.74 (dddd, 1H, J = 1.5, 2.5, 6.0, 14.0 Hz (H6e)), 2.97 (ddd, 1H, 
J = 4.5, 11.5, 14.0 Hz (H6a)), 2.59 (dd, 1H, J = 2.5, 5.0 Hz (H3)), 2.41 (s, 3H (ArCH3)), 1.98 (dsept, 
1H, J = 6.5, 9.5 Hz (CHMe2)), 1.94-1.87 (m, 1H (H5e)), 1.85 (s, 3H (MeC=)), 1.83-1.71 (m, 1H 
(H5a)), 1.60 (s, 1H (OH)), 1.02 (d, 3H, J = 6.5 Hz (Me)), 0.84 (d, 3H, J = 6.5 Hz (Me)); 
13C-NMR 
(100 MHz, CDCl3) 142.9 (QAr), 142.7 (QAr), 138.5 (C=), 129.3 (ArH), 127.4 (ArH), 114.6 
(H2C=), 66.5 (C4), 62.3 (C2), 47.1 (C3), 39.5 (C6), 30.2 (C5), 29.5 (CHMe2), 24.6 (Me=), 21.5 
(ArCH3), 20.8 (Me), 20.2, (Me) 
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128  
1-Methylcyclohex-2-enol121 
 
 
Methyllithium:  
Cerium chloride heptahydrate (1.5 eq, 30.03 mmol, 11.20 g) was dehydrated under high 
vacuum then ground and re-dried before suspending in THF (0.3 M, 100 mL) at 0 °C. The 
suspension was sonicated for 30 minutes then cooled to -78 °C. Methyllithium [1.6 M] (1.5 
eq, 30.06 mmol, 18.8 mL) was added slowly then the mixture stirred for 30 minutes allowing 
a pale yellow colour to develop. Cyclohexenone (1 eq, 20.00 mmol, 1.92 g) in THF (1 M, 20 
mL) was added and the mixture stirred at -78 °C for 3 hours before quenching with sat. aq. 
ammonium chloride. The aqueous portion was washed with ether to yield a colourless oil 
(1.81 g, 81 %).  
 
Methyl Grignard:  
Methylmagnesium bromide [3 M] (1.5 eq, 78.02 mmol, 26.00 mL) was added dropwise to a 
solution of cyclohexenone (1 eq, 52.01 mmol, 5.00 g) in THF (0.3 M, 175 mL) at 0 C. The 
mixture was allowed to warm to RT and stirred overnight before quenching with sat. aq. 
ammonium chloride. The product was extracted with ether to yield a colourless oil (4.42 g, 
76 %). 
 
Rf 0.35 (20 % EtOAc in hexane); IR (cm
-1) 3351 (br)(OH), 2933/2867 (CH), 1651 (=); 1H-NMR 
(300 MHz, CDCl3)  5.75 (d, 1H, J = 3.5, 10.0 Hz (=CHC)), 5.63 (dt, 1H, J = 10.0 Hz (=CHCH2)), 
182 
 
2.11-1.85 (stack, 2H (CH2ring)), 1.81-1.57 (stack, 4H (CH2CH2ring)), 1.49 (brs, 1H (OH)), 1.28 (s, 
3H (Me)) [Lit. agreement]; 13C-NMR (100 MHz, CDCl3) 133.8 (=CH), 129.0 (=CH), 67.9 (COH), 
37.9 (CH2COH), 29.3 (Me), 25.0 (CH2), 19.5 (CH2); m/z (ES) [C6H8]
+ 79.0, [C6H8CH3]
+ 94.1 
 
 
129  
2,2,2-Trichloro-N-(3-methylcyclohex-2-en-1-yl)acetamide121 
 
 
Potassium hydride [25 %] (0.15 eq, 6.16 mmol, 988 mg) was washed in anhydrous ether 
several times before ether (2 M, 20 mL) was added and the suspension cooled to -5 °C. 
Alcohol 128 (1 eq, 41.04 mmol, 4.60 g) in ether (1.6 M, 25 mL) was added slowly and the 
mixture stirred for 30 minutes before adding to a solution of trichloroacetonitrile (1 eq, 
41.04 mmol, 4.11 mL) in ether (1 M, 40 mL) at -5 °C. The reaction stirred at RT overnight 
then was diluted with ether and washed with water. The product was recrystallized from 
hexane to give a pale yellow solid. (4.74 g, 45 %)  
 
Rf 0.20 (20 % EtOAc in hexane); IR (cm
-1) 3255 (NH), 2940/2859 (CH), 1685 (C=O), 1536 (=); 
1H-NMR (300 MHz, CDCl3)  6.55 (brs, 1H (NH)), 5.36 (dq, 1H, J = 1.5, 2.0 Hz (=CH)), 4.42 
(dddd, 1H, J = 2.0, 3.5, 5.5, 8.5 Hz (CHNH)), 2.04-1.81 (stack, 3H (CH2CHring)), 1.75-1.54 (stack, 
3H (CH2CHring)), 1.70 (s, 3H (Me)) [Lit. agreement]; 
13C-NMR (100 MHz, CDCl3) 160.7 (C=O), 
133.5 (=CMe), 118.5 (=CH), 92.8 (CCl3), 45.2 (CHN), 30.5 (CH2C=), 29.8 (CH2CH), 22.4 (Me), 
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18.5 (CH2CH2CH); m/z (ES) [M+Na]
+ 278.0; C9H12NO
35Cl3Na requires 277.9882, found 
277.9889 
 
 
130  
3-Methylcyclohex-2-enamine121 
 
 
Acetamide 129 (1 eq, 15.60 mmol, 4.00 g) was dissolved in ethanol (0.7 M, 22 mL) at 0 °C 
then sodium hydroxide (5 eq, 77.98 mmol, 3.12 g) in water (2 M, 15.60 mmol, 1.73 g) was 
added dropwise. After stirring at RT overnight the product was extracted with petrol/ether 
(1:4) and washed with water. After careful concentration (bp 58-64 °C/30 mbar) the product 
was purified by Kugelrohr distillation to yield a clear oil (572 mg, 33 %).  
 
IR (cm-1) 3265 (NH), 1528 (=); 1H-NMR (300 MHz, CDCl3)  5.40-5.32 (m, 1H, (=CH)), 3.38- 
3.26 (m, 1H, (CHN)), 2.00-1.18 (stack, 6H (CH2CH2CH2ring)), 1.66 (s, 3H, (CH3)), 1.42 (s, 2H, 
(NH2)) [Lit. agreement]; 
13C-NMR (100 MHz, CDCl3) 133.5 (=CMe), 118.7 (=CH), 47.8 (CHN), 
30.4 (CH2C=), 22.3 (Me), 20.6 (CH2CH), 18.4 (CH2CH2CH); m/z (ES) [M+Na]
+ 134.1 
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131  
N-Tosyl-3-methylcyclohex-2-en-1-amine 
 
 
General procedure B was followed with the following amounts used:  
Amine 130 (1 eq, 2.70 mmol, 300 mg)  
DCM (0.1 M, 27 mL)  
Triethylamine (2 eq, 5.40 mmol, 0.75 mL)  
p-Toluene sulfonyl chloride (2 eq, 5.40 mmol, 1.03 g)  
DMAP (10 mol%, 0.27 mmol, 33 mg)  
Time: 20 hours  
Crude product was purified by column chromatography, eluting with 5 % EtOAc in hexane to 
yield a pale yellow oil (320 mg, 45 %)  
 
Rf 0.28 (10 % EtOAc in hexane); IR (cm
-1) 3256 (NH), 1531 (=); 1H-NMR (300 MHz, CDCl3)  
7.78 (app d, 2H (ArH)), 7.30 (app d, 2H (ArH)), 5.09 (dq, 1H, J = 1.5, 3.5 Hz (=CH)), 4.81 (d, 1H, 
J = 8.0 Hz (NH)), 3.81-3.68 (m, 1H (CH)), 2.43 (s, 3H (ArCH3)), 1.89-1.43 (stack, 6H 
(CH2CH2CH2ring)), 1.57 (s, 3H (Me)); 
13C-NMR (100 MHz, CDCl3) 141.8 (QAr), 137.5 (QAr), 
133.6 (=CMe), 129.7 (ArH), 128.7 (ArH), 118 (=CH), 52.9 (CHNH), 30.7 (CH2C=), 28.1 (CH2CH), 
22.4 (Me), 21.3 (ArCH3), 18.2 (CH2CH2CH); m/z (ES) [M+Na]
+ 288.1 
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132  
N-Tosyl-3-(3-methylcyclohex-2-en-1-yl)aminopropan-1-ol  
 
 
Amine 131 (1 eq, 1.13 mmol, 300 mg), cesium carbonate (1.5 eq, 1.70 mmol, 553 mg) and 
tert-butyl(3-iodopropoxy)dimethylsilane (1.5 eq, 1.70 mmol, 509 mg) were dissolved in DMF 
(0.1 M, 11 mL) and stirred in the dark at RT overnight. 1 M HCl was added and the reaction 
stirred for a further hour before dilution with water and extraction into ether. Column 
chromatography (5-25 % EtOAc in hexane) yielded desilylated product as a pale yellow oil 
(219 mg, 60 %).  
 
IR (cm-1) 3642 (OH), 1352/1173 (SO2N); 
1H-NMR (300 MHz, CDCl3)  7.74 (app d, 2H (ArH)), 
7.31 (app d, 2H (ArH)), 4.82-4.79 (m, 1H (=CH)), 4.49-4.39 (m, 1H (CH)), 3.87- 3.68 (stack, 2H 
(CH2N)), 3.31 (dt, 1H, J = 7.0, 16.0 Hz (CHHO)), 3.20 (dt, 1H, J = 6.5, 16.0 Hz (CHHO)), 2.45 (s, 
3H (ArCH3)), 1.99-1.23 (stack, 8H (CH2CH2CH2ring, CH2CH2N)), 1.59 (s, 3H (CH3)); 
13C-NMR (100 
MHz, CDCl3) 143.1 (QAr), 140.0 (QAr), 137.9 (=CMe), 129.7 (ArH), 127.1 (ArH), 121.7 (=CH), 
59.4 (CH2N), 55.8 (CH), 40.6 (CH2O), 34.4 (CH2CH2N), 29.4 (CH2ring), 28.5 (CH2ring), 23.6 (Me), 
21.9 (CH2ring), 21.5 (ArCH3); m/z (ES) [M+Na]
+ 346.2 
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133  
N-Tosyl-3-(3-methylcyclohex-2-en-1-yl)aminopropanal  
 
 
Procedure F was followed using the following amounts:  
Oxalyl chloride (1.1 eq, 0.73 mmol, 62 l) in DCM (0.4 M, 1.8 mL)  
DMSO (2.4 eq, 1.56 mmol, 113 l)  
Alcohol 132 (1 eq, 0.66 mmol, 215 mg) in DCM (0.8 M, 0.8 mL)  
Triethylamine (5 eq, 3.32 mmol, 463 l)  
The product (yellow oil) was purified by column chromatography (20 % EtOAc in hexane) to 
yield piperidine 134.  
 
Title compound data:  
IR (cm-1) 2884 (CH), 1744 (C=O); 1H-NMR (300 MHz, CDCl3)  9.70 (s, 1H (CHO)), 7.64 (app d, 
2H (ArH)), 7.23 (app d, 2H (ArH)), 4.66 (d, 1H, J = 1.0 Hz (=CH)), 4.42-4.31 (m, 1H (CHN)), 
3.39-3.16 (m, 2H (CH2N)), 2.36 (s, 3H (ArCH3)), 1.89-1.59 (stack, 6H (CH2CHN, CH2CHO, 
CH2C=)), 1.49 (s, 3H (=CCH3)), 1.38-1.23 (m, 2H (CH2CH2C=)); 
13C-NMR (100 MHz, CDCl3) 
199.9 (CHO), 140.5 (QAr), 137.5 (QAr), 133.9 (QC=), 129.7 (ArH), 127.1 (ArH), 121.3 (=CH), 
56.0 (CHN), 45.9 (CH2N), 37.4 (CH2CHO), 29.3 (CH2C=), 28.4 (CH2CH), 23.6 (CH3), 21.7 (ArCH3), 
21.5 (CH2CH2C=); m/z (ES) [M+Na]
+ 344.2  
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134  
N-Tosyl-5-methylenedecahydroquinolin-4-ol  
 
 
A solution of aldehyde 133 (0.22 mmol) in DCM (4.36 mL) was cooled to -78 °C and MeAlCl2 
(1M, 0.436 mL) was added dropwise. After 1 hour the reaction was quenched with water (15 
mL) then the organic phase extracted with DCM and washed with brine to yield a yellow oil 
(61 mg, 87 %).  
 
IR (cm-1) 3558 (OH), 2922 (CH); 1H-NMR (300 MHz, CDCl3) 7.64 (app d, 2H (ArH)), 7.21 
(app d, 2H (ArH)), 5.62 (d, 2H, J = 1.0 Hz (=CH)), 4.00 (app. dt, 2H, J = 2.5, 6.0 Hz (CHN, 
CHOH)), 3.64-3.60 (m, 1H (CHHN)), 3.30 (dt, 1H, J = 5.5, 13.5 Hz (CHHN)), 2.35 (s, 3H (ArCH3)), 
2.13-2.08 (m, 1H (CHC=)), 1.96-2.02 (m, 2H (CH2CHN)), 1.82 (dd, 1H, J = 2.5, 5.5 Hz 
(CHHCHOH)), 1.78 (dd, 1H, J = 2.5, 5.5 Hz (CHHCHOH)), 1.61 (brs, 1H (OH)), 1.42-1.32 (m, 2H 
(CH2C=), 1.33-1.23 (m, 2H (CH2CH2C=)); 
13C-NMR (100 MHz, CDCl3) 142.9 (QAr), 138.8 
(=CR2), 131.4 (QAr), 129.7 (ArH), 127.1 (ArH), 126.7 (=CH2), 63.5 (CHOH), 51.9 (CHNH), 43.8 
(CHC=), 35.0 (CH2N), 30.7 (CH2C=), 24.6 (CH2CHOH), 22.8 (CH2CHN), 21.5 (CH2CH2C=), 21.0 
(ArCH3); m/z (ES) [M+Na]
+ 344.2 
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138  
(S)-5-(Hydroxymethyl)pyrrolidin-2-one122 
 
 
(S)-methyl 5-oxopyrrolidine-2-carboxylate (1 eq, 6.99 mmol, 1.0 g) and sodium borohydride 
(1.25 eq, 8.73 mmol, 330 mg) in ethanol (0.7 M, 10 mL) were stirred at 0 °C for 1 hour 45 
minutes before conc. HCl was added dropwise until fuming ceased. The solvent was 
removed and the residue taken into 20 % MeOH in EtOAc, filtered through Celite® and the 
product purified by column chromatography to yield a white solid (670 mg, 83 %).  
 
Rf 0.38 (20 % MeOH in EtOAc); IR (cm
-1) 3189 (amide) 3088/1260 (OH), 2975/1439 (NH); 
1H-NMR (300 MHz, CDCl3)  7.00 (brs, 1H (NH)), 4.30 (brs, 1H (OH)), 3.85-3.74 (m, 1H (CH)), 
3.69 (dd, 1H, J = 3.5, 11.5 Hz (CHHOH)), 3.47 (dd, 1H, J = 7.0, 11.5 Hz (CHHOH)), 2.45-1.74 
(stack, 4H (CH2CH2)) [Lit. agreement]; 
13C-NMR (100 MHz, CDCl3) 179.3 (C=O), 65.9 (CH2OH), 
56.4 (CH), 30.2 (CH2C=O), 22.6 (CH2CH); m/z (EI) [M]
+ 115.0 
 
 
141  
(S)-Methyl-5-oxopyrrolidine-2-carboxylate  
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To a solution of (S)-pyroglutamic acid (1 eq, 232.3 mmol, 30.00 g) in methanol (0.8 M, 300 
mL) at 0 °C was added thionyl chloride (2 eq, 464.7 mmol, 33.90 mL). After two hours the 
solvents were removed and the residue taken up into DCM. The organic extract was washed 
with sat. aq. NaHCO3 and the product extracted into DCM to yield a colourless oil (22.20 g, 
67 %).  
 
Rf 0.57 (20 % MeOH in EtOAc); IR (cm
-1) 3308 (NH), 3170 (NC=O), 1736 (ester), 1671 (C=O), 
1480 (NH); 1H-NMR (300 MHz, CDCl3)  7.02 (s, 1H (NH)), 4.24 (dd, 1H, J = 5.0, 8.5 Hz (CH)), 
3.74 (s, 3H (OMe)), 2.53-2.13 (stack, 4H (CH2CH2)); 
13C-NMR (75 MHz, CDCl3) 178.6 (NC=O), 
172.7 (OC=O), 55.5 (CH), 52.4 (CH3), 29.3 (CH2C=O), 24.7 (CH2CH); m/z (EI) [M]+ 143.0; 
C6H9NO3 requires 143.0582, found 143.0580 
 
 
(S)-Dimethyl-2-aminopentanedioate  
 
 
To a solution of glutamic acid (1 eq, 3.40 mmol, 500 mg) in methanol (0.7 M, 5 mL) at 0 °C 
was added thionyl chloride (1 eq, 3.40 mmol, 0.7 mL). The reaction mixture stirred at RT for 
36 hours before an aqueous work up to yield a pale yellow oil in quantitative yield.  
 
Rf 0.66 (10 % MeOH in DCM); IR (cm
-1) 3407 (NH), 2955 (CH), 1733 (CO2Me), 1507 (NH2), 
1219 (CO); 1H-NMR (300 MHz, CDCl3)  6.42 (brs, 2H, (NH2)), 4.24 (dd, 1H, J = 5.0, 8.5 Hz 
(CH)), 3.70 (s, 3H (OMe)), 3.64 (s, 3H (OMe)), 2.49-1.78 (stack, 4H (CH2CH2)); 
13C-NMR (75 
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MHz, CDCl3) 172.9 (C=OCH2), 169.6 (C=OCH), 53.4 (Me), 52.6 (Me), 52.0 (CH), 29.3 
(CH2C=O), 25.3 (CH2CH); m/z (CI) [M+H]
+ 176.1; C7H14NO4 requires 176.0923, found 176.0921 
 
 
Heptan-4-yltriphenylphosphonium iodide124 
 
 
To butyltriphenylphosphonium bromide (1 eq, 2.35 mmol, 940 mg) in THF (0.1 M, 24 mL) at 
0 °C was added KOtBu (1.25 eq, 2.94 mmol, 330 mg). After 30 minutes iodopropane (1.25 eq, 
2.94 mmol, 500 mg) was added and the reaction stirred at RT overnight inducing loss of the 
yellow ylide colour. The mixture was diluted with water then treated with 1M HCl until the 
solution was just acidic then the product extracted into EtOAc.  
 
1H-NMR (300 MHz, CDCl3)  7.90-7.75 (stack, 15H (ArH)), 4.70-4.53 (m, 1H (CH)), 1.50-1.40 
(m, 4H (CH2)), 1.32-1.19 (m, 4H (CH2)), 0.70 (t, 6H, J = 7.0 Hz (CH3)) [Lit. agreement]; m/z (ES) 
[M]+ 361.2 
 
The conditions were optimised by reaction with benzaldehyde to give the mono substituted 
Z-alkene and the disubstituted alkene:  
 
1H-NMR (300 MHz, CDCl3)  7.8-7.0 (ArH), 6.24 (d, 1H, J = 11.5 Hz (=CHPhmono)), 6.09 (s, 1H 
(=CHdi)), 5.49 (dt, 1H, J = 7.0, 11.5 Hz (=CHCH2mono)), 2.40-0.65 (Alk); m/z (EI) [Mmono]
+ 146.1, 
[Mdi]
+ 188.2 
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(S)-5-((tert-Butyldimethylsilyloxy)methyl)pyrrolidin-2-one125 
 
 
(S)-5-(hydroxymethyl)pyrrolidin-2-one (1 eq, 8.69 mmol, 1.00 g), imidazole (1.5 eq, 13.03 
mmol, 887 mg) and tert-butylsilyl chloride (1 eq, 8.69 mmol, 1.31 g) were dissolved in DMF 
(1.5 M, 6 mL) at 0 °C. After 15 minutes the reaction mixture was warmed to RT and stirred 
overnight. The mixture was diluted with water and the products extracted into EtOAc and 
washed with brine to yield 1.81g as a colourless oil (91 %).  
 
Rf 0.82 (10 % MeOH in DCM); 
1H-NMR (300 MHz, CDCl3)  6.12 (brs, 1H (NH)), 3.75 (ddt, 1H, J 
= 4.0, 7.5, 12.5 Hz (CH)), 3.62 (dd, 1H, J = 4.0, 10.0 Hz (CHHOSi)), 3.45 (dd, 1H, J = 7.5, 10.0 Hz 
(CHHOSi)), 2.41-2.01 (stack, 3H (CH2CH2ring)), 1.89-1.60 (m, 1H (CH2CH2ring), 0.88 (s, 9H (tBu)), 
0.05 (s, 6 (Me)) [Lit. agreement]. 
 
 
(S)-5-((Trimethylsilyloxy)methyl)pyrrolidin-2-one126  
 
 
(S)-5-(hydroxymethyl)pyrrolidin-2-one (1 eq, 4.34 mmol, 500 mg), freshly distilled 
trimethylsilyl chloride (1.5 eq, 6.51 mmol, 0.83 mL), triethylamine (1.2 eq, 5.21 mmol, 0.73 
mL) and DMAP (20 mol%, 0.87 mmol, 106 mg) were dissolved in DCM (0.3 M, 15 mL) and 
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stirred at RT for 24 hours. Sat. Aq. NH4Cl was added and the product extracted into DCM 
then washed with brine to yield a colourless oil, which solidified on cold storage, in 
quantitative yield.  
 
Rf 0.79 (10 % MeOH in DCM); 
1H-NMR (300 MHz, CDCl3)  5.30 (brs, 1H (NH)), 3.70-3.57 (m, 
1H (CH)), 3.56-3.43 (m, 1H (CHHO)), 3.40-3.25 (m, 1H (CHHO)), 2.38-1.54 (stack, 4H (CH2CH2)), 
0.11 (s, 9H (Me)) [Lit. agreement]. 
 
 
142  
(S)-5-((tert-Butyldimethylsilyloxy)methyl)-1-(3-(tert-butyldimethylsilyloxy)propyl) pyrrolidin-
2-one 
 
 
To a solution of (S)-5-((tert-butyldimethylsilyloxy)methyl)pyrrolidin-2-one (1 eq, 0.44 mmol, 
100 mg) in DMF (0.9 M, 0.50 mL) at 0 °C was added sodium hydride [60 %] (0.2 eq, 0.52 
mmol, 21 mg). After 15 minutes the reaction was diluted with DMF (0.45 M, 1.00 mL) then 
tert-butyl(3-iodopropoxy)dimethylsilane (1.2 eq, 0.52 mmol, 157 mg) was added dropwise. 
The reaction mixture stirred at RT for 4 hours then was quenched with water and product 
extracted into EtOAc then purified by column chromatography, eluting with 20 % EtOAc in 
hexane.  
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Rf 0.42 (20 % EtOAc in hexane); 
1H-NMR (300 MHz, CDCl3)  3.79 – 3.70 (m, 1H (CH)), 3.65 (t, 
2H, J = 6.0 Hz (CH2Cl)), 3.61 (dd, 1H, J = 4.0, 10.0 Hz (CHHOSi)), 3.54 (t, 2H, J = 6.0 Hz 
(CH2OSi)), 3.44 (dd, 1H, J = 7.5, 10.0 Hz (CHHOSi)), 2.35 – 2.08 (stack, 3H (CH2CH2ring)), 1.89 
(quin, 2H, J = 6.0 Hz (CH2CH2)), 1.83 – 1.74 (m, 1H (CH2CH2ring), 0.86 (s, 9H (
tBu)), 0.82 (s, 9H 
(tBu)), 0.03 (s, 6H (Me)), 0.01 (s, 6 (Me)) 
 
 
3-Iodo-1,1-dimethoxypropane127 
 
 
Sodium iodide (1.2 eq, 44.70 mmol, 6.70 g) was suspended in acetonitrile (0.35 M, 100 mL) 
at 0 °C then acrolein (1 eq, 37.42 mmol, 2.50 mL) was added dropwise. Freshly distilled 
trimethylsilyl chloride (1.2 eq, 43.81 mmol, 5.60 mL) was added over 10 minutes and after 
stirring for 15 minutes the mixture was poured into a mixture of pentane (150 mL) and 5 % 
NaHCO3 (50 mL) to produce 3 layers. The lower aqueous layer was removed and the organic 
phases washed with 5 % Na2S2O3 (50 mL). The aqueous layer was again removed and the 
organic layers washed with brine (50 mL). The brine wash was repeated until no acetonitrile 
remained then the pentane layer was dried, filtered and concentrated to yield a pale yellow 
oil (4.89 g, 57 %).  
 
1H-NMR (300 MHz, CDCl3)  4.49 (t, 1H, J = 5.5 Hz (CH)), 3.38 (s, 6H (OMe)), 3.19 (t, 2H, J = 
7.0 Hz (CH2I)), 2.14 (td, 2H, J = 5.5, 7.0 Hz (CH2CH)); 
13C-NMR (100 MHz, CDCl3) 104.6 (CH), 
53.7 (OMe), 36.6 (CH2CH), 0.0 (CH2I); m/z (EI) [
127I] [M]+ 229.0 
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143  
(S)-1-(3,3-Dimethoxypropyl)-5-(hydroxymethyl)pyrrolidin-2-one104  
 
 
Sodium hydride [60 %] (1.5 eq, 0.80 mmol, 32 mg) was suspended in DMF (1.5 M, 0.35 mL) 
then (S)-5-(((trimethylsilyl)oxy)methyl)pyrrolidin-2-one (1 eq, 0.53 mmol, 100 mg) in DMF 
(1.5 M, 0.35 mL) was added slowly. The mixture was heated to 70 °C then 3-iodo-1,1- 
dimethoxypropane (1.5 eq, 0.80 mmol, 184 mg) in DMF (0.9 M, 0.60 mL) was slowly added. 
The reaction was stirred at this temperature for 30 hours before cooling, diluting with water 
and extracting the product into EtOAc to yield 110 mg as a yellow liquid (71 %).  
 
Rf 0.55 (10 % MeOH in DCM); 
1H-NMR (300 MHz, CDCl3)  4.43 (t, 1H, J = 5.5 Hz (CH(OMe)2)), 
3.85-3.47 (stack, 2H (CH2OH)), 3.64-3.54 (m, 1H (CHN)), 3.35 (t, 2H, J = 7.0 Hz (CH2N)), 3.29 (s, 
3H (CH3)), 3.24 (s, 3H (CH3)), 2.50-1.80 (stack, 6H (CH2CH2ring, CH2CH2N)), 1.63 (brs, 1H (OH)) 
 
 
144  
(S)-5-((tert-Butyldimethylsilyloxy)methyl)-1-(3,3-dimethoxypropyl)pyrrolidin-2-one  
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Sodium hydride [60 %] (1.5 eq, 3.27 mmol, 131 mg) and 4 Å molecular seives were 
suspended in DMF (2.4 M, 0.90 mL) then (S)-5-((trimethylsilyloxy)methyl)pyrrolidin-2-one (1 
eq, 2.18 mmol, 500 mg) in DMF (1.7 M, 1.30 mL) was added slowly. The mixture was heated 
to 70 °C then 3-iodo-1,1- dimethoxypropane (1.5 eq, 3.27 mmol, 752 mg) in DMF (1.5 M, 
1.50 mL) was slowly added. The reaction was stirred at this temperature for 20 hours before 
cooling and removing the sieves, diluting with water and extracting the product into EtOAc 
to yield a yellow liquid (469 mg, 69 %).  
 
Rf 0.43 (1 % MeOH in DCM); 
1H-NMR (300 MHz, CDCl3)  4.37 (t, 1H, J = 5.5 Hz (CH(OMe)2)), 
3.78-3.66 (m, 1H (CH)), 3.65-3.63 (m, 1H (CHHN)), 3.61 (dd, 1H, J = 4.0, 10.0 Hz (CHHOSi)), 
3.45 (dd, 1H, J = 7.5, 10.0 Hz (CHHOSi)), 3.32 (s, 3H (OMe)), 3.29 (s, 3H (OMe)), 3.12-2.98 (m, 
1H (CHHN)), 2.48-1.67 (stack, 6H (CH2CH2ring, CH2CHMe2)), 0.82 (s, 9H (tBu)), 0.00 (s, 6H (Me)) 
 
 
145  
(S)-5-((tert-Butyldimethylsilyloxy)methyl)-1-(3-chloropropyl)pyrrolidin-2-one  
 
 
(S)-5-(((trimethylsilyl)oxy)methyl)pyrrolidin-2-one (1 eq, 0.13 mmol, 30 mg), 1-bromo-3- 
chloropropane (2 eq, 0.26 mmol, 41 mg) TBAI (2 eq, 0.26 mmol, 97 mg) and powdered KOH 
(3 eq, 0.39 mmol, 22 mg) were added to a microwave tube with THF (0.25 M, 0.5 mL). The 
tube was subjected to microvave radiation with the following settings: normal absorbance, 5 
s pre-stir, time hold on, 120 °C, 10 min.  
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The products were isolated by HPLC. N.B. title compound is a minor product, major product 
is alkene 146.  
 
Title compound data: 1H-NMR (400 MHz, CDCl3)  3.74 (dd, 1H, J = 3.5, 10.5 Hz (CHHOSi)), 
3.70-3.63 (m, 1H (CH)), 3.62-3.50 (stack, 4H (CHHOSi, CHHN, CH2Cl)), 3.24 (dt, 1H, J = 7.0, 
14.0 (CHHN)), 2.45 (ddd, 1H, J = 7.5, 9.5, 17.0 Hz (CHHC=O)), 2.29 (ddd, 1H, J = 5.0, 10.0, 17.0 
Hz (CHHC=O)), 2.14-2.04 (stack, 2H (CHHCH2Cl, CHHCH)), 1.99 (quin, 1H, J = 7.0 Hz 
(CHHCH2Cl)), 1.89-1.81 (m, 1H (CHHCH)), 0.88 (s, 9H (
tBu)), 0.06 (s, 6H (Me)); 13C-NMR (100 
MHz, CDCl3) 175.9 (C=O), 64.0 (CH2OSi), 59.9 (CH), 42.6 (CH2N), 30.6 (CH2C=O), 30.4 
(CH2CHCl), 25.8 (
tBu), 21.6 (CH2CH), 18.1 (Q
tBu), -5.0 (SiMe); m/z (ES) [M+Na]+ 328.1/330.1; 
C14H28NO2NaSi
35Cl requires 328.1476, found 328.1468 
 
 
146  
(S)-1-Allyl-5-((tert-butyldimethylsilyloxy)methyl)pyrrolidin-2-one  
 
 
(S)-5-(((trimethylsilyl)oxy)methyl)pyrrolidin-2-one (1 eq, 3.27 mmol, 750 mg), allyl bromide 
(2 eq, 6.54 mmol, 566 l) and powdered KOH (3 eq, 9.81 mmol, 550 mg) were added to a 
microwave tube with THF (0.25 M, 13 mL). The tube was subjected to microwave radiation 
with the following settings: normal absorbance, 10 s pre-stir, time hold on, 120 °C, 10 min.  
The product was isolated by HPLC to yield a yellow liquid (802 mg, 91 %).  
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1H-NMR (300 MHz, CDCl3)  5.74 (dddd, 1H, J = 5.0, 7.0, 10.0, 17.0 Hz (=CH)), 5.18 (dd, 1H, J = 
1.5, 10.0 Hz (=CHH)), 5.15 (m, 1H (=CHH)), 4.30 (dd, 1H, J = 1.5, 5.0 Hz (CHHN)), 3.71- 3.55 
(stack, 4H (CHHN, CH2OSi, CH)), 2.52-2.43 (m, 2H (CH2C=O)), 2.31 (m, 1H (CHHCH)), 1.88 (m, 
1H (CHHCH)), 0.88 (s, 9H (tBu)), 0.04 (s, 3H (Me)), 0.04 (s, 3H (Me)); 13C-NMR (100 MHz, 
CDCl3) 175.4 (C=O), 133.1 (=CH), 117.3 (=CH2), 63.6 (CH2OSi), 58.8 (CH), 43.5 (CH2N), 30.4 
(CH2CH2), 25.8 (
tBu), 21.6 (CH2CH2), 18.2 (Q
tBu), -5.0 (Me); m/z (ES) [M+Na]+ 292.1; 
C14H27NO2NaSi requires 292.1709, found 292.1702  
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COMPOUND INDEX 
Compound 
number 
Sketch 
Page 
(text) 
Page 
(experimental) 
Reference 
57 
 
24 91 40 
58 
 
24 92 41 
59 
 
25 93 44 
60 
 
26 95 44 
61 
 
26 96 X 
69a 
 
31 97 109 
69c 
 
51 98 110 
69d 
 
51 - 74 
69e 
 
51 - 111 
70 
 
31 99 58 
71 
 
32 100 X 
72 
 
33 101 X 
73 
 
33 102 112 
74 
 
33 - novel 
75 
 
33 103 novel 
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Compound 
number 
Sketch 
Page 
(text) 
Page 
(experimental) 
Reference 
76 
 
33 104 novel 
79 
 
36 105 novel 
80 
 
36 106 novel 
81 
 
36 - novel 
83 
 
37 107 113 
84 
 
37 107 114 
85a 
 
37 108 114 
85b 
 
- 109 X 
86a 
 
38 110 114 
87 
 
38 111 114 
89 
 
39 112 novel 
90 
 
39 112 novel 
91 
 
42 113 115 
- 
 
43 114 116 
- 
 
43 115 116 
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Compound 
number 
Sketch 
Page 
(text) 
Page 
(experimental) 
Reference 
92a 
 
43 116 novel 
93a 
 
44 117 novel 
93b 
 
51 118 novel 
93c 
 
51 119 novel 
93d 
 
51 120 novel 
93e 
 
51 121 novel 
93f 
 
51 122 novel 
93g 
 
51 123 novel 
94 
 
44 - novel 
95a 
 
44 124 novel 
95b 
 
51 125 novel 
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Compound 
number 
Sketch 
Page 
(text) 
Page 
(experimental) 
Reference 
95c 
 
 
51 126 novel 
95d 
 
51 127 novel 
95e 
 
51 128 novel 
95f 
 
51 129 novel 
95g 
 
51 130 novel 
96a 
 
44 131 novel 
96c 
 
51 132 novel 
97a 
 
45 133 117 
97b 
 
- 134 X 
98a 
 
45 134 novel 
98b 
 
- 135 novel 
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Compound 
number 
Sketch 
Page 
(text) 
Page 
(experimental) 
Reference 
99 
 
45 136 novel 
100a 
 
47 137 novel 
100c 
 
51 138 novel 
101a 
 
47 139 novel 
101c 
 
51 140 novel 
102a 
 
47 141 novel 
102c 
 
51 142 novel 
112a 
 
54 143 80 
112b 
 
54 144 118 
112c 
 
54 145 80 
114a 
 
55 146 X 
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Compound 
number 
Sketch 
Page 
(text) 
Page 
(experimental) 
Reference 
114b 
 
55 147 novel 
114c 
 
55 147 X 
- 
 
- 148 novel 
- 
 
- 149 X 
115 
 
55 150 X 
116a 
 
55 150 novel 
116b 
 
55 151 novel 
116c 
 
55 152 novel 
116d 
 
55 153 novel 
116e 
 
55 154 novel 
- 
 
59 - novel 
117a 
 
57 155 128 
117b 
 
57 155 novel 
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Compound 
number 
Sketch 
Page 
(text) 
Page 
(experimental) 
Reference 
     
117c 
 
57 156 novel 
117d 
 
57 156 novel 
118a 
 
57 157 X 
118b 
 
57 158 novel 
118c 
 
57 159 novel 
118d 
 
57 160 novel 
- 
 
57 161 119 
-  57 162 120 
119a 
 
57 162 novel 
119b 
 
57 163 novel 
119c 
 
57 164 novel 
119d(i) 
 
57 165 novel 
119d(ii) 
 
57 166 novel 
120a 
 
57 167 novel 
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Compound 
number 
Sketch 
Page 
(text) 
Page 
(experimental) 
Reference 
120c 
 
57 168 novel 
120d 
 
57 169 novel 
121 
 
63 171 novel 
122a 
 
64 172 novel 
122c 
 
64 172 novel 
122d 
 
64 173 novel 
Der-122d 
 
69 174 novel 
123c 
 
64 175 novel 
123d 
 
64 176 novel 
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Compound 
number 
Sketch 
Page 
(text) 
Page 
(experimental) 
Reference 
der-123c 
 
66 176 novel 
124a 
 
64 177 novel 
124d 
 
64 178 novel 
125 
 
69 - novel 
126 
 
68 179 novel 
- 
 
68 180 novel 
128 
 
73 181 121 
129 
 
73 182 121 
130 
 
73 183 121 
131 
 
73 184 novel 
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Compound 
number 
Sketch 
Page 
(text) 
Page 
(experimental) 
Reference 
132 
 
73 185 novel 
133 
 
73 186 novel 
134 
 
73 187 novel 
138 
 
78 188 122 
139 
 
78 - 123 
141 
 
79 188 X 
- 
 
79 189 X 
- 
 
81 190 124 
- 
 
81 190 X 
- 
 
81 191 125 
- 
 
81 191 126 
142 
 
83 192 novel 
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Compound 
number 
Sketch 
Page 
(text) 
Page 
(experimental) 
Reference 
- 
 
83 193 127 
143 
 
83 194 novel 
144 
 
83 194 novel 
145 
 
83 195 novel 
146 
 
83 196 novel 
 
X indicates a compound that is known in the literature but for which no data is available. This was 
usually because it was referenced back many times to old articles with incomplete data or the only 
literature reference was in a language other than English. 
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X-RAY DATA  
Data tables for 122c, der-123c, der-122d and 126   
 
 
